-- phpMyAdmin SQL Dump
-- version 5.2.0
-- https://www.phpmyadmin.net/
--
-- Host: 127.0.0.1
-- Generation Time: Jan 09, 2023 at 12:07 PM
-- Server version: 10.4.25-MariaDB
-- PHP Version: 8.1.10

SET SQL_MODE = "NO_AUTO_VALUE_ON_ZERO";
START TRANSACTION;
SET time_zone = "+00:00";


/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8mb4 */;

--
-- Database: `accounts`
--

-- --------------------------------------------------------

--
-- Table structure for table `added_users`
--

CREATE TABLE `added_users` (
  `user_id` bigint(20) UNSIGNED NOT NULL,
  `added_by` bigint(20) UNSIGNED NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

--
-- Dumping data for table `added_users`
--

INSERT INTO `added_users` (`user_id`, `added_by`) VALUES
(2, 1);

-- --------------------------------------------------------

--
-- Table structure for table `blogs`
--

CREATE TABLE `blogs` (
  `id` int(11) NOT NULL,
  `title` tinytext NOT NULL,
  `slug` tinytext NOT NULL,
  `content` longtext NOT NULL,
  `other` longtext CHARACTER SET utf8mb4 COLLATE utf8mb4_bin DEFAULT NULL CHECK (json_valid(`other`)),
  `category_id` bigint(20) NOT NULL,
  `status` enum('draft','publish') NOT NULL DEFAULT 'draft',
  `author_id` bigint(20) NOT NULL,
  `created_at` timestamp NOT NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

--
-- Dumping data for table `blogs`
--

INSERT INTO `blogs` (`id`, `title`, `slug`, `content`, `other`, `category_id`, `status`, `author_id`, `created_at`, `updated_at`) VALUES
(1, 'test blog', 'test-blog', 'hi this', '{\"thumbnail\":\"http:\\/\\/localhost:8000\\/uploads\\/blogs\\/thumbnails\\/1672985977-test_image.jpg\",\"file\":\"http:\\/\\/localhost:8000\\/uploads\\/blogs\\/files1672986533-HELLO PD.pdf\"}', 1, 'publish', 1, '2023-01-05 05:27:42', '2023-01-06 01:19:03'),
(4, 'rtgvf', 'rtgvf', '<p>fvfd</p>', '{\"thumbnail\":null,\"file\":null}', 1, 'draft', 1, '2023-01-05 06:32:21', '2023-01-05 06:33:41'),
(5, '5y', '5y', '<p>rtg54y<img style=\"width: 25%;\" src=\"data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEASABIAAD/4gxYSUNDX1BST0ZJTEUAAQEAAAxITGlubwIQAABtbnRyUkdCIFhZWiAHzgACAAkABgAxAABhY3NwTVNGVAAAAABJRUMgc1JHQgAAAAAAAAAAAAAAAAAA9tYAAQAAAADTLUhQICAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAABFjcHJ0AAABUAAAADNkZXNjAAABhAAAAGx3dHB0AAAB8AAAABRia3B0AAACBAAAABRyWFlaAAACGAAAABRnWFlaAAACLAAAABRiWFlaAAACQAAAABRkbW5kAAACVAAAAHBkbWRkAAACxAAAAIh2dWVkAAADTAAAAIZ2aWV3AAAD1AAAACRsdW1pAAAD+AAAABRtZWFzAAAEDAAAACR0ZWNoAAAEMAAAAAxyVFJDAAAEPAAACAxnVFJDAAAEPAAACAxiVFJDAAAEPAAACAx0ZXh0AAAAAENvcHlyaWdodCAoYykgMTk5OCBIZXdsZXR0LVBhY2thcmQgQ29tcGFueQAAZGVzYwAAAAAAAAASc1JHQiBJRUM2MTk2Ni0yLjEAAAAAAAAAAAAAABJzUkdCIElFQzYxOTY2LTIuMQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAWFlaIAAAAAAAAPNRAAEAAAABFsxYWVogAAAAAAAAAAAAAAAAAAAAAFhZWiAAAAAAAABvogAAOPUAAAOQWFlaIAAAAAAAAGKZAAC3hQAAGNpYWVogAAAAAAAAJKAAAA+EAAC2z2Rlc2MAAAAAAAAAFklFQyBodHRwOi8vd3d3LmllYy5jaAAAAAAAAAAAAAAAFklFQyBodHRwOi8vd3d3LmllYy5jaAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAABkZXNjAAAAAAAAAC5JRUMgNjE5NjYtMi4xIERlZmF1bHQgUkdCIGNvbG91ciBzcGFjZSAtIHNSR0IAAAAAAAAAAAAAAC5JRUMgNjE5NjYtMi4xIERlZmF1bHQgUkdCIGNvbG91ciBzcGFjZSAtIHNSR0IAAAAAAAAAAAAAAAAAAAAAAAAAAAAAZGVzYwAAAAAAAAAsUmVmZXJlbmNlIFZpZXdpbmcgQ29uZGl0aW9uIGluIElFQzYxOTY2LTIuMQAAAAAAAAAAAAAALFJlZmVyZW5jZSBWaWV3aW5nIENvbmRpdGlvbiBpbiBJRUM2MTk2Ni0yLjEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAHZpZXcAAAAAABOk/gAUXy4AEM8UAAPtzAAEEwsAA1yeAAAAAVhZWiAAAAAAAEwJVgBQAAAAVx/nbWVhcwAAAAAAAAABAAAAAAAAAAAAAAAAAAAAAAAAAo8AAAACc2lnIAAAAABDUlQgY3VydgAAAAAAAAQAAAAABQAKAA8AFAAZAB4AIwAoAC0AMgA3ADsAQABFAEoATwBUAFkAXgBjAGgAbQByAHcAfACBAIYAiwCQAJUAmgCfAKQAqQCuALIAtwC8AMEAxgDLANAA1QDbAOAA5QDrAPAA9gD7AQEBBwENARMBGQEfASUBKwEyATgBPgFFAUwBUgFZAWABZwFuAXUBfAGDAYsBkgGaAaEBqQGxAbkBwQHJAdEB2QHhAekB8gH6AgMCDAIUAh0CJgIvAjgCQQJLAlQCXQJnAnECegKEAo4CmAKiAqwCtgLBAssC1QLgAusC9QMAAwsDFgMhAy0DOANDA08DWgNmA3IDfgOKA5YDogOuA7oDxwPTA+AD7AP5BAYEEwQgBC0EOwRIBFUEYwRxBH4EjASaBKgEtgTEBNME4QTwBP4FDQUcBSsFOgVJBVgFZwV3BYYFlgWmBbUFxQXVBeUF9gYGBhYGJwY3BkgGWQZqBnsGjAadBq8GwAbRBuMG9QcHBxkHKwc9B08HYQd0B4YHmQesB78H0gflB/gICwgfCDIIRghaCG4IggiWCKoIvgjSCOcI+wkQCSUJOglPCWQJeQmPCaQJugnPCeUJ+woRCicKPQpUCmoKgQqYCq4KxQrcCvMLCwsiCzkLUQtpC4ALmAuwC8gL4Qv5DBIMKgxDDFwMdQyODKcMwAzZDPMNDQ0mDUANWg10DY4NqQ3DDd4N+A4TDi4OSQ5kDn8Omw62DtIO7g8JDyUPQQ9eD3oPlg+zD88P7BAJECYQQxBhEH4QmxC5ENcQ9RETETERTxFtEYwRqhHJEegSBxImEkUSZBKEEqMSwxLjEwMTIxNDE2MTgxOkE8UT5RQGFCcUSRRqFIsUrRTOFPAVEhU0FVYVeBWbFb0V4BYDFiYWSRZsFo8WshbWFvoXHRdBF2UXiReuF9IX9xgbGEAYZRiKGK8Y1Rj6GSAZRRlrGZEZtxndGgQaKhpRGncanhrFGuwbFBs7G2MbihuyG9ocAhwqHFIcexyjHMwc9R0eHUcdcB2ZHcMd7B4WHkAeah6UHr4e6R8THz4faR+UH78f6iAVIEEgbCCYIMQg8CEcIUghdSGhIc4h+yInIlUigiKvIt0jCiM4I2YjlCPCI/AkHyRNJHwkqyTaJQklOCVoJZclxyX3JicmVyaHJrcm6CcYJ0kneierJ9woDSg/KHEooijUKQYpOClrKZ0p0CoCKjUqaCqbKs8rAis2K2krnSvRLAUsOSxuLKIs1y0MLUEtdi2rLeEuFi5MLoIuty7uLyQvWi+RL8cv/jA1MGwwpDDbMRIxSjGCMbox8jIqMmMymzLUMw0zRjN/M7gz8TQrNGU0njTYNRM1TTWHNcI1/TY3NnI2rjbpNyQ3YDecN9c4FDhQOIw4yDkFOUI5fzm8Ofk6Njp0OrI67zstO2s7qjvoPCc8ZTykPOM9Ij1hPaE94D4gPmA+oD7gPyE/YT+iP+JAI0BkQKZA50EpQWpBrEHuQjBCckK1QvdDOkN9Q8BEA0RHRIpEzkUSRVVFmkXeRiJGZ0arRvBHNUd7R8BIBUhLSJFI10kdSWNJqUnwSjdKfUrESwxLU0uaS+JMKkxyTLpNAk1KTZNN3E4lTm5Ot08AT0lPk0/dUCdQcVC7UQZRUFGbUeZSMVJ8UsdTE1NfU6pT9lRCVI9U21UoVXVVwlYPVlxWqVb3V0RXklfgWC9YfVjLWRpZaVm4WgdaVlqmWvVbRVuVW+VcNVyGXNZdJ114XcleGl5sXr1fD19hX7NgBWBXYKpg/GFPYaJh9WJJYpxi8GNDY5dj62RAZJRk6WU9ZZJl52Y9ZpJm6Gc9Z5Nn6Wg/aJZo7GlDaZpp8WpIap9q92tPa6dr/2xXbK9tCG1gbbluEm5rbsRvHm94b9FwK3CGcOBxOnGVcfByS3KmcwFzXXO4dBR0cHTMdSh1hXXhdj52m3b4d1Z3s3gReG54zHkqeYl553pGeqV7BHtje8J8IXyBfOF9QX2hfgF+Yn7CfyN/hH/lgEeAqIEKgWuBzYIwgpKC9INXg7qEHYSAhOOFR4Wrhg6GcobXhzuHn4gEiGmIzokziZmJ/opkisqLMIuWi/yMY4zKjTGNmI3/jmaOzo82j56QBpBukNaRP5GokhGSepLjk02TtpQglIqU9JVflcmWNJaflwqXdZfgmEyYuJkkmZCZ/JpomtWbQpuvnByciZz3nWSd0p5Anq6fHZ+Ln/qgaaDYoUehtqImopajBqN2o+akVqTHpTilqaYapoum/adup+CoUqjEqTepqaocqo+rAqt1q+msXKzQrUStuK4trqGvFq+LsACwdbDqsWCx1rJLssKzOLOutCW0nLUTtYq2AbZ5tvC3aLfguFm40blKucK6O7q1uy67p7whvJu9Fb2Pvgq+hL7/v3q/9cBwwOzBZ8Hjwl/C28NYw9TEUcTOxUvFyMZGxsPHQce/yD3IvMk6ybnKOMq3yzbLtsw1zLXNNc21zjbOts83z7jQOdC60TzRvtI/0sHTRNPG1EnUy9VO1dHWVdbY11zX4Nhk2OjZbNnx2nba+9uA3AXcit0Q3ZbeHN6i3ynfr+A24L3hROHM4lPi2+Nj4+vkc+T85YTmDeaW5x/nqegy6LzpRunQ6lvq5etw6/vshu0R7ZzuKO6070DvzPBY8OXxcvH/8ozzGfOn9DT0wvVQ9d72bfb794r4Gfio+Tj5x/pX+uf7d/wH/Jj9Kf26/kv+3P9t////2wCEAAIDAwMEAwQFBQQGBgYGBggIBwcICA0JCgkKCQ0TDA4MDA4MExEUEQ8RFBEeGBUVGB4jHRwdIyolJSo1MjVFRVwBAgMDAwQDBAUFBAYGBgYGCAgHBwgIDQkKCQoJDRMMDgwMDgwTERQRDxEUER4YFRUYHiMdHB0jKiUlKjUyNUVFXP/CABEIAu4D6AMBIgACEQEDEQH/xAA5AAEBAAIDAQEBAQAAAAAAAAAAAQIEAwUGBwgJCgEBAQACAwEBAQAAAAAAAAAAAAECAwQFBgcICf/aAAwDAQACEAMQAAAA/jUPonnAURKAAFBACUAAlABKAAAAAQFABIpQCVAUEBUpAAUKCSUUCKAAAAJQBAUAACUAAAAEsKlAIoBQJSggAEIWipSBCywoAAQAKCAUEAAEKQoAAAAAAAAAAAQFlEBQAEoSgAAAESlAEKAAAQoJQAAAAAAABQAABEoUAAKCABCpQAAEBYoAABEUAAAAAJaACAAAAAAAAAAABCoqgioAACgiUJQAAAJQQoAACUAAASlAAAABAUAKlIBEpQJQAAAlAAEBQQAACUAAAACUAAAAAAlLAlAAEKQoEoEKAAABKAAAAABCgAAAAC0IAAAAAAACiWAAAJQABAUCUAAQQoAAAAAAABCgAAAAAAAAAAAAAAASgCUAAAAACUAAJVAAAAAAAAAAAACggAAAAAAKCAAAAQAFBAAAAULJSAACUAAAlAAAAKCAAAAAAAJQAABQAQAAFAAAAlAAAAAAAAKCAAUAEAAAAAAAAABAAAUAKCAQAFAABAUEAAASgFBAAJQAAlFBAAAAUEABQAAAAAoIABQQAFBAoIBQAAAAQAAAFABAAAQAFAAAABAUAEAC0IBAAUEBQAAQAFAAAAAABAUCwAoWIFBAAAAAUAqoqIAKCABSKIAsAAAAsCAAAAAAAoIAAAAAAAACgQJQsCAUAAAKCAAQFAACggCwAKgWCwAULBZYKCAAAFgsUgCqiolQsKpAWIoJaiolgKIUgoIFsipYEFqCLCgAAlBABVgQAKAACAoAIWKAsAsgUhagUJFgpAFBFhagAFqLAIFJSiIsABZVBIoBREKoAIiiUtEiksolikSqSwoIoiiKhKqKIoSwKIoliKirHFHLdWYtq6aTcmoNtqDbag3GmNxpDcaY3Zpk3GmXcaQ3Wkk3WkXemkN26JN6aNN1pZW7bX58rkjJYpFgVEqWABLSVQRQAESlJURSylgQAAFCS0WBKAFgShQIACykgUCggAAACUAAAE1MN/Pq47OGWny9z2s6vzPN7La2cXwl98uHgXvy+Avv1ngH0AeAfQB8/fQKfPr9AJ8/fQR8+fQh89v0G189fQx89fQh89v0IfPX0Knz2fQ1nzrg+kaWOfzrg9z0+rmdBt3Unbdg0tzPGjZxgIoAAlAIAAJaBUqAAslFBAUIACrAKIsgKAFiKqLIACgAQFAAABAAVhdPi9rhs8na8P1Ov2m13fb+K4PQbftey8n5rsPcbvJ4fgH0K2fPX0G189v0Gp8+fQR8/v0BHz99AV4C++L4F78eBvvSeBvvR4N70eCe9lvhL7tJ4R7seFe6V8/6z6fpS/H/ADn1/wATxuZ846r3HSdX6/x2t6Pq+n9vM9Hc5vk8hyuoABRYgsBQgKAKIsgKKJQiwKIoioilCwIAACgAAhKAACUCggKCAAocWnl8O9y955T7Fob/ADc3Pw2+76zuPS/J++9n4n1vb+H9PudVsb+Lv3RputIbt0abrSG60RvNKG80RvNEbzRRvNFW80Yb7QG+0Eb7r1dg68bmnhrHWeN9P5PRyui6Tvep6f3XQ6Pc8XmPrXmev9j0PCus4+X1vxoNvFAlIASqlBKEqJSggACxSAAACioiwqAAACxSLAAKCAABSAWKCCwAOPvfPfSu17TseXyv3LzvFz6Xf+G7XsOi2/V/GvTek8H2Hb+B+i8/gObbwvdvDLPcvDD3M8OX3Dw49w8OPcPDj27xA9u8OPcPDj27w49xPED288QPbvEI9s8TD2zxKPZ8HkeA77z2r1+rm7HXYavUe/nPpb/k/s271Hq+HofdfKr2/S+s+DZj0HzkAWsaQAAAWAtQQAKRYAAAVBRQQAABKhQARRFCUAJZVSwFRUQFQWKcftfHfQvBfo30Ghv9F1P0bqNHLr/SfKew5upz9P8AK+52/OcvYeH9Ry+Y5LxPSvOWz0Lzy30LzyvQvPF9C8+X0Dz5fQToB37oIegnQD0E6Ad+6CJ6B58egeeSegeekeheekd/xdHx4u31Ot4pyez4tHDge63+w6HsfMfU/Z7/AEXeeb+seK8d9B8B3Xy+2X3X56lKlliKJUBaiolQsUiwKAoIAATIQAFQWAAAALUVElAAAAAAEpQQAlkzv0L537b51+m/R+b3Oh095pdflo978x2bou+8Pvcuhzczz+/yanM2894E3bDgTLYa5lsXWsz2GuZbN1Uy2mqXaapdlrE2WtDZmuY7DXXHmcMY804lx5ZxLhlxNe8fLj4eFx9xouH6Psex6LsOg91670fie96L6bPAex8VyfOcw+ifmgACUAAoSKAAAAqoIsUSiLBQirUpJSAAEoSiUolgACKIUlAKSoASiTKTZw+v8f6/55+kOXpe56THmdVo7en2/gOLLj+4cnX80/Rn6k7f5f8Asr413P06+a+sfMX05jt+Yvpw+Yvpw+Yvpw+YvpyvmL6cj5i+nK+Yvpw+YvpxPmL6cPmL6cX5i+nI+YvpyvmL6cPmL6cX5H87/T+PI6n+bHgP6xflD335o/I6PffmLY3tDe6j0/d910nddP8AQeHx/r/Ibeu2Ev0L82pRKELUVEURRFVBCgJSkAAJQAAAAURRFEVUWQKRYFgAAVUURZBSQKAlkz4PXeQ9d89/SHL0nd9JjzOn093R7bwH1H+h/gfo3x799zZ1u18/9R973v0P1XpfjnxJ9ubeF8Rfbh8SfbifEX26HxJ9tp8Rfbi/EX24nxF9tL8Sn28nxC/bofEn20vxKfb4fEX28fEL9tHxF9uHwT5j+ufzH1ntPHK6X6B+Pfyp/WH+X/1z8P8AS7ujveo+Id13XR931H0Di8h67yGzgbKvoX5tgAsBQAgAKLIAAqAAAAWosgolKCQKACAoAAAAAAAEBQAEsmWt63yXrPnn6P5ul7npsed0/sPH/ZtnXfvXteu3/hv9HOs2NbHLf9Y7r4a53n/uT4cy1fc58OqfcHw8fcL8PJ9wfEB9uvxG19tnxIfbnxKJ9ufER9ufEYv2+fEZH298Qi/cHw+H3B8Pi/cHw8fZ/lvUNHZ59l1m9xefw/iT9wflf0fyb8a72hvfYPwX3Pd9H3fUfQOLyHr/ACGzgbQ+hfm4LiCgAAAAAAJQAAAEAoWAoIAAAACFigAAgUAAAAAAlTLU9Z5L1vzz9H83S9z02HP6j7V8U+1YP3lnhfin9E9fh5eHPk6c18cuTu5auabOetzseTLjzxwyRJlljnccrOWa+NmswmclwmWLKY5S5SQysIxjHLKYY8WWfLx8fDjls73T9om1s6m1jw8/zH+m/wAx958y/GO9o7v2b+evc930fd9T9A4/I+t8lnwdov0P83QXEAAAAAJQQLQAgEBSwAAKWKSKAUCKQAACKAAIqyKiKpKiKqKIqZaXrPJes+efo7n6buOmw5/Tfa/in2rB+88o+Kf0U1uHm4c+V1fHnxXm8vNr8zDl59fmyw5eTjzw10Mc+Hn1Jf7e/iT94/XPrf8AND/PNh/bj+Y/g/19+f0vR/Z5jmwvDjy4s+PDkxuzES445YZZ8PHnx558fFnxYbL2nVdrMdja1dmcLP8AMX6d/MXefMvxfv8AX9h9l/np3PddJ3fVe+4/Jes8nnw9qy/QvzfFXCKoJQQLUqIqyKliiUEoigAsAUApCliiKEoiiKIokyEKSZQTIY2wiiMokURSxlCUl0PV+U9V8+/RWx03b9Nr7HqPtXxT7Xrv7zsvxX+imtwc3Dny+p4ObWvO5+bX5WOxy8HLlq2eTj5MNVsrHPQ3+vZf3H9t4f2/3n+UHe+h8Dz7fPfn/wDmt/crY8l9q/z1v6N/z8+fftPp8M3A9zw483Fjs4mWLZOPPiyz4eLk4rs4+LLjm3LtOo7eYbWzrbM4Of5h/T35h7v5l+L9/r9/7N/PPue76Pu+q97h5L1vktnE3C/QPzklZYRRGUIolsIolCUCiKIoiwKIoiiKAKLQQFBAAAUElACKEoigICoolAJeu9T5X1Pz79FbHTdx02rsOn+1/FPtevL96WX4p/RXV4Obg2cvp9Xn1M+fs83Bz4zY5tfny0bXJw82Gm5Y5Mcuu7HrGf8Acf3Hhfdfdv5R3Kcm7qMdvhw14+r8zr9jjp/mn+Nf9DXxjxH6a/iVx/oD4B4b9gcGOWOjvcOHk189uHFnrts4cuGb+Xt+l7i6d3Y1tnXwc/zF+nfzD3nzH8Xb+hvfZf54913fR931fvsPJ+s8pnxdzLHL6F+cwy1gAAAAoIAACgAAAABQRQRRFACUJRKEoRRFEoRUkURVsVAJFEUvWeo8v6f59+h9npu46bV2XT/bPiX23Xn+87L8V/otq6+xrZ8rpNXZ1L2Oxz6uxZtc2vzOPtc+tsTTnYmHJ1nZdY2f3D974H3v3b+UfJycPJn0/LhJrY4XHksu68J+F8+2/pl/GD8lz5r+wPdYzi8R+nJr5cGW2cN4JucLjy3c3ddF3k0b+xr7GHX8n5h/T35h7v5j+Ld/Q3vsv88e57rpe66z3mPlPV+Uz429Zl9A/OkVnglEogSxRKWRSxRFAAAAAAWhIUBIAKSZQCAoISiKJQlCKIKFIoiwAsI6v1Hl/T+A/Q2x0/b9Rp7PpvtvxL7Zr2fvSx8V/otrau1qZ8votXY1r2PLz63JW9z6fPNG3taW1dOwxyw0uv7Drbt/uH775/777v8AyizvHeT0/JOL4bOX9r/KX4I/HnR/efvf524dvxP6NfRPO+p6L6P7OavPwfQY8GfBMsOHLhvIxxYzLl7zoO9aez2Nfnx63k/MX6d/MXd/MfxZvaO99l/nh3Hd9H3fWe8nlfVeVz4+9ljl9A/Oot1RVRUQtSgAAlEUACxioCooAilBKttxZQihKqKiTIRamKlikiiKqKiKIoiqkyRjMxiyHUem8x6b5/8AoXZ6jtun09n0/wBt+JfbdWz95j4r/RjX0tzRz5XQ63Nw59lyZ8WcbGxpbDDd2NHYcff5dPYmrl6rsujmz+5nvfAd/wDe/wCT/ovn342/mrx/f/tr8BeP2PDfp3j2d7uOg+g9d2+7u8T0k7Li2eL6Hs9rrtnXsvFOFlOK4zZMDJn3nRd3NXb7GvsYdZn+Y/03+Y+7+Zfizf0N77N/O3uO66Tuus948t6ny2Wjfzw5PoH53xtZ6YoiqxtRJkIoiliiTIRRGSsWUiUEoigsCrSliiMokUsZRIpYySYqtikiiKIoiiKIoikilijpfS+a9J8+/QOz1HbdRp7XqPtvxH7dq2fvNHxb+jGv13Y9ZlzOh488NnPZYmXLycPJhNnY0ti693l1Odo5PLeh81cv6a/zz+D9L7/8v87Z7roPo/Xd1v8AZcD1Orvc/NxfQYc2XJr595MeTDk8vLwZRlxsFYJQlmXcdN28w7zZ1tjX1uf5j/Tn5j7r5h+K9/Q3vs387e27zo+7633Ty/p/MZaew5OPl+gfnmK2aooiiUIoiiMoRRFLFJFEUsURRFRFUBVSxRFEUkURRFEVUURURRFEVUURRFEURSdH6Pzno/n/AN/2eo7bqdHa9P8AbviP23Xu/eY+K/0Z1uq7Xpsub0uFwz5fJFuV5OLPG82xqcqbuWpm1Xoe00Mp4rq/bafO8n1/Z8+1q7Hj5+Tl09phyZZYcnG023PHLFUQxkySpTCxry7bqO0j0OzrbGHW8n5j/Tn5j7r5h+K93R3vs/8AOzt+66Tuus91fMem8zdXY8vHy/QPz2lZ6UoiqiiUIoioiiLAqoqIUiqipYqoqSKDJLiyGLIYsoRkMWSsWQxZDFkMWQxtGLIYskYrTFkrFkTFkMWcOh9F530Xgfvmz1HbdVo7bpvq3ynl29P/AFXvlL8P/qD33RdP1ueXa4+ex28b0mXmi+lvm8pl6W+asy9NfMl9Fw9HhcO34esmXH7bm6TJl3uXR3Hd3zoTPv3QF9A8/E9BPPk9A87E9DPPS4ehecMfR73jtybPo2/877bTv9j+Tf0b+DvTfD/k+/ob31j8Cdt3XS911nunmvS+auvsubi5vf8A59jKZ6ZMlY2jFkMWQxZDFaYshiykRkMWQxZDFkrFkjFkMWSsWSLQSiKIolAABKIoCgAgAKCAoElDz3ofPeh8F962up7XquN2/T6G/wBf2Xh/1R9v/nV+xPnv7D930vX+V6L6x6bD59xdj5L6Nl84V9IvzezL6Rl82sy+kvm9l+j35xZl9HfN6v0e/Ny/SHzen0h83h9InziJ9GfOFn0fH5zLj9Gx+dRh9GnzrGz6K+crh9H7D5V3GrmfVu4+c9p1ftN78E+l8t9V/CW3vaW72nzntu66Xues91fN+k83lh2nPwc/vvz8GeiKAoAAIAAAigCKIoigCKAAyBQQAFAAAAAAAAgKAACAee9B5/vvA/dtzqe16njd31Ohv9f2PhdKXR5vQfeu/wDyzydB9Q+8aXyXJt+s35LGP1t8kL9cfIx9cvyIv12/IR9dvyFH158hH158hH158hH158hH16fIlfXZ8jJ9cfJB9afJCfWnyUfX/T/nnSw3/pH4b5Dn7Hwm/uae53Pldzd0d7rvSdt3PSdz1nueTzfoPN3X3HPw830D4AGzQCggAAAKAAAAAAAEAFJFWxRFiFAEUsoiUsWCyoQAAAoAIAEvnOy6/Dxn1n0HXTT4HpODR5tLn+R4tLn1Of53X4OXheeDDWAAAAAAAAAAEABQAADY4eXOb23123v7zsN3qtvrfSd32nn97r/Xdh0Gzp7OF6unuvi4UFAAAgBRFhUolEURSxRFEURRFIoRSRkMaAEURRFigARYAoQJFYoymMM5iMmA67z/AK7xHRes7bi03S+tmplrcrpMdbLh53nuPjzx1dTBKAAAAAAAAAAAAAAAW2XPG5Ycuzp8u3sN/Z6/Z4fpO02Os5OF3nPv9B7Lsug37x30fis2Cs7gM2IyS0FABSwUIKJRFEtJAJkXFRGQKQBKIpIoiiKJLVxWEUslihCMcFklWItYyXKYxc5hDk873vHo5XiMsNfzfrObgcO3iY8OXFu6DKS4cYrKYsmNkyGLKVFSxamLIYrTFkrFkMWQijG0RRFJKpKZSpC8nBnN21saXPj3u21s+P2Hb+w0Nr0PmeW8V5XB5XHTkYVM2NsuWFTO4ZFFFZJVQoFYxRFEUsURRFEVBhbjkxGTEZMaViMmIySLkgrGoQIrLFZLMc8cbjLiSMZmkxWzHHDZnjhjM+ScOOOev4z3PU8HneXwcPCxsxuvrrYSpDKSGTFLkxGTEZMRkxGTEZMRkxGTEZMRkxGTEZMRlcLZlcLZlICTHLmz1+TbzOf12h33M37V1sufwtjLgyy182XDllhy3jyuHJcMrjnccrhcpkgZLYsyQxyYjJjSsRkkXJiMmJMmMM2IyYjFGXGopcUVBURbirJiMmFMpEZSCoKxS3GxZjlFxw5cZlxY8kl4cOfixz4cOXiw3cfHlr6t9w1tPTzb53ucOJt6JuafD4RGGNQVIZMRkxGTEuTEmTEuTEZMSZMRkxLkxJkxLkxGTEZMSZXEZSCm3llwei1eTmc3vOTptrma+z5dPn28PZz4ubbxss3Js1TPK5a5lcrisrG5Y2rcRkiyosyYjJiMpBbiMmIyQVBUFRWCsMIyRiyVitjFaYshiylRkjFkrFkMWQxZDFmMGauNySOOco4cdgy1cNyY3Q4uykz6fW7/AI8OR5nV9Xw6uT47S9xxadng+P3eGjHwuPuePDLxM9pMb4x7FHjnsZJ497AeOvryeQevh5GevHkXrknkXrh5F66r5B68eQevtvj3sB497Gr42+yzyni77Xkyx8Rye35M54/b9Tyci+d2e/5tuvpdrts9vH67l3rno1eTYXDhvMuPFeRZhchiyGLIYskYslYsoRRFEZIxURkMVVFEUFFZs88WQwcheNyDjuYwZlwZjBmMWRlizGDOy8dzS4OQvG5KvG5LMuJyl4ryWZcTms28V5ctfM4Mdia+Vq8e3i1aWO7M+PotxdWk2yabcLptwuo2zLTbiNSblXTbkNRtl1G2NRtjUbZNRtk1G5DUbazUbVTUbazUu0TVu1Y1ctms+DPmyx5PHly2beKc+OfH4HPNnD4ZzLp4XKuPFOUx4nIs42azjZkwZk43JLMGYwZkwZkwnIONyQwchONyQwZkwZjJlceRgzGDkLxuQcdzS4OSLizLiyLiyphci4sqywuSXG5VlgzLiyTKMrM8Lnljv48s2vlRnnq7PinM18/XnOTXx2F1602Vx1ZtLr1WyYazZpqtouq2hqtoaraGrNsajbGo2xqXZGq2hqtoaraMdVtDWbNXWbJlrtlM9e89ODLlyl4nMZ8Lmwz4nHhzNvW8M5cdnEwmcy04zNcMGcYYMlxwZrMJmY4M4YsiYMycbkJxuSJhORXG5Ccc5KcbMmDMmSpsBUyEUsURSxQLMopSlhWUqzIFLlNmNtmctuO9cmvlTK56+djblp7zBm1dtg5bq5fC2MtPI1G4l022yx1G2TUbitRujSb0NJvU0G8s0W8s0W9DSbqNG7iZabcGnNwabcJpNwabbLqXbY3UbQ1Wzhnr4XLjv4eDNs4uE5cM+t4nJhu6TDHlw2cDjZzZxuNyS6sGUy14M5cMVJiphJlGMUkVZFEURSSZCBCwBKEBRVgClili1YpSlimUUqrM5WWOwqZrWO9lbr5ErPDnMq19qtuj0K58nC7bDPPk4nP4sufLRzte7Fx3azZq6t2hrXbymepd3ObNG9hnNnW5dlmy6rLtKvU3tbXUzt5L1Dt8I6rHtonUTtZceqnZ4NfXTfwy16Tblw021GOs2RrTaxuOrhuce3i6eG3x8nrtZzYcrhccznK6fHDkm7ouGcmOzquPHlmzh8czxz48mUurBnjlhJV14qSKY4slxxmRjioikikiiLEBADIkUS2BTKKIoimQMhQVnLbMoyk2Lcsc8clx3TNlhyJVw5bNnh2MtunuseScvF9BeS58DtpyuXi9pM8+TjdnxXmyw5XDeazPhy5c5nxZ8nJjv4s+Tkx3cWfLy3PX5OfOzWu1llNRuq05u4Rpzcxxz0+PdwjV4t7CNPDcwY6eG3hdOpjuceWnVc66tZzrhr4bWGWvVw2uLdwNXj2OPldTrY7GHL63WnNx83qsFcjz3HhzYbOo41bOv45yYZ8bCZzZxsJky14quOMyMMRcEsQEimMUkUkUkmQxWmKksBQAVFoWKWFUVlFMllZspksq47GUuO1bcN9tY8iZTPXz8quvs7a1d7efi5uB3ufJjy8Ht8uXDn4vb553k4nc8eeeWHK4ry5TPjzyzx24Z55TbhyZcjZjlycjLHPk5MnHlsXZjwXYWa2O3JdObWGGWljt8eN1eLc441cNrjk1pz4NfBjzS6tebGGWrXx2Jlq4MdjG69fg2+Hd1+px8/HzOk4OPn4uX1XBxc/Fzuqxx5MeX57DHObOm4Vm3rpjmz4fEsz4+LKZacJky1Y45y44rGGNGCUxiiFYxRFIlEmUSKAoWJRQtCAVZWQrKMilMrZkzKw2jLHbcplhyLKx5V5MM9fOuTLX2y1o7/Pm4ufgd3nyY8nB7fPY49jid1ycrk4ffYZW4b5cs5twzyym1llnN05HJM3LORleScua5XkyYOUcePPiutjs8eN18OfjjW4tvhxa+GxhMeDi2eNhwYbGGWrgnLjdXFOSZaePHll18Gvua27r9Ph2eDnee4uLY4uV1OvxbHD2HUYY5zmdFhjnjt6Tjxzw2dWGfB48eTHLRgsz0THOZasZljlrkyMZjkY4sokljAAGIIBFWRQFgQKoKUsZJZVZY2lKZFrJSbC3DYymWO7Ky48hZlhyrnjnr7K5zLX20yXR3/Jy8fN1/cZ8vHycLuObZ19rh95sZzLhehmVTfcmWG25OSbnJMsd9znJN2XLjy3K8vHy5Y5545bNNlWJTLj4+Xjwyw488cdnFhy4Y3g4+fCThx5cGriw5sMtXDjyY5aOKZ43Vxs8c9GOtt62zhafBs6/P8zxcfJhy+o4eDY4ud1PErndDhhyY7ek48c8NnV4q2cHHDkxvG45njnoxWZ6mOUuGMzl1YqY4rGMUmLIxxUkmUIssLAClyxlIS2UWZSgWWlSisixlkGyrJmyrHbauO62XDezlx5mWeGWvsc8sctfbMpeP3/Ly8XLwO45ebh5+D3PNs62zwu+2eTHk4XosM2WO65TKbcs5nhyJySzdnycPKy5M8Mq5eTjzz18+WHJu0LlLONcJlMbjjlhhlxYZzHPjx2Y4XjwyvFyYMZhni1cePJjlp4ceXHLRxMmWvj1trW3cDU19nW7Dy/Fhnx8vp+Ph5uHm9VgXndFhhyYbeiwxzw2dXgrZwMZljlxsJnM9GEyl1QmeuTI14MowkpjFEUxkyJissixIyEUn//EACoQAAEDAwMDBAMBAQEAAAAAAAEAAhEDEhMEEBQHFiAFBhVgFzBQQAig/9oACAEBAAECAP8AwCn/ANNBJq5s2bNmzZs2bNmzZs2bNmzZs2bNlzZcuXLly5cubMKwd9Vc81oFJtAabjcbjcbjcbjcbjcXi8Xi8bi8Xi8bi8Xi8Xi8Xi8Xi8Xi8U6V2mdQLG1G1PqJLqgYyjT0zNIzRN0PB4HA4PA4HA4PB4HB4PA4HA4HA4HA4HB4HA4HA4HA4HA4B0D9FU0lTTPoljagP05ziWU2UadCjpqOkpaJuh4Hx/x/A+P+P+P+P+P+P+P+P+P+P+P+P+P+P+O+O+O+O+O+O+O+O+O+O+O+OPp1XQ1tJX0tSg+jUpAtd9McUynSpU6VGjQo6TTU6LaWLFixYsWLFixYsWLFixYsWLFixYsWPHix4sZp1Keso16NajVpVab6SafpZVOi2lTZSZRbQGkTEPCfCfCZ3mdpmZmZkl61aris2qyox1KrRH0t5oUWUbGCmqRou0r2VBUyZMmTJkyZMmTJlyZcmTLkyZcmTLlyZcmTJkNR9TVVKz6pqJwsfRr0WfQj5lUWabTuouALHU306mmrjVDV8vl8vl8vl8zl8zmczmczmczmczmczm83m83m83m83m83mnWu1mp1FSo973FMDKOq09Zn0hy0dLTUagrG5r21GVmV21xXz5+RyORn5GfPyM+fkZ+Rnz58/Iz8jkcjkcjkZ+QdQa7tQ+u+s6o591E0xqaWspN+kNWipgV3VXFweKgqtrCuK+fPnz58+fPnz58+fPmz58+fPnz58+fPnz585rmu6sauQvDqTqDnDXM+kacaFpOqfUc54ffeKoqirly5cuXLly5cmXLly5cmTJkyZMmTJly5c2bLlNU1cmQva+k/SvB14q/sH9zSLRF7tS+o9z777w8OBuuuuuuuuuuuuuuuuuuuvvuvvuuuuukuLi+8Pva6m/TVGv1rtQf7EftK0h0731q76ji668OBaYhRER/hiIiIgokkm64OpuoPbV1L9QfoxWmVFPNY1HFxdPpXo/pPRzS9LPxz+Ovx1+Ovx1+O/wAdfjr8dfjr8dfjr8dfjr8dfjr8dfjr8dfjr8dfjr8dfjr8dfjr8dfjv8d/jv8AHdfpl6p0c9f9ouMgg0zRTFXWo/2H+WVplRVRVlUTtvY3Tz030tRbbbbbbbbZbZbbbbbZZZbbbbbZbZbbbbans979LSE1U1STFXWo+jlaZUVUVZVE5ew/aNGiqVPQ+2Ozuzuzuzuzuz+zuzuzuzuzuzuzuzuzuzuzuzuz+zuzuzuzuzuz+z+zuzuzuz+z9R7R1el26q+y01U1RTFWWo+jlaZUVUVVVE4+yPb8LRn0Z8zN103XB111111111111111111103Xap3rTyo1Wl9d9ICpqimKutR9HK0yop6rKovZnpwDmFUn+n+4u7O7e7O7O7O6+7O6+7O7O6+6+6+6+6+6u7O7O7O6+6+6+7O7O7O7O7D7s7s7s7sr+6dXXVFtZvWf05qpqimKutT9HK0yop6rKoukrKarPV2XLlzZsuXLky5MmS+++/JkyZMmTLly5cuXLmy5blQdqD1qY1U1STFXWp+jlaZUU9VlUXSNBOJJLqwrCrkyB0qZlDymVMztNxflNU1hXa4FpcutSaqaopirLU/SNMqCeqyqLpEgnIoqomobBDxAAa7aIhR5FFHY7BU0E1Fdak1U1RTFWWp+kadUE9VlUXSJBORTlUQQQQTfLUP8ATOmfvz/np7N4RHidiiiigqaCaiutaaqaopirLU/SNOqJeqqqLpEgnIpyegggQgUPDWn2dq6Oq989J/fXR4eJCO5RRRR2CpoJiK61pqYqKYqy1P0jTqinqqqi6RIJyKcnoFBBN2Gw21x9rJp0/qDKnv3oB7s9kblEblFFFFFBUkExFda01U1STFWWpQ+j0FRT1WVRdIUE5FPVVBAhBBBDYba5e1N6dSh6hr9B79/5v9U9K2IKIRTkUUUS1UkExFda01MVJU1WWpQ+j0FRT1WVRdIUE5FPVRAghBBDcba5e09wFS1FDW+6PZ3vz/nshEHYpxKJKKaqSCYiutaamKkmKstSh9HoKgnqsqi6QpqcinqqUCCEE1DYba5e0dgAIIVDW0dV766S++ukMnYokooopiooJiK61pqpqkmKstSh9HoKgnqqqi6QoJyKqKrsCC0hMQ2G2uXs/YIbFHZrqHqNT1XrLRRTnEuJJJLFRQTUV1rTVTVJMVZalN+j0FRT1VVRdIU1ORVRVSC0tITU0jw1y9n7BAyiSvVPWff/AF+9wdQvRq0uJJJJJJLDRQTU5da01U1STFWWpTfo9FUE9VVUXSFNTkVVVXYIIIIEHfXr2d4StRqffPW33n1ZrV9NT0aY8kolxcSiWGiQmpy61piYqSYqq1Kb9HpKinqqqi6Qpqciqqq7BAtIILSDtr17OKmXP939Uff3XLXepBrKOm09FtBxJJJKKJaaGzU5da01MVJMVVahN+j0lRTlVVRdIU1ORVY1NggWkFpBaRt6ivZqBXuH3l1D/wCgfV/cgDKVLT06FOmwUSSS4kndq06CaiutaamKkqaqrUJn6Y/dH86kqKcqqqLpAgnIqsqm4IIcC0ggz6hU9mL1T1nqB/0B7l9/y2nSoUtO2kxjWhMMlxM7hachNRXWtNTFSVNVVqEz6PTVFPVVPXSBBORVdP3BQLSCHSXa1+p62e8+rtXUMZSoUtPTotYGtaEEDJJKO4WnITUV1rTUxUkxVVqFT/iH+HTVFOVVVF0hQTkVqC7wCCCaggXmufU2Np06FLTU6DKTWhoaBsFJKJ3C06CaiutiamKkmKqtQqf0emqKcqqqLpCgnbaglDcbAtIU1HVlrNPT01Ogyk1gaGqPCUT4BachMRXWxNTFSTFVWoVL6OxUU5VU9dIUE5FalO8QQQ4OuqF4qUxRawNAAjceE+IWnTU1FdbE1MVJU1UWoVL6OxUU5VVUXS/VhznPq1q5ffffcH3h+TIXlxJQIIddfdN1xffddffffeH0atKu1xd1t1jUxUkxVFqFS/jRtG0fojwhRtHlDVRTlVT1oNfp/U6muqah+pdquVyuVyuVyuVyuVyeTyM+cajkcjkcnk8nk8nlcrlcnlcrlcoapmpp6ilrOb1L9ZamKkmKotQqPhEfujwjeP5IVBOVVVE5dNfcb61XUVdW7Wczmczmczmczm8zmczmczmczmczmc3mczmczmczmczmczmcwaynq6Wpp1/c/uI1GJipJiqLUKj9HCoJyqqonrSaz0D3RqK9fVv1vO5/O53O5/O53P5/O5/O5/P53O5/P5/P5/P5/O53O53O53ObrqGs0+o1PqvuX3G1NTFSTE9ahUPo4VBOVVPT09afWene+6+qrV+RyeTyeTyeVyuVyuVy+VyuVyuVyuVyuVyuVyuTyeTyeTyeTT1Glra33f6v6+xNTUxU1TT1qFQ+jk0C5VVUT09PRVLVD1j5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5f5c+sVtfLU1NTUxUlTNR2odRH0auqLy+q57nlxeXfxWphaWuYabmPqVKrmj6NrxSqZKj3ucXFxd/ECCaWlrmuY5tSpUpD6HMqdexjw9z3FxcST/ECCBBBaWuve/wBOZO8/258nB4Dy5ziXEk/w42CBBaQ4vc7S0vGZ/uTvPqVEOuJcSSdoiFCiN4UKIiFEKN4iIjyaQQ4u0NFTP9Q/tmZUvFencSSST/rn9Uggg3NGnpTtM/35mZmdXQci4knef98zO4Mg6HTTMzOw/lTKnaf1Eo7EzMkl2r07hM+MzMzMzMzMzMzMzMzMzMz5TIWj0t03TMz+2f8ANP8ApIR2JJJLi/UUqjP5TGaegHhwcCNhsB/IlTMzMzMqZneFEFEEEFOLi95e4voHeZUzMzMqZmZmZlTMzKmZmZ2kJlBqDm1GuaQgAAAIQ85mVP8APiItLbDTNM0XaZ2kdpHaZ+nOlOnw4seOyyyyyyyyyyyyyyyyyyyyyyyyyyzHiwigNMyg3Tt0jdG3SjTiiKQZbERH++P0x/iiIi2yzGaZpmmaRomgdPxzpuLxeLxOJw+Hw+HwuFwuHwuFwuFw+Fw+HwuHw+JxOJxBpeLxhpxQFEURTFMUxTFOy22IiIUbR5x+iPKP1woUREREREQoiIiIiLYttLCyyzHjx4seLFixYsWLFixY8WPHixYsWLFixYsWLFix48eOyyyy0NttttiIiIiIiIiIiIhRH7Y2j98REREKIiIiIiIiCIi22222Iti222IttttttttiIiIiLbbbbbbbbbbYiIiIiIiFEREREf4o/TERERCiPGPGN4gBRBBaRbbbbFtttttttsRbbbbFtttttsW2xbEWxbFtttttsBsQoiPGIUR5RERCj9EKI2jwj98bxtGwEKIiIiIiIttti22LYttttiItti222LYi2IiIiIjaCNo/XH7oiIiP9kbRHhG8W2222222222222222222222222222222222222222xEREQo8D/ajxjaIgC22y2yy22yyyyzHZZZjsx2WWWWWWWWWWWWW222WW22kRCjYjzj+5G8QBAFtttllllttoZZZjx4sWLFixYsWPHjx2WW2WWWW2222kFpbEbHYjaP64/QPAIACA2Iti2222wMDLAywMsssstsLLbCyyywsLCy22220ttttgtgiPAojY/vj+QNxuBsNgIAAAAi2IttDYDbQ220NttttsststLbbSLS20i0ttiLYIIIIIIIIO58CP9cbj/CP0RsABuA0BAIACAI2i0CIADYDYAAi0iLS0tIgtttIgtLYiFBBBBBBBBEbncjzP8mPIIbjxCAQQQACiLbQAIiICgNgNttDS220ttIIIggiC2IiIhEEEHYo+JH9KI8QgNwPAIAIIBoAgCIgBQBAAAAAAbFtttpaRaQQWkEQQiIIiIIIcHIogog+J3KjaP6I8B5AAABBNAAAEbQAgAIAADQAAoiC0iCCCIIggiII2ggghwIKKIKO52I/sBR4DwAGwQAAG4AEAbAABAAAAREQUQi2CCERBRBBCjaCHAo7FFHxPgR/JjwHgEB4DYDYJqGwTU1DwCGwACCCAAACA8BsdiiiCDsURBBHgU9EFFFEHwOxG58j/HjxHgPIIIIIIJqHiAgNggAhsFPiUQdiTsQQiiiiD4FOTkdinI+B2PgUf0H/ADj/ABjxG42CCCCCamoeQ8BuNgo2COxRRRRBR2O5EFEQoKenIooo/rP6z5kfsj9MIbjYbRuBsEDsE1BBBBNQ2HgBuEENgggR4Hdxko7E7QUdiCNinJyciiij4x4HeD5nxCP6I//EAEcQAAECAgUGCggEBAYDAQAAAAEAAgNRBBARIWEFBiAxUmASIjBBVXSRkrLREyMlJkBxcsMUJFBzMmKBsRVjcIChwQewwtL/2gAIAQEAAz8A/wDU3MHOmyKwR2UZI7KMkZIyRkjJHZRknSCdJOkE6QTpBOkE6QTpBOkE6QT8E/BOwT0/BPwT8E/BPT09GSYcE06jus0Jx1JxRKKKMkZIyRkjJFFGSMkZIooyRkiiijKs1FFGSKKMkUUUZIhOCe1NdukAidSJVqwRPMsFgsFgsFgsFgsFgsFgsFgsFgsFgsFgsFgsFgsFgsFgsFgsFgsFgsK7ERrQIu3PACLjoYLBGSOynbKdsp2ynbKdsp2ynbKdsp+ynbKdsp2ynbKfsp2ynbKdsp2ynbKdsp+ynyTpJ0k7ZTtlO2U7ZTpJ0k7ZTtlWcyw0HMKDhuaAEXHSZwRcmy5AVBDQCGkKghWEEEK28E3IaJaVaNzC51d+hxdIVj4AaAQ0eKdG2otduXzVXVX6HFrHx4V2hfVaKubcoudarbFwVZogDWmTTbNabNNmmTTZps02abNMmmTTZpk0yabNNmmzTZps0yabNMmmTTU2aZNNmmzTZps01NmmzTZoHRtVoVlqLX27lW2LgttQQtrx0casasVisVisa8VisVisVihNYoTWKxWKE1isVisVisVjpjhBBWstWtXbkWxFqQAVjTy+NePwuNZ0bQEC0rWrHkbkWxD81qV1V/KlFFFGaKM0ZozRRRRRRRRWKKx5W+q5C1ysij9du5O8VXK8/pJ0r1crbVxx89x7irwrAirSeQKMkZIyRkjJGSMkZJ0k6SdJOknJycnJycnJydJGSdJOknJyKcnIo8iVaFxtx7jVxUUbTo5VypSPQ0KiRI7+fgi5uLnG4KlvaHZQyi2F/lwG8M99/kszoIHDg0iMZvjv/s0gLMjopvff5rMnopnff5rMjopnff5rMjopnff5rMjopnff5rMnopvff5rMnopnff5rMnopnff5rMjopnff5rMnopnff5rMjopnff5rMjopnef5rMjopnff5rMjopnff5rMjopnff5rMjopnff5rMjopnff5rMjopnff5rMjopnff5rMjopnff5rMjopnff5rMjopnff5rMjopnff5rMnopnff5rMjopnff5rMnopnff5rMnopnff5rMnopnff5rMnopnff5rMnotvff5rMnotvff5rMyKLqHEh4sjxG/8Aaojg51AynEYeZkdoiN7W2FZwZEJNLohELmjwzw4Xe5v6ojQKvVyuXG3HuNV1V50KXl1zKVSS6DQAf4h/HGs5mSE3LJ+TaIyjUOjMgQmamMFn9TM1FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFGpj2Oa5oc1wsIItBCaGPpuRoVllpiUMajjC//KsOhfVcuNuPdVdVrrdnBlYtigiiQOC6kO2pQxi7nwUKDCZDhsaxjGhrWtFgAGoAVF7gFHjMDrgCE/aCiTCfMJ+0E+YT5hRJhPmE+YT9oJ8wn7QT9oKJMJ8wnzCftBPmE+YT5hRJhPmE+YT5hPmE+YUSYT5hPmE+YT5hRmtJBCdAiFp1itkEvyzRIdjXOH4tg1AnVFH/ANK/QuXFXG3HuquVyvNWBOA1lNyJm7RaOWj0zx6WkGcR+vu6gjZUPSNTTRYfyTUE1NTU1NTU1NTUxNTU1NTU1NTU1NTU1NTU1NTU1NTfRuQdSXnE1FQKVRo0CNDD4cVjmPadRa4WEKLknLNMoMQkmBELQ7abra7+orvVyuV+5F9d5qGUM7MkwHC1npxEeP5YQ4f9wFaU0MV64LgvQQQyzUsEZL+VYLBYI7KMkZBGQR2UdkIyR2QsAjJGSOyjIIyCMkdkIyCwCMgjIIyWARkjJGS4bCOCvSPJqBC4L02FlnJ9MDbPxEB0N2LoRtH/AA6u9XLiq/cm6rXUHZ5MOzQ6QR2sC44Q4NZRRRRRmjNGaM0UUUUUUUUUUUUUUUZoooooooozrsQJCH+EZJfZeKY4dsN1d4quV+5N1V5q98D1GP4mK9GyshHkDyR5Moo2q0VGr2Hkvr32n16qrlfuRerqrzV74O6jH8TNG/lIZe5ge0uaLS0EWgYj4S9XaHsPJfXvtP0Llcr9yL1doe+B6jH8TKrqruUfDosd7TY5sJ7mnEC0LMHKOZGS8nxci0WJAFGhkPDeDFDy2+IIg4wedpZw5JMSlZEc7KdEFpMA2ClQx4Yg7CnMe9jmlrmO4L2uBa5rhra4Gwg4H4K9XaHsPJnXvtPrvquV+5F6uGh74nqEfxMququV/J2UKk/sv8JUSFkOgc7fQQ/CFCijWs0c7WOi0qjegpvB4LKdAsZGGDuZ7cHLO/NQxY8SD+NoDdVMo7SQ0f5rLyz53hAgEEEEWgg2gg/AXq7Q9h5L699p+jcr9yLwrtD3xPUI/iZVdVdyn5Ok/sxPCvYVA6vD8IRabQbE5tgeoUVvMbVmzlz01KyXwcl055LiWMto8Vx24YssJ2mrOfNaliDlWgGAHushxmnhwIv0RJ4Gw/AXaHsPJnXvtP0blfuRertD3xPUY/iZocXlPydJ/Zf4V7Byf1eF4RW9htaUDc+5ZNynQo1GpdGhUiBGaWxIUVgex4PMQUx3DpWbMcQzrNAjvPAP7US8twDrQspZLp8Sh06iRqLSYYtdBit4LwJjmLcRaOWu0PYeS+vfafVfXdVduPertD3xPUY/iZoXcp+TpP7T/CvYOT+rwvCNGJDNxUN9xNhWbWc9A/DZUoEOkMFpY43RIZ1cKG8XtOIWcWSDFpWRnOynRBaTBsApUMfIWCIBhYUQ57SCHMcWvaQQ5rhra4G8Ec4PKXaHsLJnXvtPr1VXK9XDce9XaHvieox/EzQu5T8lSf2n+Fe7+TurQvCNOJDuN4UKKNazRzta6LSaP+HpvBsbTYFjYuAfzPGDlndmn6SNGgimUBtp/G0dpLWj/NZeYfhQLQQQQRaCNRB5G/R9hZL699p9eqq5Xq4bj8ZXaHvieox/EzQu5T8lSf2n+Er3eyb1aF4RyBBtBTm3P7VksMPpKTCAsvtcFm3A/wDIeUW5G9AKO+BAixGwSOA2O8v9JYBqtsBI5G/R9hZL699p9d4quV6uG4/GVwqvNXvi7qMfxM0Llfyf5Kk/tP8ACvd3JvVoXhHIZOybR3RaVHbDaJlUajMiwaA4N1jhrLmVqS8/iYgDjr4RTgRwnWl2snnPI36PsLJfXvtPr1VXVcUbj8dXaHvi7qMfxM0Llfyf5KkftP8ACvd3JnVoXhGlAo8MvixGsaNZJWRskQ4kOiPbEibSy1lqPE9e4g43KNGeXRHlxVr9SIAVrByF+j7CyX177T69VV1XFHy3H46uFWur3xd1GP4maN/J/k6R+0/wle7mTOrQvCNBrQSTYFkDIMF4MZsSKOYFZWyrEiQ4UUhnMAqZTIhdGiF1vMiUSVZYrFxOR1aHsLJfXvtPqvruq4rfkNx+OfmrtD3wd1GP4maFyv5P8pH/AG3+Fe7eTOqwvCK8h5EgOdSKQ3hAXMBvVIj+kgUN/AZJqynlOM58WM6w41E1BAKzlvYWS+vfafVfXdVxG/Lcfjn5q7Q98T1GP4mVXV38iKh+Gj/tv/svdrJfVYXhCydk2A6LSY7WADnKo1EZFg0FwHNwllnLMd5dGdY485TnOJJJJ5yiagNGw8hfo+wsl9e+0+q8V3GriN+Q3H45+ZV2h74u6jH8TNC5X8kbE50KMBrLHAdiyDkTNTJ0Gix2xY/4SEDhY1Zay1HiWR3EEzUeO/hxHlxRKJ+F9hZL699p9V9dxq4jfkNx/WH5lXK6v3xd1GP4maFyv5K6p3pibTYQrUTZdVZ8L7CyX177T6r6rgrjV6tvyG4/rHfMq5XGv3wd1GP4maFx5Pi1FxRkgPhLq/YWTOvfafoXK41erZ8huP6w/Mq5XV++B6jH8TOXtqtQHwl6ur9hZM699p+hcrjV6tnyG4/rXfUVcrq2wM9KEHGwRoUaEDiQHDw1sbrKaUEEE1BBBBBBBBBBBBBBBBCaCCCCCCagggggg0pjhrrb+GyPRucxYsUjBreB/wDWhcuKavVM+kbj+td9RVyurfQMoUWlstto8ZsS7nDTeP6hNjQIcRhBa9oc0zBvTiplY1Y1YoTWNWKxWKxrFWKCxrxWKxWKx0BNCdWNWKxTxzor/EM6IzQ61lFYIIlwv4naPFKvXqmfSNx/Wu+o1XaAj0A5Niu9ZRhbC/mhSH01YrFYrFYoTQmsUKsVisVihNCaxQmsUJrFYrFCaxWKxQnVihNCaxWKxWKxqh5HyPGpFoMU8SCzaef+hrKe97nPcXOcSXE6yTeToXK4q9epZ9I3H9c76jVdoUih0uDSIL+BEhO4TXKiZYofDbYyMwD0sK29pmJtKsqv1rFYrFYrFYrFYrFYrFYrFYrFYrFYrFYrFYrFYrFYoTQmhtLFYq/WredE2KiUGiPj0iKGQ2C8zwEyqRlvKHpnjgw2Atgw9lvmefRuXFKvXqWfSNx/Wu+o1XaNKokdsaBFdDiN1OaqPSGBlMaIUTVwx/AfJQ4jOEx4c06iDajbrRmnTRmjNOmjNGaM0ZozRmjNGaM0ZozRmjNGaM0ZozRmjNGaM0ZozRmjNGaNutTKybQIbg13p4o1MYbgcXLKGVY/DjxOKDxIYuawYaVy4qvXqWfSNx7I7/qKCu048E+riOZ8jYqfzxeF8wFTJt7FTJt7FS5t7FS5t7FS5t7FS5t7FS5t7FTJt7FS5t7FS5t7FS5t7FS5t7FS5t7FS5t7FS5t7FS5t7FS5t7FS5t7FTJt7FS5t7FS5t7FS5t7FS5t7FS5t7FTJt7FS5t7FS5t7FS5t7FS5t7FS5t7FTJt7FTeZ4HyCpkYWPjPIlbdyAQ4KvXqmfSNx+DSXq5XfqVytKsAG49kVrpj+1V36nw47BjuRbBt2Tb+q2ve+Qs3IBaQdRCdDiOadYP6mSV6OC0c+s7k6og+R/U/SRgTqbfuU1zS0i0EJ0KKWn9Rc9wAFpKEKEG9p3LEaH/MNRTmkgiwj9PtXo28Jw4x/wCBuaIo4Q/iH/KLSQReP04Mse/XzCW57IgkZpzDYf0tzjYAmQ7Cb3blFGoooooOF62VYf0gn+I2JrRYEUUUUUUdxwggUEVEUU8yiyUWSi7KibKfsp8k+SdJPknyT5J8k+SdJOknyT5J8k+SfJOknyTpJ0k+SfJOknST5J8k+SfJPknyUTZKibKi7KiSUUamqKnGoIIIbo4LCrBYISQkhJCSEkJLDQGlgsK8EJISQkhJCSElgsFgsFhumKwgggggmpqagmpqagmoIJqCaggmoIIIJqampqamoJqahJBBCSCFY/0JG5R0j8Gd6B/ttHxB3qHworGgP9chvrbyh/1sHJj9MG4p38PKj/bXZuN//8QAJhEAAQMDBAMBAQEBAQAAAAAAAQACEQMSFAQFEBMgQFAVMAZwYP/aAAgBAgEBAgD/AN6P+ej/AJ6P+Kzffffffffffffff2X3g/Kc6RTFHp6Ojo6Ojo6Ojo6Ojo6Og0DTJa/49Wsx1EMphlttttttttttttttpa6nVD3Ua3xaj6lfTvolvpOVdah9OvTqfE3Gt26U0S19999999999999999/Y59Y6oipt1b4msqUxplSN1911111111111111911U6hVBoanwyq6pNoqm4VO7u7u3t7e3t7e3s7e3t7u4VTUqOrKq3T/ABHKsqapqvq9b/qDun6X6X6X6X6X6X6X6X6X6X6X6X6X6X6VLedr/wBO9VVUVD4hVVU1TW87i0U9LiYmJiYmJiYmJiYmJiYmJq6C/wA5uVRVFRQ+GVVVNayogm6nLy8vLy8rKysrLy8vLy8upWWw1KiqKih8Mqqqa3HwHB8I/iVsqeqioofDKrKmtx8jwVW2zWbUolHwKK2ZPVRUUPRHp1Uxbj4hHnSFzNdsmq0UIoI8lbMnqoqSHwoVVMW48jgI86VE3Ppa7YK1EoeBWzJ6qKkm/ErJi3HwKCPOlTgA1PdvesA5PGzJ6qKkm/Eqpi3HwHjpEW26rddRq6zvLZk9VFSTfhQqyYtxQ5IQJC0Q1Wv1e5OqOqE+WzJ6qKkmeMe9WTFuKCHgeAjur6r6hcSUCh4bMnp6pJnxKyYtxQQ5PITajnE8HgDw2ZPT1STPVnieJU+IVdMWopWhnX19fX19dtlllnXZ19fWWFv+foPT1SVM8TPM+E8T5xxCiOYVdMTVvW2UqA0mJiYmJiYmJiYmJiYmJiYj9K6htG2vT1SVMRChQo9vUBiYg2rtA0ODg4ODg4ODg4ODg4ODg4Ltu0e3vT09UlT+Jq2NDAwOPotT08PFJg96ZnnXUw1gCPpgvBbo6XMz79VhYwOKj+keALxbQp+Q9iPCZrU1MzMzMzMzMzMzMyDRpzIPMe6QQU9jm+mGsYCEAB60RERERFtttpaabqJ02LjY2NjY2Nj4+Pj42NjY2NijSiiKYZbbbbERERHoTMzMzMyXXXXXTMzMqZUzMqZuuuuBBmZmZmf4zM/xnwJJm66666666666666666666666QQQeJ/lM+hJJJJcanb29vd3dvd29vb29vb293d3d3b2ioHyCCD70klFOLi5xdfff2dnb29vb29vb29vZffeHBzXtcCCDI4n2SjwUU8uc4k3XXXXTMqVMzdddILXNLSwhD3DweCiinpxciZumZkGZmZmZmZBaWlhYQghwPcKKKcnlxeSeJmUDMzMqVMqWFpaWEcDge0eCiinJ6cn/AMAhyfEFDhiYmqmggghyPaKKKcHpyej5QEBEI+I4CYmJqYgggghwP6f/xAA9EQACAQEEBggDBgQHAAAAAAAAAQIDEBEhUQQgMVBhcQUSIiUwQFSTcnOxEyMkQVLBFGCRoTIzcIGQkuH/2gAIAQIBAz8A/wCIxEcyOZEiRzIkSJEiRIkSJEiRFutIkxsYxjGMYxjGMYxjGMlET3QoczrOxCEIQhCEIQhCEIQhWdUU1d+e5lCDkxym22XmzytzHGSaYpwUluW5qOQ3I2WoQhCEK1aiEKy+zFjUi++L5rcvWqTebL5I2WsY/DY9XFl0i6rB8dyYOzHXYxjGMYxjGMdisvMS5rcmD1KGjUHUqz6sV/d5I0yrJqgvso53XyZ0nJ3/AMXW/wC7OkvV1vckdJerre5I6R9XW9yR0l6ut7kjpL1db3JHSPq63uSOkfV1vckdI+rre5I6R9XW9yR0l6ut7kjpH1db3JHSPq63uSOkfV1vckdI+rre5I6R9XW9yR0pTd60qo/ifW+pCrNU9JShJ7Jr/C+eRgbdzYO3YS0vS3dL7uDugv3L2UXFYFHIo5FHIo5FHIo5FHIo5FHIo5FHIo5FHIo5FHIpwSasnXoSoVJXypJdV5x/83Pg7XT0GvJbVTld/S2qldeVcyrmVcyrmVcytmVsytmVcyrmVcytmVsyrmVf1E57XY4dK0btkusn/Tc+Fvd2kfLethqPw+89G+J/TUw3Hhb3dpHy3rYW6LpOjwbp3PqpKUcGjStGvd3Xh+pfutbZbhZ3no3xP6amC3N3dpHy34P4eHIizR618oL7Oea2M0nRpXVIcpLYxPwO89H+J/TUwW5MbO7tI+W/B/Dw5K2FSLTimntTxQm3Kg+q/wBD2f7Mq0puM4OMlnrYHeej/E/pqYLcmJid36R8t2Y6/wCHhyWpTjBubSWbKFaEYQV90r+s9bA7z0f4nqdlbkxdnd+kfLfg/h4craFG9U+3L+xWrSvnK8v1sDvPR/iep2Vy3Ji7O79I+W/B/DQ5I0egne+tLJFevg31Y5KxvwO89H+LU7MeS3Ji7O79I+W/AvKr0anCHYSji8/E7z0f4tTsR5LcmLs7v0j4H4GI1G4fh956Pz/bU7EeS3J2nY62jVYLbKDS5tDGMYxjGMYxjGMYxjGSqdJQd2EE5P6anYjyW5O07XTrOvCN8Ju+XBl9jyHkPIeQ8h5DyHkPIeQ8h5DyHkPIaWwk5JJXtu5JH8Hoz63+ZO5y4ZLU+7hyW5O3LnapJpq9MoqXWpvq8NqJrInwJ8CfAlwJcCXAlwJcCXAlwJcCXAnwJ8CfAnLbJI0ehNSSvl+pmGp93DktyXVp89THyeFrcks9y9pSztuj5TCy9l9W/wDKO5VODQ0/BWqvAxt+zppfm9u5utitpd5a9CT6z8urEIVi8O8a8o3sQlqIQtRCsQrFavKIiITIizZxHmPMeZIkSJEiRIeY8x5jzOLI8RCREW53YhCEIQhERCEIQhCEKx/zOvK8d5sYxjH/ACA/9LMPMY70fh4+W//EACcRAAEDAwMEAwEBAQAAAAAAAAEAAgMEERIFExQGEBUWBzBQQCCQ/9oACAEDAQECAP8Akde973ve973ve972/Kjhka+Uzb29vb29vb29vb29vb29vCZksbZYPx6KifTVokeTe/2gxvohHTVtF+LTU9Jp1VT6i2T+KJac2lgrNOqYPxOmaFlFXt1JsrC3DHHHHHHHDHHDDDAMiZpjdPD6Pqah/E6cpax1c/UGyRmPa2trZ2dnZ2NjY2dna2toRxs04UD6R3U1N+GwaM+vnrH1bTRjTRpg03xvjvHDT/H+P8f4/wAd47xvjfFu00UtI2jfQVGtu/DjWlqtNUdK0Xp/4hZ0l6v6v6v6v6v6v6v6v6v6v6v6v6v6v6xWdDdYfEcYpVRLVvxGLTFWqpXQPS0jqrXPPee8957z3nvPee8957z3nvPee89oWpL5Y6VpVRLVUfw2LS1WLp+lesZND9f9f8B4DwHgPAeB8B4DwHgPX/X/AF+l02QfJFLSqiWqo/htWmKsXSXZqtYg9iib3Q/wBZ4eOvlTKiWqJ34bVpirF0l2CARR7MFD1t0p8lq4I7BBBSJ66+VMqJaonfhhaWqxdJdmoIgo9olqofT9L/KXTvVoQKCCaJE9dfKmVEtTT/wwtMVWukezU0Hse0S1UIiJdK/MmmaogggJE9dfKmVEtTT/AMTS1VrpHs1NRRR7RLVv8UGifGnQwADQBInrr5Uyolqaf+Jpiq10j2aginA9olq3anpdA+OaDS9LgIAAUieuvlTKiWpqT+W33aWqtdI9mIdiCCIRq40DoXRunIaSCkhY4AdpE9dfKnVGtSUv32/k0tVa6Q7M/wAEEA0vRsFLT0UcLWD/AC5OXXyp1RrUlL+Jpaql0j2jRQ7EFrxNQw07Iw23clFOXX6p1RrUlN+JpaqlpWoNjMhrRWit5vNNYahtSKrmczmc3m83msrLfLFfTKjWoqb8TS1VKpXxp11Wam7Wxrfm/Oeb855zzfnPOec855vzfnPOU+sw6p8hdZU6o1qKn/E0l1UqlGWk+Tndd+8e8+8+8+8+9e9e9e9e9e9e8+8+8e8R/IevdcwGnVGdQM34mkVE81Q+Zzz/AA3p3wPppq+pJ/D0modPM+ok/jp3wvjm1Op/Bta0EjZpXyu7XV+173v9DDE/dqZbWt/q/wBGV73yve973vdDsAGhkTpHnvZWta1rWta1rWt2jc9xZiR3ve973vfK+V8r5ZZZZZZXyyzzzz3BKJmzMe8Fv8YDGuc6UzGXczzzzyyyyyyyyvll/EA0Nfu55Xve973vle973vnubxkciD/FbHHHHHHHHHHHAMwwEYiZBsOhMO1tbeGGGGOOOOOOOGG3tbQibDsPgMRjwLMMMccccccccbY2xta1sbWta1sccQ0MYxkQgNNwzRGj4fE4fD4fE4nE4nE4fD4Yo+GKPh8Tj7L43xlmBbjja1rWxxxxtiR9lgAA1rY2QxMhEAp+NxuLxeLxeLxeKKXi8Xi8Xi8Xiim4zqd1O6GWKRjmkEEKxH8oQ7NADGxMhjYxkbYRBsCnFMKXicPh8PicPhcM0nG4+xsGF8T43xzMlY9haexH1j/N+4Q7BANADGxthZE1jY2MjEW2IhEI9vb29vb29vbMZiMW1tOjkjkY9szJGyNcCD2P3j6QmhqYIhA2IRtiaxgYGBgYGYY44YY4YYFhYWYFkrJGyCUTNka8EOBB/jHcIIBqYIxEIREIxC1jQ0MDA0Nww28MMMMMS0tLC0tmbIJBKJxIHpyKKPc/TfuD3uh2CamqNRCFRqNU4aAAAA0CxRN0O9i0ghETiVSKUTKRPTkUUUe90fvHYAJqaozEoVEolAmIJoCHa5JN0CCCCUUUQRMplIpVMJDInJyKPY/Tb//EAEQRAAECAgUGCAsHBAMAAAAAAAEAAgMEBREhIlEQEiAxUFIGIyYwQWFx0RNAU1VjcnN0kZSyJTJigZKhsRQWM8FCgpD/2gAIAQMBAz8A/wDI4YoYoIIYoYoYoYoYoYoIYoYoYoYoY7Me/ULMU1gy9fiLYiezWKxjsh0d1Z+6P3WbDqAqAVVaKKKKKKKKKKKKOQoooo1qupZ0O0V1p0B1YBzT+2xnx4zWN6dfUEGQmgNqACzWFVEq3xK1VlqrYEHwnAtrBCfAjOhu6Ni54MQi1xqHYE1sDUgM4K8VaUUUUUUUUUUUUUUUUcloV5qBzQmugLMLYgGo1HsOxQ2DCbgAEGwiqyVWSrx0CijgjgjgjgnYJ2COCKOheCqIVoQdCCDoEYfhOxK3t7UGgFAsVZKzii4p2COCOCOCOC6l1IYIYIYIYZDgupHBHdTh0ItOpVKohVMQe12xOMb2hXAjmlGsqkaXn4crKQDEiO+DR0ucegBUFJwmPn3Om43S0EshtPUBUSuC8NtTaGkgPYMP8hcGvNEj8uzuXBnzPI/Ls7lwZ8zyPy7O5cGfM8j8uzuXBnzPI/Ls7lwZ8zyPy7O5cGfM8j8uzuXBnzPI/Ls7lwZ8zyPy7O5cGfM8j8uzuXBnzPI/Ls7lwZ80SPy7O5cGvNEj8uzuXBrzRI/Ls7lwa80SPy7O5cEptha+iZdtfTCb4I/FlSjykGJNUW98xDaK3QHWxAMW1feVRWpXQrh2Jfb2hXQrq1qFQdCQs+GBNTDWvmHdIJ1M7GohhIVINjvAcBUcFSO+qR31SO+qS31SW+qS3/2VJb6pHfVI76pLfVJb6pHfVJb6pHfVI76mpl7hEIIGSFR9IwqRloYbBm3ERWjU2Lrr/wCytCuq4VbsO83tVwK6mTXCSioLxW103CzhiA4EhHOaFWFJveXFlpUl5NSW4pLcUl5NSXk1I+TUj5NSPk1I+TUl5NSXk1JeTUjuKS8mpLyagSxOY2qtHNTJngXP5wth+DiNOBa8LUrqulWnYd4dquhWLldRHvTMoqQQ0epDINAIIZOR1L+xH1BWhXVdKvHYd4K6FYuV1Ee9My2aIMRo6wuE9AUtNGFNujwnRnufCjEvY6s2nEHrCoCncyEX/wBLNGoeAin7x/A7Ueb5HUt7IfUFaFdCuK8e3YdoV0KxcrqH96YrclmjxrO0L7RmfaO/lA2iwqn6GLIE3XOyoqFTzxjB+F/+iqCp6BnyUyHOArfBddiM7W/7FnMWLkdS/sh9QVoV0K6rzu3YdquhWLldQ/vTFatSs0eMZ6wX2lNe0d/OQEVEKZlo7I8tGfCiMNbXMcWuB6iFMwMyXpqEYjdQmYYqePXbqKo+kZVkxKTLI8J2p7DX+RwPUdKxcjaX9kPqCtCsCuq+7tOxLoVi5XUP70xXslg0eMZ6wX2lNe1d/OhPUnFEOBAL+voCmKFn40y+dc4vgljoTRU3WDWdKxcjaX9kPqCtCsCuq+7tOxLoVi5XUR70xXslmjxjPWC+05r2r/5yTExFDIUMvcdQAUSJmxZ52aNfgwpWUhNhwILWNGARZaVUToWKxcjaX9kPqCtCsCuLjH9p2JdCsXK6iPemK8rRpHwje0JxpWaABJMV38qkZ4tiRx4GF16yqNo6GGwIIzulxtJTndCaKrEGq3QuqxcjKX9kPqCtCsVxca/1jsS4FdXK6iPemK8r2lmtJVHSVIzMYs8K90Ulpd0BPdVUKggKkBp3VYuRlL+yH1BWhWBXFxsT1jsS41XVyuoj3pivK9pXKk0xc6pNCHMXSrFyMpf2Q+oK0KxXCuOiesdiXG9iupshTchNO+5BmIb3+q1wJQIDgQQRWCocPprTMUzFMUNQ0xMKYmJmKYmJiZimJmKhmxMdqKZJcDphhIz5qJDhM+Oef2arQrFcK46J6x2Jcb2K6rSoc5RsOjJmKBMy7c2CSf8ALDbq/NqzK7U3O+8m7ybvJu8m7ybvJu8m7ybvJu8m7ybvJu8m7ybvJu8g533lDZCdEiRGsYxpc5zjUABrJK/uGmGiCT/SSwLIP4ifvP8AzVoViuFcfF9d2xK4bOwK6rSokKI17HuY5pra5pqII6QQqSZCEKdhiYAFQiA5r/z6CqPea6ow6iB3qj/S/pUh6X9KkPS/BSHpf0qQ9L8FI+l+CkfS/BSPpfgpH0vwUj6X4KR9L8FIel/SpD0v6VIel/SpD0v6VJQLWQIsR2BqaFTVMN8C+J4KXr/wssB9bHJaFYhmLjonrnYnEQrf+I/ZVtVpyVu8Sty1BDMJwFaJOxKmFmBrCrb4tUclQXEkV2us2KYcQOQq15KzlOichynTqOUxYnUNXjIQQ5sgVI6ZynROmUaqtMaAQyDxE6QQTcUxw1ojxQlMaNdqbimobEKenjpTspxCdiE/qT8An4BRMAomAUTAKJgFEwCiYBPwCf1J3Uj1ZXYBRCnlHxgc8MhRRRRRTk5OTk5OTk5ORRRRR0BzQ8brydSOCOCOCOCOCOCOCOCOCOCOCOCOCdgjgjgjgjgjgjgjhks0RsQIIYIYIYIYIYIYIYIYIYIYIYIYIYIYIYIYIYIYIYIYZTsHUgrdEaQQTU3BBBDmQrNiauYGCHNjZFvj9uifGRoWjQtHMhBBDmbNlWhWaQyDnLuhVsLVksWrmrecu6I0bMlnNf/Z\" data-filename=\"test_image.jpg\"></p>', '{\"thumbnail\":null,\"file\":null}', 1, 'draft', 1, '2023-01-06 01:45:18', '2023-01-06 01:45:18');
INSERT INTO `blogs` (`id`, `title`, `slug`, `content`, `other`, `category_id`, `status`, `author_id`, `created_at`, `updated_at`) VALUES
(6, 'gvrt', 'gvrt', '<header _ngcontent-c21=\"\" class=\"masthead example-class bg-white-new\" style=\"background: url(&quot;&quot;) 0px 0px / cover no-repeat; position: relative; color: rgb(33, 37, 41); font-family: Roboto, sans-serif; font-size: 16px; margin-bottom: 0px !important; padding-bottom: 25px !important;\"><div _ngcontent-c21=\"\" class=\"container\" style=\"width: 1350px; padding-right: 15px; padding-left: 15px; max-width: 1350px;\"><div _ngcontent-c21=\"\" class=\"row\" style=\"margin-right: -15px; margin-left: -15px;\"><div _ngcontent-c21=\"\" class=\"col-lg-8 col-md-10 mx-auto\" style=\"position: relative; width: 899.987px; padding-right: 15px; padding-left: 15px; -webkit-box-flex: 0; flex-basis: 66.6667%; max-width: 66.6667%;\"><div _ngcontent-c21=\"\" class=\"post-heading\" style=\"color: rgb(255, 255, 255); padding: 35px 0px 0px !important;\"><h1 _ngcontent-c21=\"\" style=\"font-weight: 900; font-family: &quot;Titillium Web&quot;, sans-serif; color: rgb(0, 0, 0); font-size: 30px !important;\">Treatment and Management of Diabetes Mellitus in Elderly Population: A Literature Review</h1></div></div></div></div></header><article _ngcontent-c21=\"\" class=\"bg-white-new\" style=\"background: rgb(255, 255, 255); padding: 30px 0px; color: rgb(33, 37, 41); font-family: Roboto, sans-serif; font-size: 16px;\"><div _ngcontent-c21=\"\" class=\"container\" style=\"width: 1350px; padding-right: 15px; padding-left: 15px; max-width: 1350px;\"><div _ngcontent-c21=\"\" class=\"row\" style=\"margin-right: -15px; margin-left: -15px;\"><div _ngcontent-c21=\"\" class=\"col-lg-8 col-md-10 mx-auto\" style=\"position: relative; width: 899.987px; padding-right: 15px; padding-left: 15px; -webkit-box-flex: 0; flex-basis: 66.6667%; max-width: 66.6667%;\"><h2 style=\"font-weight: 700; font-size: 2rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">ABSTRACT</span></h2><p>Diabetes mellitus in elderly population presents various clinical challenges. This group of population differs in terms of mental status as well as physical status. The elderly population has a high risk of complications such as falls, hypoglycemia, and depression in this patient population. All these complications can have a negative impact on the glycemic control and quality of life among elderly patients with diabetes.</p><p>We identified 40 articles with a search strategy using keywords: “diabetes mellitus”, “diabetes in elderly population”, “treatment of diabetes in elderly population”, “current recommendations for treating diabetes in elderly population”, “treatment options for diabetes in elderly population”, and “care and management of diabetes in older population”, and “lifestyle modifications in elderly patients with diabetes”. Essential data were extracted from selected studies into a separate bibliographic report. Of 30 articles, 27 relevant articles were selected for the literature review.</p><p>The treatment and management of diabetes mellitus in the elderly population are challenging as this group of population is considered as heterogeneous. Metformin is usually recommended in elderly patients, but if not effective, other drugs such as meglitinides, sulfonylureas, alfa-glucosidase inhibitors, basal insulin, and pioglitazone can be added.&nbsp;The care and management of diabetes in elderly diabetic patients depend upon the functional and cognitive heterogeneity of patients. There are some problems/risks such as cardiovascular diseases, blood glucose control, blood glucose control, dyslipidaemia, kidney diseases, diabetic neuropathy, and stroke associated with diabetes that need more attention and require proper management in&nbsp;elderly patients with diabetes.</p><p>In addition, lifestyle modifications such as diabetes self-management education, nutritional therapy, weight management, physical exercise and psychosocial care are the fundamental aspects of diabetes care. Patients and healthcare providers should focus on how to improve lifestyle from the beginning of the treatment throughout all following evaluations and follow-up, in order to enhance diabetes care.&nbsp;</p><p>The population of elderly patients with diabetes mellitus is increasing at a faster rate. Currently, there are various effective treatment options for the management of diabetes in elderly patients that can decrease the levels of HbA1c. These therapeutic regimens appear to provide improved glycemic control with reduced risks of hypoglycemia when used in combination with lifestyle changes.&nbsp;</p><h2 style=\"font-weight: 700; font-size: 2rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">INTRODUCTION</span></h2><p>Diabetes is a metabolic disease that results from defects in insulin secretion and/or insulin action. At the chronic stage, the disease is characterized by hyperglycemia which can result in dysfunction, long-term damage, and failure of different organs such as heart, eyes, and kidneys.1 The prevalence of diabetes in the elderly population has increased in the past few years. As per the current data, 22% to 33% of adults over 65 years are diagnosed with diabetes in the United States. This prevalence is expected to increase to 25% to 28% by the year&nbsp;2050. These projections are based on the increasing elderly population in the United States and the long life expectancy of the patients living with diabetes.2&nbsp;</p><p>Elderly patients with diabetes have a strong genetic predisposition. Patients with a family history of the disease are more likely to develop it as they age. Several other factors such as age-related changes in carbohydrate metabolism and lifestyle factors also contribute to the high prevalence of diabetes in the old population. In some older people, the development of diabetes takes place in middle age, and they face years of comorbidity; some are diagnosed newly having years of undiagnosed comorbidity. Also, some older people with diabetes are frail and have other underlying diabetes-related chronic condition or declined cognitive functioning. Therefore, like in younger patients, it is important to control the glycemic levels in the older population to prevent long-term complications as well as the risks of hyperglycemia.3, 4&nbsp;</p><p>Till now, various treatments options for diabetes are approved, but the elderly patients are vulnerable to diabetes treatment and involve multiple risk factors. The goals of treatment in the elderly population include treatment-associated risk factors reduction and hyperglycemia control. Therefore, functional limitations and comorbid diseases are considered while setting treatment targets for the elderly population; individualization of the treatment is necessary. Also, in the treatment of vulnerable elderly patients with diabetes, hypotension and hypoglycemia should be monitored, and use of multiple drug causing drug interactions should be avoided.5</p><p>The older patients are at a higher risk of hypoglycemia than younger patients, even after the adjustment of glycemic control, therefore the management of diabetes in elderly population requires the need to reduce this risk.6 To help elderly patients in maintaining good metabolic control, individualized pharmacological treatment in combination with lifestyle changes is necessary. Therefore, the primary focus of this review article was to assess the recent advances in the treatment options for the elderly population with diabetes. The guidelines for the management and care of the elderly population with diabetes are also discussed in this review.</p><h2 style=\"font-weight: 700; font-size: 2rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">METHODS</span></h2><p>This literature review was conducted to describe the evidence-based literature related to the recent advances in the treatment options of diabetes mellitus in elderly population. We identified 40 articles by searching PubMed, and 27 relevant articles were selected for this review. To create a search strategy, the following terms were used: diabetes mellitus”, “diabetes in elderly population”, “treatment of diabetes in elderly population”, “current recommendations for treating diabetes in the elderly population”, “treatment options for diabetes in the elderly population”, and “care and management of diabetes in older population”, “lifestyle modifications in elderly patients with diabetes”. Important data from selected studies were extracted into a separate bibliographic report. Of 40 articles, 27 relevant articles were selected for the literature review.</p><h2 style=\"font-weight: 700; font-size: 2rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">DISCUSSION</span></h2><p>The recent treatment options for the elderly population with diabetes mellitus are presented in&nbsp;<span style=\"font-weight: bolder;\">Table 1</span>&nbsp;and discussed in this section.</p><p>The treatment and management of diabetes mellitus in the older population are challenging as this group of population is considered as heterogeneous. Although numerous treatment options are available in most of the cases, they come with the side-effects such as hypoglycemia. Metformin is usually recommended in elderly patients, but if not effective, other drugs such as meglitinides, sulfonylureas, alfa-glucosidase inhibitors, insulin, and pioglitazone can be added. Currently, the most effective therapies considered for the treatment of older patients with diabetes are incretin-based therapies, SGLT2 inhibitors and basal insulin therapies.7</p><h2 style=\"font-weight: 700; font-size: 2rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">Effective Therapies for Treating Diabetes in Elderly</span></h2><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><i><span style=\"font-weight: bolder;\">Incretin-Based Therapies</span></i></h3><p>Incretin-based therapies can be beneficial in controlling glycemic levels in older adults and elderly patients suffering from diabetes without any significant risk of hypoglycemia. The approved incretin-based therapies include GLP-1 receptor agonists such as liraglutide, exenatide, and DPP-4 inhibitors such as alogliptin, linagliptin, sitagliptin, and saxagliptin. Both GLP-1 and DPP-4 inhibitor use the antidiabetic properties of the incretin hormone, GLP-1. This hormone makes glucose-induced insulin secretion in a highly glucose-dependent manner, therefore preventing GLP-1 alone from provoking hypoglycemia.8&nbsp;</p><p>Exenatide has been approved by the Food and Drug Administration (FDA) in addition to exercise and diet for the improvement of glycemic control in elderly patients with diabetes. An extended-release formulation of exenatide when administered subcutaneously once weekly, it significantly reduced HbA1c level and was proved to be well-tolerated in a randomized phase 2 study involving 155 patients.9&nbsp;A post-hoc analysis analyzed pooled data of 16 randomized controlled trials including 2,067 patients. The patients with diabetes treated with exenatide 10 μg BID demonstrated significant improvements in glycemic control in patients aged ≥65 years.10&nbsp;The cardiovascular effects of GLP-1 receptor agonist “liraglutide” were evaluated in elderly patients with type 2 diabetes in a clinical study “LEADER” including 9340 patients, of which, 4668 patients received liraglutide 1.8 mg, and 4672 received a placebo. The rate of death due to cardiovascular in elderly patients with diabetes was lower in the liraglutide group (4.7%) than in the placebo group (6.0%) (p=0.007; HR: 0.78; CI [0.66-0.93]).11&nbsp;A pooled analysis comparing the effects of two doses of liraglutide (1.8 mg and 1.2 mg) and placebo included data from six randomized trials involving 3967 diabetes patients aged &lt;65 years (n = 2,231) and ≥65 years (n = 552). The reduction in the HbA1c levels from baseline was statistically significantly greater with both doses of liraglutide in patients aged ≥65 years as well as in patients aged &lt;65 years than the placebo (P &lt; 0.0001).vsvs12. The efficacy and safety of another GLP-1 receptor agonist “lixisenatide” were evaluated in a GetGoal phase III program. This program included a pooled analysis of 6 phase III studies in which 3188 patients with type 2 diabetes received lixisenatide 20 µg once or placebo daily. Significant reductions in HbA1c levels were observed in lixisenatide 20 µg groups as compared with placebo. The least-square mean treatment difference in HbA1c was −0.56% (±0.039), −0.66% (±0.076), −0.58% (±0.035) and −0.50% (±0.241) for patients aged &lt;65, ≥65, &lt;75 and ≥75 years, respectively. This data suggest that lixisenatide is well tolerated and effective in elderly patients with type 2 diabetes mellitus.13</p><p>&nbsp;</p><p><span style=\"font-weight: bolder;\">Table 1: Recent Treatment Options for Diabetes in Elderly Patients</span></p><figure class=\"table\" style=\"margin-bottom: 1rem; width: 869.987px; color: rgb(33, 37, 41);\"><table><tbody><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\"><span style=\"font-weight: bolder;\">Drug Class/Name</span></td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\"><span style=\"font-weight: bolder;\">Dose</span></td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\"><span style=\"font-weight: bolder;\">No. of Subjects</span></td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\"><span style=\"font-weight: bolder;\">Outcome</span></td></tr><tr><td colspan=\"4\" style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\"><span style=\"font-weight: bolder;\">Incretin-based therapies</span></td></tr><tr><td rowspan=\"2\" style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Exenatide9,&nbsp;10</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">5 to 10 μg BID</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">155</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Well-tolerated, significant reductions in HbA1c levels</td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">10 μg BID</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">2067</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Significant reductions in HbA1c levels, improvements in glycemic control</td></tr><tr><td colspan=\"4\" style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\"><span style=\"font-weight: bolder;\">GLP-1 receptor</span></td></tr><tr><td rowspan=\"2\" style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Liraglutide11,&nbsp;12</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">1.8 mg</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">9340</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Significantly lower rates of deaths in liraglutide group</td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">1.2 mg, 1.8 mg</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">3967</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">HbA1c reduction for both doses of liraglutide was statistically significantly greater than the placebo</td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Lixisenatide13</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">20 µg once daily</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">3188</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Reduced HbA1c levels in Lixisenatide group</td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Alogliptin14</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">25 mg QD</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">441</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Maintained glycaemic control and lowered the risk of hypoglycemia</td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Linagliptin15</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">5 mg once daily</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">6991</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Linagliptin resulted in a non- inferior risk of a cardiovascular outcome</td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Sitagliptin16</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">50 mg or 100 mg</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">206</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Both doses of sitagliptin significantly reduced Hb1Ac levels and improved glycemic measures</td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">saxagliptin17</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">5 mg</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">240</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Reduction in HbA1c levels</td></tr><tr><td colspan=\"4\" style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\"><span style=\"font-weight: bolder;\">SGLT2 Inhibitors</span></td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Dapagliflozin18</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">2.5 mg, 5 mg, or 10 mg</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">546</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">All the doses of dapagliflozin statistically significantly reduced HbA1c</td></tr><tr><td rowspan=\"2\" style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Canagliflozin19,&nbsp;20</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">100 mg and 300 mg</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">1452</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Both doses of canagliflozin&nbsp;significantlyreduced HbA1c levels</td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">100 mg and 300 mg</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">714</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Both doses of canagliflozin significantly reduced HbA1c levels&nbsp;</td></tr><tr><td colspan=\"4\" style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\"><span style=\"font-weight: bolder;\">Basal Insulin</span></td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Insulin glargine22</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\"><p>Gla-300 or Gla-100</p><p>Insulin naïve patients: 0.2 units/kg</p><p>Pre-treated with insulin: Starting</p><p>dose equivalent to median basal</p><p>insulin dose of the 3 days before baseline</p></td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">1014</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Both the doses of insulin glargine significantly reduced HbA1c levels</td></tr><tr><td rowspan=\"3\" style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Insulin degludec23,&nbsp;24,&nbsp;25</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">NR</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">744</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Reduction in HbA1c levels, reduced risks of hypoglycemia</td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">NR</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">773</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Long-term glycemic control</td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">NR</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">4330</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Improvements in HbA1c, fewer hypoglycemic episodes</td></tr><tr><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">LY260554126</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">NR</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">195</td><td style=\"padding: 0.75rem; vertical-align: top; border-top-color: rgb(222, 226, 230);\">Reduced HbA1c levels, lower nocturnal hypoglycemia, reduced intraday variability and weight loss</td></tr></tbody></table></figure><p>QD = once daily, BID = twice daily, NR = not reported</p><p>The DPP-4 inhibitors including linagliptin, sitagliptin, alogliptin, and saxagliptin are FDA-approved agents and have shown to be effective for use as monotherapy as well as in combination therapy, in elderly patients with diabetes. A randomized double-blind study evaluated the efficacy and safety of DPP-4 inhibitor alogliptin vs glipizide monotherapy in elderly patients with diabetes. Patients received alogliptin 25 mg (n = 222) or glipizide (n = 219) 5 mg titrated to 10 mg once daily. The mean percent change in the HbA1c level from a baseline was -0.14% in the alogliptin group and -0.09% in the glipizide. The study demonstrates that alogliptin is non-inferior to glipizide in reducing the HbA1c level. Therefore, alogliptin successfully maintains glycaemic control and lowers the risk of hypoglycemia.14&nbsp;Another DPP-4 inhibitor linagliptin was evaluated in a randomized, multicenter, placebo-controlled, non-inferiority trial. The study evaluated the effect of vs placebo on kidney and cardiovascular outcomes in older patients with type 2 diabetes. Of the 6991 enrolled patients, 3494 patients received linagliptin 5 mg once daily, and 3485 received a placebo. The cardiovascular events occurred in 434 (12.4%), and 420 (12.1%) patients in the linagliptin and placebo groups, respectively and the kidney events occurred in 327 (9.4%) and 306 (8.8%) patients, respectively. Linagliptin resulted in a non-inferior risk of a cardiovascular outcome in older patients with diabetes.15&nbsp;One more DPP-4 inhibitor sitagliptin was evaluated in a randomized, double-blind, placebo-controlled, parallel-group study in which two doses (50 mg or 100 mg) of sitagliptin monotherapy were evaluated in the elderly patients with type 2 diabetes mellitus. A total of 206 patients aged ≥65 years received sitagliptin or placebo. In sitagliptin treated groups, the reduction in the HbA1c level was statistically significant compared with the placebo group (p &lt; 0.001). Sitagliptin was well-tolerated and improved glycemic measures without any incidences of hypoglycemia.16&nbsp;The efficacy and safety of saxagliptin 5 mg as an add-on therapy to insulin was examined in a subgroup analysis involving 240 patients with diabetes mellitus. From baseline to week 16, HbA1c levels increased by 0.40% in the saxagliptin whereas decreased by 0.51% in the placebo group. From week 16 till week 52, the reduction in HbA1c level in the saxagliptin group was maintained. A similar reduction in HbA1c level was seen while switching from placebo to saxagliptin. No incidences of hypoglycemia were reported. Saxagliptin was safe and improved glycemic control when added to insulin therapy.17</p><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><i><span style=\"font-weight: bolder;\">SGLT2 Inhibitors</span></i></h3><p>SGLT2 inhibitors such as dapagliflozin and canagliflozin inhibit the reabsorption of glucose in the kidney and increase the glucose excretion in the urine. A 102-week, phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study evaluated dapagliflozin at the dose levels of 2.5 mg, 5 mg, or 10 mg vs placebo in combination with metformin in 546 patients with type 2 diabetes mellitus. There was a statistically significantly reductions in the HbA1c level from baseline with dapagliflozin at all dose levels: 2.5 mg (p = 0.0008), 5 mg (p &lt;0.0001)), and 10 mg (p &lt;0.0001) groups as compared with placebo. All dapagliflozin groups also reported reductions in body weight and fasting plasma glucose (FPG).18</p><p>Another SGLT2 inhibitor canagliflozin has also shown improvement in the glycemic control in various clinical trials. A randomized, double-blind, active-controlled, phase 3 study compared the effect of canagliflozin 100 mg and 300 mg vs glimepiride in 1452 patients aged 18 to 80 years. At 52 weeks, canagliflozin 100 mg showed non-inferiority to glimepiride whereas canagliflozin 300 mg showed superiority to glimepiride. Canagliflozin demonstrated a significant reduction in the HbA1c level compared to glimepiride and was well-tolerated in patients with type 2 diabetes.&nbsp;19Another 26-week, randomized, double-blind, placebo-controlled, phase 3 study evaluated the safety and efficacy of canagliflozin 100 mg and 300 mg in 714 patients aged from 55 years to 80 years. At week 26, both the doses of canagliflozin significantly reduced HbA1c levels (p &lt; 0.001) compared with placebo.20</p><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><i><span style=\"font-weight: bolder;\">Basal Insulin</span></i></h3><p>Insulin is considered as one of the most effective therapy for diabetes treatment. Recent findings suggest that elderly patients aged ≥70 years can achieve the same level of metabolic control with insulin treatment as young diabetic patients.21</p><p>An open-label, two-arm, parallel-group, multicenter phase 3b study enrolled 1014 elderly patients (mean age: 71 years) to evaluate the safety and efficacy of insulin glargine 300 (Gla-300) vs insulin glargine 100 (Gla-100). Comparable reductions in the HbA1c levels were observed in both the treatment groups from baseline to Week 26. This study demonstrated that Gla-100 and Gla-300 are safe and effective with comparable reductions in HbA1c levels in the elderly population with type 2 diabetes and is suitable for use in the vulnerable elderly population.22&nbsp;The long-acting basal insulin lowers the hypoglycemia risk. The efficacy and safety of insulin degludec, and ultralong-acting basal insulin analogue, have been assessed in different trials and meta-analysis of patients with type 2 diabetes mellitus. These studies suggest that insulin degludec is able to achieve improvements in the glycemic levels with fewer episodes of hypoglycemia.23-25&nbsp;Another novel basal insulin LY2605541 was evaluated in a randomized open-label phase 2 study. This study evaluated the effects of LY2605541in lowering FBG in comparison to insulin glargine. Comparable glycemic control was observed with both LY2605541 and insulin glargine, but LY2605541 resulted in lower nocturnal hypoglycemia, more reduction in intraday variability, and weight loss.<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Bergenstal%20RM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22787177\" style=\"color: rgb(0, 123, 255); text-decoration: none;\">26</a></p><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">Care and Management of Diabetes in Elderly&nbsp;</span></h3><p>The care and management of diabetes in elderly diabetic patients depend upon the functional and cognitive heterogeneity of patients. In managing diabetes, the primary focus is always on changes in lifestyle and food habits. An older adult with diabetes may have unpredictable and irregular food consumption. This may result in decreased intake of food leading to under-nutrition and weight loss. Diets should be tailored as per preferences and their personal goals. This can increase the quality of life, nutrition status, and meals satisfaction in elderly patients with diabetes. As per the International Diabetes Federation, the elderly diabetic patients are classified into three categories (<span style=\"font-weight: bolder;\">Figure 1</span>).</p><p><img src=\"https://app.quantinova.ai:8443/img/image-1583240870226.png\" style=\"border-style: none;\"></p><p>Figure&nbsp;1: International Diabetes Federation Categories of Elderly Patients with Diabetes</p><p><i>Category 1–Functionally Independent:&nbsp;</i></p><p>These are the patients who live independently, have no significant impairments in activities of daily living, and requires minimal or none caregiver support care. These patients have other medical comorbidities that may impact diabetes care. Diabetes may be the primary medical problem.&nbsp;</p><p>Category 2–Functionally Dependent:</p><p>This category represents individuals who, due to function loss, have impairments of activities of daily living such as personal care, dressing, and bathing. They need additional medical care as well as social care. They are at risk of admission to nursing homes. This category of further divided into two groups requiring special consideration:</p><ul><li>Sub-Category A: Frail:</li></ul><p>This category is characterized by significant fatigue, weight loss, severe restriction in strength and mobility, increased tendency to falls, and at high risk of institutionalization. Some frail older people with diabetes may not require dependency, but with time, dependency may develop.</p><ul><li>Sub-Category B: Dementia:</li></ul><p>Individuals in this category have cognitive impairment that results in significant memory problems, change in personality, disorientation, and unable to self-care.</p><p><i>Category 3–End of Life Care:</i></p><p>Individuals in this category have significant malignancy or medical illness and have reduced life expectancy of less than one year.</p><p>There are some problems/risks listed below that needs more attention and require proper management in older patients with diabetes.</p><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">Cardiovascular Risk Management</span></h3><p>The risk factors associated with cardiovascular diseases (CVDs) include smoking, blood pressure, dyslipidemia, peripheral arterial disease, renal dysfunction, glycaemic control, obstructive sleep apnoea, depression periodontitis, and obesity. The risks associated with CVDs can be prevented by controlling blood pressure, lipids and blood glucose levels, and lifestyle modifications.</p><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">Blood Glucose Control</span></h3><p>The use of glucose-lowering agents is required in older people with diabetes. Generally, the glucose-lowering agents are recommended when glycaemic goals are not attained by lifestyle modifications after three months period. These agents are started at lower doses. Maintaining appropriate glycaemic levels reduce the risks of CVDs in older patients (<span style=\"font-weight: bolder;\">Figure 2</span>).</p><p><img src=\"https://app.quantinova.ai:8443/img/image-1583240914556.png\" style=\"border-style: none;\"></p><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">Blood Pressure Control</span></h3><p>The first step to managed high blood pressure in older people is the implementation of non-pharmacological interventions such as stopping smoking, salt intake, restricting alcohol consumption, and encouraging physical activity regularly. If these non-pharmacological interventions fail to achieve targets blood pressure (systolic blood pressure (SBP) ≥140 mm Hg; diastolic blood pressure (DBP) ≥90 mm Hg) after six months. The angiotensin-converting enzyme inhibitors (ACE) are recommended first, but for people for whom ACE-inhibitors are not suitable, angiotensin II receptor blockers (ARBs) are the choice as initial therapy. If ACE-inhibitors and ARBs fail to achieve target blood pressure, calcium channel blockers or diuretics are used. Addition of beta-blockers is considered for patients with coronary artery disease and tachycardia. There are some combinations that are avoided including ACE-inhibitors and ARBs, beta-blockers and verapamil, and potassium-sparing diuretic and either an ARB or ACE inhibitor. The blood pressure measurement at every routine visit must be done.</p><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">Dyslipidaemia Prevention</span></h3><p>The management of lipids is the first approach to prevent dyslipidaemia. Since the older population is at high risk of CVD, statin therapies are considered beneficial for the management of dyslipidaemia. Other lipid-lowering therapies such as fenofibrate, ezetimibe, bile acid-binding resins, concentrated omega-3 fatty acids and sustained-release nicotinic acid may be suitable in some individuals are intolerant of medications and fails to reach lipid targets. In end of life care patients, withdrawal of lipid-lowering therapy may be appropriate. Niacin should be avoided in older people with diabetes. Regular monitoring of lipids is generally not required but careful monitoring of side-effects related to statin therapy should be considered. The pharmacotherapy should be used cautiously in people with advanced dementia.</p><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">Renal Impairment Monitoring</span></h3><p>The management of kidney diseases requires assessment of blood glucose level and blood pressure levels. The early detection and prevention of developing kidney damage and parameters monitoring are useful in promoting improved cardiovascular protection. Blood pressure levels and micro and macroalbuminuria should be checked regularly. Chronic kidney disease should be managed with the help of ACE or ARBs in individuals with micro or macroalbuminuria. Nutritional assessment at baseline as well as at regular intervals should be done in all frail older people with diabetes and chronic kidney disease. Withdrawal of medicines should be considered in the patient with the end of life care along with the measurement of serum creatinine and potassium levels.</p><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">Diabetic Neuropathy Monitoring</span></h3><p>The peripheral nerves of older patients with diabetes should be examined. It is important to consider the tolerability and safety of therapies to manage neuropathic pain. Doses should be titrated, and the use of anticonvulsants, antidepressants, and tricyclic medicines should be recommended for painful neuropathy. For the management of joint abnormalities or musculoskeletal issues, non-steroidal anti-inflammatory medications can be used. The presenceof gastroparesis, neurogenic bladder, and cardiovascular autonomic neuropathy should be considered. In patients with dementia, opiates should be used with great care as they may result in confusion with existing cognitive problems in older people. In the end of life care patients, pain relief remains an important consideration pharmacotherapy for pain relief helps in the improvement of quality of life.</p><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">Stroke Prevention</span></h3><p>Diabetes increases the risk of stroke in the elderly population. The stroke can result in an acute disturbance in the metabolism of glucose. Blood glucose levels should be monitored at regular intervals, and hyperglycaemia should be treated with insulin. Antiplatelet therapy should be considered for people in sinus rhythm and anticoagulation should be considered for people with atrial fibrillation, unless there are no contraindications. In patients with severe (&gt;70%) or symptomatic carotid stenosis, carotid endarterectomy or stenting should be considered. Hypoglycaemia should be treated to retain blood glucose levels between 6.0 to 0.0 mmol/L (110-180 mg/dL) and confirmed that it is avoided. In the end of life care patients, the use of anticoagulation or antiplatelet therapy must be done after discussing with the patients, their families, and caregivers.27</p><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">Care and Management of Diabetes in Aged Care Homes</span></h3><p>Elderly patients with diabetes in old-age homes usually depend on medical attendants and other staff for their needs. A few significant issues are found in these homes, e.g., weight loss, nutritional deficiency, risks of hypoglycemia, and high disease rates. In most of the cases, diabetes in the elderly remains undiagnosed. Therefore, old-age homes focused on the treatment of diabetes should implement guidelines recommended for old patients with diabetes.</p><p>On admission to the aged home care, all patients should be evaluated for undiagnosed diabetes. Every aged care home should provide training and education to its staff about caring for older diabetic patients. An individual care plan should be made for every patient taking into account the health status and wish of the patient. Family and other relevant caregivers should be involved in the care management process.28</p><h3 style=\"font-weight: 700; font-size: 1.75rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">Lifestyle Modifications</span></h3><p>Nutritional Therapy: For some people with diabetes, the most significant part of the treatment plan is figuring out what to eat and following a proper eating plan. There is certainly not a common eating example for people with diabetes. The nutritional therapy treatment has an important role in the general management of diabetes, and every individual with diabetes ought to be effectively occupied with self-administration, treatment planning, and training. All elderly people with diabetes should get individualized nutrition treatment, ideally given by an enlisted dietitian who is educated in giving diabetes eating plan. Nutritional therapy helps in:</p><ul><li>Nutritional therapy helps in maintaining healthy eating patterns</li><li>Nutritional therapy helps in maintaining blood pressure, glycemic and lipid targets</li><li>Nutritional therapy helps in maintaining eating pleasure by providing health messages about food choices</li><li>Nutritional therapy helps in delaying and preventing diabetes complications</li></ul><p>Weight Management:<span style=\"font-weight: bolder;\">&nbsp;</span>The management of body weight is important for obese and overweight people with diabetes. Weight management projects should be serious and have regular follow-up to accomplish a noteworthy decrease in excess body weight. There is proof that weight reduction can postpone the movement from prediabetes to type 2 diabetes. Weight reduction can be accomplished by lifestyle management programs. The eating regimens utilized in these programs include food items such as grains, organic products, vegetables, lean meats, nuts, and seeds.</p><p>Physical Activity:<span style=\"font-weight: bolder;\">&nbsp;</span>It is a general term that incorporates the overall development of the body that builds energy and is a significant part of the diabetes management plan. Exercise is an increasingly explicit type of physical movement that is organized and intended to improve physical wellness. Both physical exercise and activity are important. Exercise has been appeared to improve blood glucose control, decrease cardiovascular hazard factors, and add to weight reduction.</p><p>Psychosocial Issues:<span style=\"font-weight: bolder;\">&nbsp;</span>Psychosocial care ought to be incorporated with a community-oriented understanding focused methodology and furnished to all individuals with diabetes with the objectives of improving wellbeing results and personal satisfaction.</p><p>Other psychosocial issues affecting health outcomes and self-management of elderly patients with diabetes include attitudes towards the illness, hopes from medical outcomes and management and psychiatric history. The psychosocial assessment and treatment should be incorporated into routine care to avoid specific problems resulting in the psychological or metabolic status of patients. In case of referrals to mental health specialists, providers should find out mental and behavioral health providers, ideally, those who have knowledge of psychosocial aspects and treatment of diabetes to whom they can refer patients.28</p><h2 style=\"font-weight: 700; font-size: 2rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">CONCLUSION</span></h2><p>The population of elderly patients with diabetes mellitus is increasing at a faster rate. The management and care of elderly patients with diabetes are complicated, due to their functional and clinical diversity and the presence of complications such as depression, and cognitive impairment. Currently, there are various effective treatment options for the management of diabetes in elderly patients that can decrease the levels of HbA1c. These therapeutic regimens appear to provide improved glycemic control with reduced risks of hypoglycemia when used in combination with lifestyle changes. Health care providers must utilize these options by selecting correct treatment agents by keeping all risk factors in mind.</p><h2 style=\"font-weight: 700; font-size: 2rem; font-family: &quot;Titillium Web&quot;, sans-serif;\"><span style=\"font-weight: bolder;\">REFERENCES</span></h2><p>1. American Diabetes Association 2010. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2010; 33:S62–S69.</p><p>2. Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010; 8:29.</p><p>3. Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003; 51:S265-80.</p><p>4. American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012; 35:S11–S63.</p><p>5. Yakaryılmaz FD, Öztürk ZA. Treatment of type 2 diabetes mellitus in the elderly. World J Diabetes. 2017; 8(6):278-285.</p><p>6. Peter Bramlage, Anselm K Gitt, Christiane Binz, et al. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol. 2012; 11:122.</p><p>7. Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging. 2008;25(11):913-25.</p><p>8. Michael. A. Nauck, MD, Tina Vilsbøll,Baptist Gallwitz, et al. Incretin-Based Therapies. Diabetes Care. 2009; 32:S223–S231.</p><p>9. Henry RR, Rosenstock J, Logan DK, et al. Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes. Diabetes Care. 2013;36(9):2559-65.</p><p>10. Pencek R1, Blickensderfer A, Li Y, et al. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012; 124(4):21-32.</p><p>11. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22.</p><p>12. Bode BW, Brett J, Falahati A, et al. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother. 2011; 9(6):423-33.</p><p>13. Raccah D, Miossec P, Esposito V, et al. Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme. Diabetes Metab Res Rev. 2015; 31(2):204-11.</p><p>14. Rosenstock J, Wilson C, Fleck P. Alogliptin vs glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013; 15(10):906-14.</p><p>15. Rosenstock J,, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019; 321(1):69-79.</p><p>16. Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011; 27(5):1049-58.</p><p>17. Kadowaki T, Muto S, Ouchi Y, et al. Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension. Expert Opin Pharmacother. 2017; 18(18):1903-1919.</p><p>18. Clifford J Bailey, Jorge L Gross, Delphine Hennicken, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013; 11:43.</p><p>19. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin vs glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382(9896):941-50.</p><p>20. Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013; 41(2):72-84.</p><p>21. Zafon C, Creus C. A comparison on insulin regimen treatment of elderly (&gt;70 years) and younger (&lt;70 years) type 2 diabetic patients in actual clinical practice. Acta Diabetol. 2013; 50(1):33-7.</p><p>22. Ritzel R, Harris SB, Baron H, et al. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care. 2018; 41(8):1672-1680.</p><p>23. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825):1498-507.</p><p>24. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012; 35(12):2464-71.</p><p>25. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013; 15(2):175-84.</p><p>26. Bergenstal RM, Rosenstock J, Arakaki RF. A randomized, controlled study of once-daily LY2605541, a, novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012; 35(11):2140-7.</p><p>27.&nbsp;<a href=\"https://www.idf.org/component/attachments/attachments.html?id=985&amp;task=download\" style=\"color: rgb(0, 123, 255); text-decoration: none;\">International</a>&nbsp;Diabetes Federation. DF Global Guideline for Managing Older People with Type 2 Diabetes. Last accessed: July 17, 2019;</p><p>&nbsp; &nbsp; &nbsp; &nbsp;Available at:<a href=\"https://www.idf.org/component/attachments/attachments.html?id=985&amp;task=download.\" style=\"color: rgb(0, 123, 255); text-decoration: none;\">https://www.idf.org/component/attachments/attachments.html?id=985&amp;task=download.</a></p><p>28. American Diabetes Association. Older Adults: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018; 41:S119-S125.</p><p>29. American Diabetes Association. Lifestyle Management. Diabetes Care 2017; 40:S33-S43.</p></div></div></div></article>', '{\"thumbnail\":null,\"file\":null}', 2, 'draft', 1, '2023-01-06 02:21:57', '2023-01-06 02:21:57');

-- --------------------------------------------------------

--
-- Table structure for table `blog_categories`
--

CREATE TABLE `blog_categories` (
  `id` int(11) NOT NULL,
  `name` varchar(255) NOT NULL,
  `slug` varchar(255) NOT NULL,
  `created_at` timestamp NOT NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

--
-- Dumping data for table `blog_categories`
--

INSERT INTO `blog_categories` (`id`, `name`, `slug`, `created_at`, `updated_at`) VALUES
(1, 'White Paper', 'white-paper', '2023-01-04 01:24:25', '2023-01-04 01:24:25'),
(2, 'Review', 'review', '2023-01-04 01:24:37', '2023-01-04 01:24:37');

-- --------------------------------------------------------

--
-- Table structure for table `blog_tags`
--

CREATE TABLE `blog_tags` (
  `id` int(11) NOT NULL,
  `name` varchar(255) NOT NULL,
  `slug` varchar(255) NOT NULL,
  `created_at` timestamp NOT NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

--
-- Dumping data for table `blog_tags`
--

INSERT INTO `blog_tags` (`id`, `name`, `slug`, `created_at`, `updated_at`) VALUES
(1, 'test tag1', 'test_tag1', '2023-01-06 04:52:54', '2023-01-06 04:52:54'),
(2, 'test tag2', 'test_tag2', '2023-01-06 04:52:54', '2023-01-06 04:52:54');

-- --------------------------------------------------------

--
-- Table structure for table `blog_tag_relations`
--

CREATE TABLE `blog_tag_relations` (
  `blog_id` bigint(20) NOT NULL,
  `tag_id` bigint(20) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

--
-- Dumping data for table `blog_tag_relations`
--

INSERT INTO `blog_tag_relations` (`blog_id`, `tag_id`) VALUES
(4, 1),
(4, 2);

-- --------------------------------------------------------

--
-- Table structure for table `countries`
--

CREATE TABLE `countries` (
  `id` int(11) NOT NULL,
  `name` varchar(250) NOT NULL,
  `code` varchar(50) NOT NULL,
  `isd_code` varchar(50) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

--
-- Dumping data for table `countries`
--

INSERT INTO `countries` (`id`, `name`, `code`, `isd_code`) VALUES
(1, 'Afghanistan', 'AF', '93'),
(2, 'Albania', 'AL', '355'),
(3, 'Algeria', 'DZ', '213'),
(4, 'American Samoa', 'AS', '1'),
(5, 'Andorra', 'AD', '376'),
(6, 'Angola', 'AO', '244'),
(7, 'Anguilla', 'AI', '1'),
(8, 'Antigua and Barbuda', 'AG', '1'),
(9, 'Argentina', 'AR', '54'),
(10, 'Armenia', 'AM', '374'),
(11, 'Aruba', 'AW', '297'),
(12, 'Ascension', 'AC', '247'),
(13, 'Australia', 'AU', '61'),
(14, 'Australian External Territories', 'AX', '672'),
(15, 'Austria', 'AT', '43'),
(16, 'Azerbaijan', 'AZ', '994'),
(17, 'Bahamas', 'BS', '1'),
(18, 'Bahrain', 'BH', '973'),
(19, 'Bangladesh', 'BD', '880'),
(20, 'Barbados', 'BB', '1'),
(21, 'Belarus', 'BY', '375'),
(22, 'Belgium', 'BE', '32'),
(23, 'Belize', 'BZ', '501'),
(24, 'Benin', 'BJ', '229'),
(25, 'Bermuda', 'BM', '1'),
(26, 'Bhutan', 'BT', '975'),
(27, 'Bolivia', 'BO', '591'),
(28, 'Bosnia and Herzegovina', 'BA', '387'),
(29, 'Botswana', 'BW', '267'),
(30, 'Brazil', 'BR', '55'),
(31, 'British Virgin Islands', 'VG', '1'),
(32, 'Brunei Darussalam', 'BN', '673'),
(33, 'Bulgaria', 'BG', '359'),
(34, 'Burkina Faso', 'BF', '226'),
(35, 'Burundi', 'BI', '257'),
(36, 'Cambodia', 'KH', '855'),
(37, 'Cameroon', 'CM', '237'),
(38, 'Canada', 'CA', '1'),
(39, 'Cape Verde', 'CV', '238'),
(40, 'Cayman Islands', 'KY', '1'),
(41, 'Central African Republic', 'CF', '236'),
(42, 'Chad', 'TD', '235'),
(43, 'Chile', 'CL', '56'),
(44, 'China', 'CN', '86'),
(45, 'Colombia', 'CO', '57'),
(46, 'Comoros', 'KM', '269'),
(47, 'Congo', 'CG', '242'),
(48, 'Cook Islands', 'CK', '682'),
(49, 'Costa Rica', 'CR', '506'),
(50, 'Cote d\'Ivoire', 'CI', '225'),
(51, 'Croatia', 'HR', '385'),
(52, 'Cuba', 'CU', '53'),
(53, 'Cyprus', 'CY', '357'),
(54, 'Czech Republic', 'CZ', '420'),
(55, 'Democratic Republic of the Congo', 'CD', '243'),
(56, 'Denmark', 'DK', '45'),
(57, 'Diego Garcia', 'DG', '246'),
(58, 'Djibouti', 'DJ', '253'),
(59, 'Dominica', 'DM', '1'),
(60, 'Dominican Republic', 'DO', '1'),
(61, 'East Timor', 'TL', '670'),
(62, 'Ecuador', 'EC', '593'),
(63, 'Egypt', 'EG', '20'),
(64, 'El Salvador', 'SV', '503'),
(65, 'Equatorial Guinea', 'GQ', '240'),
(66, 'Eritrea', 'ER', '291'),
(67, 'Estonia', 'EE', '372'),
(68, 'Ethiopia', 'ET', '251'),
(69, 'Falkland Islands', 'FK', '500'),
(70, 'Faroe Islands', 'FO', '298'),
(71, 'Fiji', 'FJ', '679'),
(72, 'Finland', 'FI', '358'),
(73, 'France', 'FR', '33'),
(74, 'French Guiana', 'GF', '594'),
(75, 'French Polynesia', 'PF', '689'),
(76, 'Gabon', 'GA', '241'),
(77, 'Gambia', 'GM', '220'),
(78, 'Georgia', 'GE', '995'),
(79, 'Germany', 'DE', '49'),
(80, 'Ghana', 'GH', '233'),
(81, 'Gibraltar', 'GI', '350'),
(82, 'Greece', 'GR', '30'),
(83, 'Greenland', 'GL', '299'),
(84, 'Grenada', 'GD', '1'),
(85, 'Guadeloupe', 'GP', '590'),
(86, 'Guam', 'GU', '1'),
(87, 'Guatemala', 'GT', '502'),
(88, 'Guinea', 'GN', '224'),
(89, 'Guinea-Bissau', 'GW', '245'),
(90, 'Guyana', 'GY', '592'),
(91, 'Haiti', 'HT', '509'),
(92, 'Honduras', 'HN', '504'),
(93, 'Hong Kong', 'HK', '852'),
(94, 'Hungary', 'HU', '36'),
(95, 'Iceland', 'IS', '354'),
(96, 'India', 'IN', '91'),
(97, 'Indonesia', 'ID', '62'),
(98, 'Iran', 'IR', '98'),
(99, 'Iraq', 'IQ', '964'),
(100, 'Ireland', 'IE', '353'),
(101, 'Israel', 'IL', '972'),
(102, 'Italy', 'IT', '39'),
(103, 'Jamaica', 'JM', '1'),
(104, 'Japan', 'JP', '81'),
(105, 'Jordan', 'JO', '962'),
(106, 'Kazakhstan', 'KZ', '7'),
(107, 'Kenya', 'KE', '254'),
(108, 'Kiribati', 'KI', '686'),
(109, 'Kuwait', 'KW', '965'),
(110, 'Kyrgyzstan', 'KG', '996'),
(111, 'Laos', 'LA', '856'),
(112, 'Latvia', 'LV', '371'),
(113, 'Lebanon', 'LB', '961'),
(114, 'Lesotho', 'LS', '266'),
(115, 'Liberia', 'LR', '231'),
(116, 'Libya', 'LY', '218'),
(117, 'Liechtenstein', 'LI', '423'),
(118, 'Lithuania', 'LT', '370'),
(119, 'Luxembourg', 'LU', '352'),
(120, 'Macao', 'MO', '853'),
(121, 'Macedonia', 'MK', '389'),
(122, 'Madagascar', 'MG', '261'),
(123, 'Malawi', 'MW', '265'),
(124, 'Malaysia', 'MY', '60'),
(125, 'Maldives', 'MV', '960'),
(126, 'Mali', 'ML', '223'),
(127, 'Malta', 'MT', '356'),
(128, 'Marshall Islands', 'MH', '692'),
(129, 'Martinique', 'MQ', '596'),
(130, 'Mauritania', 'MR', '222'),
(131, 'Mauritius', 'MU', '230'),
(132, 'Mexico', 'MX', '52'),
(133, 'Micronesia', 'FM', '691'),
(134, 'Moldova', 'MD', '373'),
(135, 'Monaco', 'MC', '377'),
(136, 'Mongolia', 'MN', '976'),
(137, 'Montenegro', 'ME', '382'),
(138, 'Montserrat', 'MS', '1'),
(139, 'Morocco', 'MA', '212'),
(140, 'Mozambique', 'MZ', '258'),
(141, 'Myanmar', 'MM', '95'),
(142, 'Namibia', 'NA', '264'),
(143, 'Nauru', 'NR', '674'),
(144, 'Nepal', 'NP', '977'),
(145, 'Netherlands', 'NL', '31'),
(146, 'New Caledonia', 'NC', '687'),
(147, 'New Zealand', 'NZ', '64'),
(148, 'Nicaragua', 'NI', '505'),
(149, 'Niger', 'NE', '227'),
(150, 'Nigeria', 'NG', '234'),
(151, 'Niue', 'NU', '683'),
(152, 'North Korea', 'KP', '850'),
(153, 'Northern Mariana Islands', 'MP', '1'),
(154, 'Norway', 'NO', '47'),
(155, 'Oman', 'OM', '968'),
(156, 'Pakistan', 'PK', '92'),
(157, 'Palau', 'PW', '680'),
(158, 'Palestine', 'PS', '970'),
(159, 'Panama', 'PA', '507'),
(160, 'Papua New Guinea', 'PG', '675'),
(161, 'Paraguay', 'PY', '595'),
(162, 'Peru', 'PE', '51'),
(163, 'Philippines', 'PH', '63'),
(164, 'Poland', 'PL', '48'),
(165, 'Portugal', 'PT', '351'),
(166, 'Puerto Rico', 'PR', '1'),
(167, 'Qatar', 'QA', '974'),
(168, 'Reunion', 'RE', '262'),
(169, 'Romania', 'RO', '40'),
(170, 'Russia', 'RU', '7'),
(171, 'Rwanda', 'RW', '250'),
(172, 'Saint Helena', 'SH', '290'),
(173, 'Saint Kitts and Nevis', 'KN', '1'),
(174, 'Saint Lucia', 'LC', '1'),
(175, 'Saint Pierre and Miquelon', 'PM', '508'),
(176, 'Saint Vincent and Grenadines', 'VC', '1'),
(177, 'Samoa', 'WS', '685'),
(178, 'San Marino', 'SM', '378'),
(179, 'Sao Tome and Principe', 'ST', '239'),
(180, 'Saudi Arabia', 'SA', '966'),
(181, 'Senegal', 'SN', '221'),
(182, 'Serbia', 'RS', '381'),
(183, 'Seychelles', 'SC', '248'),
(184, 'Sierra Leone', 'SL', '232'),
(185, 'Singapore', 'SG', '65'),
(186, 'Slovakia', 'SK', '421'),
(187, 'Slovenia', 'SI', '386'),
(188, 'Solomon Islands', 'SB', '677'),
(189, 'Somalia', 'SO', '252'),
(190, 'South Africa', 'ZA', '27'),
(191, 'Republic of South Korea', 'KR', '82'),
(192, 'Spain', 'ES', '34'),
(193, 'Sri Lanka', 'LK', '94'),
(194, 'Sudan', 'SD', '249'),
(195, 'Suriname', 'SR', '597'),
(196, 'Swaziland', 'SZ', '268'),
(197, 'Sweden', 'SE', '46'),
(198, 'Switzerland', 'CH', '41'),
(199, 'Syria', 'SY', '963'),
(200, 'Taiwan', 'TW', '886'),
(201, 'Tajikistan', 'TJ', '992'),
(202, 'Tanzania', 'TZ', '255'),
(203, 'Thailand', 'TH', '66'),
(204, 'Togo', 'TG', '228'),
(205, 'Tokelau', 'TK', '690'),
(206, 'Tonga', 'TO', '676'),
(207, 'Trinidad and Tobago', 'TT', '1'),
(208, 'Tunisia', 'TN', '216'),
(209, 'Turkey', 'TR', '90'),
(210, 'Turkmenistan', 'TM', '993'),
(211, 'Turks and Caicos Islands', 'TC', '1'),
(212, 'Tuvalu', 'TV', '688'),
(213, 'US Virgin Islands', 'VI', '1'),
(214, 'Uganda', 'UG', '256'),
(215, 'Ukraine', 'UA', '380'),
(216, 'United Arab Emirates', 'AE', '971'),
(217, 'United Kingdom', 'GB', '44'),
(218, 'United States', 'US', '1'),
(219, 'Uruguay', 'UY', '598'),
(220, 'Uzbekistan', 'UZ', '998'),
(221, 'Vanuatu', 'VU', '678'),
(222, 'Vatican City', 'VA', '379'),
(223, 'Venezuela', 'VE', '58'),
(224, 'Vietnam', 'VN', '84'),
(225, 'Wallis and Futuna', 'WF', '681'),
(226, 'Yemen', 'YE', '967'),
(227, 'Zambia', 'ZM', '260'),
(228, 'Zimbabwe', 'ZW', '263'),
(229, 'Republic Of South Korea', '', ''),
(230, 'West Indies', '', ''),
(231, 'Kosovo', '', ''),
(232, 'Guernsey', '', ''),
(233, 'Not Provided', '', ''),
(234, 'Trinidad And Tobago', '', ''),
(235, 'Bosnia And Herzegovina', '', ''),
(236, 'Antigua And Barbuda', '', ''),
(237, 'Saadia: 146 Sherber', '', ''),
(238, 'Us Virgin Islands', '', ''),
(239, 'Democratic Republic Of The Congo', '', ''),
(240, 'Cote D\'Ivoire', '', '');

-- --------------------------------------------------------

--
-- Table structure for table `degrees`
--

CREATE TABLE `degrees` (
  `id` int(11) NOT NULL,
  `name` varchar(250) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

--
-- Dumping data for table `degrees`
--

INSERT INTO `degrees` (`id`, `name`) VALUES
(1, 'BAMS'),
(2, 'BChD'),
(3, 'BDent'),
(4, 'BDS'),
(5, 'BM'),
(6, 'BMBCh.'),
(7, 'BMed'),
(8, 'CSc'),
(9, 'DAOM'),
(10, 'DDS'),
(11, 'Dipl. Med.'),
(12, 'DM'),
(13, 'DM SC'),
(14, 'DMD'),
(15, 'DO'),
(16, 'DPM'),
(17, 'Dr. hab'),
(18, 'Dr. nauk med'),
(19, 'Dr.Med'),
(20, 'Drnauk'),
(21, 'DRPH'),
(22, 'DVM'),
(23, 'FAAD'),
(24, 'FAAP'),
(25, 'FACC'),
(26, 'FACE'),
(27, 'FACP'),
(28, 'FACR'),
(29, 'FACS'),
(30, 'FCCP'),
(31, 'FRACP'),
(32, 'FRCA'),
(33, 'FRCGP'),
(34, 'FRCOG'),
(35, 'FRCOpht'),
(36, 'FRCP'),
(37, 'FRCPath'),
(38, 'FRCPC'),
(39, 'FRCR'),
(40, 'FRCS'),
(41, 'FRCSC'),
(42, 'FRNZCGP'),
(43, 'FRSC'),
(44, 'GP'),
(45, 'Hon MD'),
(46, 'JD'),
(47, 'K.M.H.'),
(48, 'Lek. Med.'),
(49, 'M.S. Sci'),
(50, 'MA'),
(51, 'MAOM'),
(52, 'MB'),
(53, 'MB ChB'),
(54, 'MBA'),
(55, 'MBBS'),
(56, 'MD'),
(57, 'MD (Ay)'),
(58, 'MD Siddha'),
(59, 'Med Dr'),
(60, 'MPA'),
(61, 'MPH'),
(62, 'MRCGP'),
(63, 'MRCP'),
(64, 'MS'),
(65, 'MSC'),
(66, 'MSCN'),
(67, 'MUDr.'),
(68, 'OD'),
(69, 'PA'),
(70, 'PHARM'),
(71, 'PHARM D'),
(72, 'PHARM M'),
(73, 'PhD'),
(74, 'PsyD'),
(75, 'RN'),
(76, 'RPH'),
(77, 'SCD');

-- --------------------------------------------------------

--
-- Table structure for table `failed_jobs`
--

CREATE TABLE `failed_jobs` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `uuid` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `connection` text COLLATE utf8mb4_unicode_ci NOT NULL,
  `queue` text COLLATE utf8mb4_unicode_ci NOT NULL,
  `payload` longtext COLLATE utf8mb4_unicode_ci NOT NULL,
  `exception` longtext COLLATE utf8mb4_unicode_ci NOT NULL,
  `failed_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `migrations`
--

CREATE TABLE `migrations` (
  `id` int(10) UNSIGNED NOT NULL,
  `migration` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `batch` int(11) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `migrations`
--

INSERT INTO `migrations` (`id`, `migration`, `batch`) VALUES
(11, '2014_10_12_000000_create_users_table', 1),
(12, '2014_10_12_100000_create_password_resets_table', 1),
(13, '2016_06_01_000001_create_oauth_auth_codes_table', 1),
(14, '2016_06_01_000002_create_oauth_access_tokens_table', 1),
(15, '2016_06_01_000003_create_oauth_refresh_tokens_table', 1),
(16, '2016_06_01_000004_create_oauth_clients_table', 1),
(17, '2016_06_01_000005_create_oauth_personal_access_clients_table', 1),
(18, '2019_08_19_000000_create_failed_jobs_table', 1),
(19, '2019_12_14_000001_create_personal_access_tokens_table', 1),
(20, '2022_12_20_042221_create_permission_tables', 1);

-- --------------------------------------------------------

--
-- Table structure for table `model_has_permissions`
--

CREATE TABLE `model_has_permissions` (
  `permission_id` bigint(20) UNSIGNED NOT NULL,
  `model_type` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `model_id` bigint(20) UNSIGNED NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `model_has_roles`
--

CREATE TABLE `model_has_roles` (
  `role_id` bigint(20) UNSIGNED NOT NULL,
  `model_type` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `model_id` bigint(20) UNSIGNED NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `model_has_roles`
--

INSERT INTO `model_has_roles` (`role_id`, `model_type`, `model_id`) VALUES
(1, 'App\\Models\\User', 1),
(2, 'App\\Models\\User', 2);

-- --------------------------------------------------------

--
-- Table structure for table `oauth_access_tokens`
--

CREATE TABLE `oauth_access_tokens` (
  `id` varchar(100) COLLATE utf8mb4_unicode_ci NOT NULL,
  `user_id` bigint(20) UNSIGNED DEFAULT NULL,
  `client_id` char(36) COLLATE utf8mb4_unicode_ci NOT NULL,
  `name` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `scopes` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `revoked` tinyint(1) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  `expires_at` datetime DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `oauth_access_tokens`
--

INSERT INTO `oauth_access_tokens` (`id`, `user_id`, `client_id`, `name`, `scopes`, `revoked`, `created_at`, `updated_at`, `expires_at`) VALUES
('21a934668c61ab80a7141ac175cc0e8ee514573aa5ff192b08dd7686486a1475bca8ea21020e0207', 1, '98060491-874e-47ac-8fc9-f65c9152fa4a', NULL, '[]', 0, '2022-12-20 03:20:51', '2022-12-20 03:20:51', '2022-12-26 08:50:51'),
('24bdbed76f391591de6bc4160f2134daa65408e0ba104b805ed66c2310b0969ca81446b498c6a3cd', 1, '98060491-874e-47ac-8fc9-f65c9152fa4a', NULL, '[]', 0, '2022-12-20 03:15:39', '2022-12-20 03:15:39', '2022-12-26 08:45:39'),
('c4bf5a9d47f3da76436f8cb88d2da738927e162f65d0f155138fad4d776c609d6766eaff484f1aa4', 2, '98060491-874e-47ac-8fc9-f65c9152fa4a', NULL, '[]', 0, '2023-01-09 05:19:53', '2023-01-09 05:19:53', '2023-01-15 10:49:53');

-- --------------------------------------------------------

--
-- Table structure for table `oauth_auth_codes`
--

CREATE TABLE `oauth_auth_codes` (
  `id` varchar(100) COLLATE utf8mb4_unicode_ci NOT NULL,
  `user_id` bigint(20) UNSIGNED NOT NULL,
  `client_id` char(36) COLLATE utf8mb4_unicode_ci NOT NULL,
  `scopes` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `revoked` tinyint(1) NOT NULL,
  `expires_at` datetime DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `oauth_auth_codes`
--

INSERT INTO `oauth_auth_codes` (`id`, `user_id`, `client_id`, `scopes`, `revoked`, `expires_at`) VALUES
('06eb07f1ee65a7ad81317ae32692c245a93b89862ad2893966b7a7d6b3bc825a48ddcde75a18c130', 1, '98060491-874e-47ac-8fc9-f65c9152fa4a', '[]', 1, '2022-12-20 09:00:50'),
('77cf5fda5e70208e8fdd5a2eac5e0091df7b15f82524b76b0676495c5c45ab06964eb28b06b280cb', 2, '98060491-874e-47ac-8fc9-f65c9152fa4a', '[]', 1, '2023-01-09 10:59:51'),
('8f411d53adaccd9a03d921df6d199ec8a220f63e62fd87926708c599b42db5aeec96767f0e86c592', 1, '98060491-874e-47ac-8fc9-f65c9152fa4a', '[]', 1, '2022-12-20 08:55:05');

-- --------------------------------------------------------

--
-- Table structure for table `oauth_clients`
--

CREATE TABLE `oauth_clients` (
  `id` char(36) COLLATE utf8mb4_unicode_ci NOT NULL,
  `user_id` bigint(20) UNSIGNED DEFAULT NULL,
  `name` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `secret` varchar(100) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `provider` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `redirect` text COLLATE utf8mb4_unicode_ci NOT NULL,
  `personal_access_client` tinyint(1) NOT NULL,
  `password_client` tinyint(1) NOT NULL,
  `revoked` tinyint(1) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `oauth_clients`
--

INSERT INTO `oauth_clients` (`id`, `user_id`, `name`, `secret`, `provider`, `redirect`, `personal_access_client`, `password_client`, `revoked`, `created_at`, `updated_at`) VALUES
('9805ffe8-8727-4128-a6dc-94f17ce4d68a', NULL, 'Laravel Personal Access Client', 'eyJPSPwC5wS1ccZ1iBxkpuEiUNuV5AAeDAArbF2y', NULL, 'http://localhost', 1, 0, 0, '2022-12-20 00:19:16', '2022-12-20 00:19:16'),
('9805ffe8-923e-4de5-857d-bed7a690c08c', NULL, 'Laravel Password Grant Client', 'ihFmGaHP4ajBzC6ZXxm2so221Ju9Z1Ytb8Dm4fPa', 'users', 'http://localhost', 0, 1, 0, '2022-12-20 00:19:16', '2022-12-20 00:19:16'),
('980603d3-b72b-43ba-8d41-6de6649701b5', NULL, 'quantinova', 'SyoiJMCmjkyXepsxSRjLqYdPm9Ei5zraBtloULCN', NULL, 'http://localhost:2000/callback', 0, 0, 0, '2022-12-20 00:30:14', '2022-12-20 00:30:14'),
('9806045d-357c-4837-9ff7-12887cb6a537', NULL, 'renova', '2jwxlAHkRwdZZzZyqTiOOUk6NMwnbomSO5O3z3ed', NULL, 'http://localhost:4200/callback', 0, 0, 0, '2022-12-20 00:31:44', '2022-12-20 00:31:44'),
('98060491-874e-47ac-8fc9-f65c9152fa4a', NULL, 'stanova', 'jklBSNnMcdrGIQXv9K2ENfs8sr5GZ62N3rvo5eo6', NULL, 'http://localhost:9000/callback', 0, 0, 0, '2022-12-20 00:32:18', '2022-12-20 00:32:18'),
('980604c3-bc00-4847-a80c-ebf01559b112', NULL, 'sonova', 'uo95OSEvqwAPHuGy2yONP8A8Ts9LJkIuXYRggqFo', NULL, 'https://connect.quantinova.ai/callback', 0, 0, 0, '2022-12-20 00:32:51', '2022-12-20 00:32:51'),
('980604ea-f4ed-4cdf-8bde-41a2458bf597', NULL, 'jnl', 'fXEuqQafxyVsUZddlLji3h1VGe4eJ4q6L7mryiFK', NULL, 'https://neotericlifescience.com/callback', 0, 0, 0, '2022-12-20 00:33:17', '2022-12-20 00:33:17');

-- --------------------------------------------------------

--
-- Table structure for table `oauth_personal_access_clients`
--

CREATE TABLE `oauth_personal_access_clients` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `client_id` char(36) COLLATE utf8mb4_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `oauth_personal_access_clients`
--

INSERT INTO `oauth_personal_access_clients` (`id`, `client_id`, `created_at`, `updated_at`) VALUES
(1, '9805ffe8-8727-4128-a6dc-94f17ce4d68a', '2022-12-20 00:19:16', '2022-12-20 00:19:16');

-- --------------------------------------------------------

--
-- Table structure for table `oauth_refresh_tokens`
--

CREATE TABLE `oauth_refresh_tokens` (
  `id` varchar(100) COLLATE utf8mb4_unicode_ci NOT NULL,
  `access_token_id` varchar(100) COLLATE utf8mb4_unicode_ci NOT NULL,
  `revoked` tinyint(1) NOT NULL,
  `expires_at` datetime DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `oauth_refresh_tokens`
--

INSERT INTO `oauth_refresh_tokens` (`id`, `access_token_id`, `revoked`, `expires_at`) VALUES
('354f1109e0b32de7b76dec98da09be49aa26cbe3e129102c6261cdfd7471aee9ba13cf8d5a96b382', '21a934668c61ab80a7141ac175cc0e8ee514573aa5ff192b08dd7686486a1475bca8ea21020e0207', 0, '2023-01-04 08:50:51'),
('a418dc9da4f0b5160ee8f5c6c1e570072e891c955a45da0354ea74bc5016b13710a39c0e7fb585d4', '24bdbed76f391591de6bc4160f2134daa65408e0ba104b805ed66c2310b0969ca81446b498c6a3cd', 0, '2023-01-04 08:45:39'),
('f90879a6aaa65ef986414e6f5b406f7b83807a882772d32386b1f4cc40fbd327eba580475a4890d7', 'c4bf5a9d47f3da76436f8cb88d2da738927e162f65d0f155138fad4d776c609d6766eaff484f1aa4', 0, '2023-01-24 10:49:53');

-- --------------------------------------------------------

--
-- Table structure for table `organizations`
--

CREATE TABLE `organizations` (
  `id` int(11) NOT NULL,
  `name` varchar(250) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

--
-- Dumping data for table `organizations`
--

INSERT INTO `organizations` (`id`, `name`) VALUES
(1, 'p53 Lab'),
(2, '10X Genomics'),
(3, '20/20 GeneSystems'),
(4, '3-Dimensional Pharmaceuticals'),
(5, '3M Pharmaceuticals'),
(6, '3SBio'),
(7, '3-V Biosciences'),
(8, '4SC'),
(9, '5715qc'),
(10, '7TM Pharma'),
(11, 'A & G Pharmaceutical'),
(12, 'A. Menarini Research & Business Service'),
(13, 'A4P Consulting'),
(14, 'AADi'),
(15, 'AAIPharma'),
(16, 'AB Science'),
(17, 'Abacus International'),
(18, 'Abaris Healthcare'),
(19, 'Abbott'),
(20, 'Abbott Biotherapeutics'),
(21, 'Abbott Healthcare India'),
(22, 'Abbott Laboratories'),
(23, 'Abbott Molecular'),
(24, 'Abbott Northwestern Hospital'),
(25, 'Abbott Nutrition'),
(26, 'Abbott Vascular'),
(27, 'AbbVie'),
(28, 'AbbVie - Abbott'),
(29, 'Abbvie Biotherapeutics'),
(30, 'AbbVie Corporation'),
(31, 'AbbVie Deutschland GmbH & Co KG'),
(32, 'AbbVie Farmacutica'),
(33, 'ABC Corporation'),
(34, 'ABC Farmaceutici'),
(35, 'Abeille Pharmaceuticals'),
(36, 'Abgenix'),
(37, 'AbGenomics'),
(38, 'Abiant - ADM Diagnostics'),
(39, 'Ability Pharmaceutical - AB Therapeutics'),
(40, 'Ability Pharmaceuticals'),
(41, 'Abiogen'),
(42, 'Abiomed'),
(43, 'ABIVAX'),
(44, 'Ablative Solutions'),
(45, 'Ablynx'),
(46, 'ABNOVA'),
(47, 'ABR Analytics'),
(48, 'Abraxis BioScience'),
(49, 'ABsize'),
(50, 'AbVitro'),
(51, 'Abzena'),
(52, 'AC Immune'),
(53, 'Acacia Pharma'),
(54, 'Academic Pharma'),
(55, 'Acadia Pharmaceuticals'),
(56, 'Acambis'),
(57, 'Acaster Consulting'),
(58, 'Acasti Pharma'),
(59, 'Acceleron'),
(60, 'Acceleron Pharma'),
(61, 'AccelLAB'),
(62, 'Accentia'),
(63, 'Accera'),
(64, 'Access Care'),
(65, 'Access Oncology'),
(66, 'Access Pharma'),
(67, 'Acclarent'),
(68, 'Accumetrics'),
(69, 'AccuraGen'),
(70, 'ACEA Biosciences'),
(71, 'AcelRx Pharmaceuticals'),
(72, 'Acerta Pharma'),
(73, 'Acetylon'),
(74, 'Achaogen'),
(75, 'Ach'),
(76, 'Achillion'),
(77, 'Achmea Health Care'),
(78, 'Acino'),
(79, 'Agency for Science, Technology and Research (A*STAR)'),
(80, 'Baxter Innovations'),
(81, 'CogState'),
(82, 'Highscreen'),
(83, 'Neuropsychology Consultants, PLLC'),
(84, 'Prothena'),
(85, 'PTC Therapeutics'),
(86, 'SynAging'),
(87, 'ACO HUD Nordic'),
(88, 'Acologix'),
(89, 'Acorda Therapeutics'),
(90, 'ACORN Research - The West Clinic'),
(91, 'ACORN Research'),
(92, 'Acousys Biodevices'),
(93, 'Acromion GmbH'),
(94, 'Acrux'),
(95, 'ACT Biotech'),
(96, 'ACT Genomics'),
(97, 'Actavis'),
(98, 'Actelion'),
(99, 'Actimis'),
(100, 'Actinium Pharmaceuticals'),
(101, 'Action Cancer'),
(102, 'Action Pharma A/S'),
(103, 'Actis Biologics'),
(104, 'Activartis Biotech'),
(105, 'Activartis Biotech - Trimed Biotech'),
(106, 'ActivBiotics'),
(107, 'Active Biotech'),
(108, 'ActiveLife Scientific'),
(109, 'Activus Pharma'),
(110, 'ActivX Biosciences'),
(111, 'ActoGeniX'),
(112, 'Acucela'),
(113, 'Acuitas Therapeutics'),
(114, 'Acuity Pharmaceuticals'),
(115, 'Acura Pharma'),
(116, 'Acusphere'),
(117, 'Acuvax - Australian Cancer Technology'),
(118, 'Acuvax -Avantogen'),
(119, 'Acuvax - Innovate Oncology'),
(120, 'Adamas Pharmaceuticals'),
(121, 'ADAMED'),
(122, 'Adamis Pharmaceuticals'),
(123, 'Adams Respiratory Therapeutics'),
(124, 'Adapative Biotechnologies'),
(125, 'Adaptimmune Therapeutics'),
(126, 'Adaptive Biotechnologies'),
(127, 'ADC Therapeutics'),
(128, 'Addex Therapeutics'),
(129, 'Addrenex Pharmaceuticals'),
(130, 'Adelphi Real World'),
(131, 'Adelphi Research'),
(132, 'Adelphi Values'),
(133, 'Adenosine Therapeutics'),
(134, 'Synthetic Biologics'),
(135, 'Adera Labs'),
(136, 'Aderis'),
(137, 'Adherex Technologies'),
(138, 'Adial Pharmaceuticals'),
(139, 'ADIENNE'),
(140, 'Adimmune'),
(141, 'AdiStem'),
(142, 'Adjuvantis'),
(143, 'ADM Diagnostics'),
(144, 'ADMA Biologics'),
(145, 'Admera Health'),
(146, 'AdnaGen'),
(147, 'Adnexus Therapeutics'),
(148, 'Adocia'),
(149, 'Adolor'),
(150, 'Adprotech'),
(151, 'ADT Pharmaceuticals'),
(152, 'Aduro BioTech'),
(153, 'Advance Health Solutions'),
(154, 'advanceCor'),
(155, 'Advanced Accelerator Applications'),
(156, 'Advanced Analytic Solutions'),
(157, 'SAS Institute'),
(158, 'Advanced BioScience Laboratories'),
(159, 'Advanced Biotherapy'),
(160, 'Advanced Breast Technologies Consulting'),
(161, 'Advanced Cancer Therapeutics'),
(162, 'Advanced Cell Diagnostics'),
(163, 'Advanced Cell Technology'),
(164, 'Advanced Diving Systems'),
(165, 'Thorlabs'),
(166, 'Advanced Immuni T'),
(167, 'Advanced Life Sciences'),
(168, 'Advanced Neuro-Science Allies'),
(169, 'Advanced Plant Pharma'),
(170, 'Advanced Targeting Systems'),
(171, 'Advanced Testing Laboratory'),
(172, 'Advanced Tissue Sciences'),
(173, 'Advanced Viral Research'),
(174, 'AdvancedMEMS'),
(175, 'Advancell'),
(176, 'Advancing Synergy'),
(177, 'Advancis'),
(178, 'Advantage Health'),
(179, 'Advantagene'),
(180, 'Advaxis'),
(181, 'Advenchen'),
(182, 'ADVENTRX Pharmaceuticals'),
(183, 'Advinus'),
(184, 'Advitech'),
(185, 'ADX NeuroScience'),
(186, 'Adynxx'),
(187, 'AECOM'),
(188, 'Aegera'),
(189, 'Aegerion'),
(190, 'Aeglea Biotherapeutics'),
(191, 'Aeolus Pharma'),
(192, 'Aeon Imaging'),
(193, 'Aerial BioPharma'),
(194, 'Aerie Pharmaceuticals'),
(195, 'AeroGen'),
(196, 'Aeromics'),
(197, 'Aerovance'),
(198, 'Aerpio'),
(199, 'Aesgen'),
(200, 'Aesku Diagnostics'),
(201, 'AESKU.Kipp Institute'),
(202, 'Aeson Therapeutics'),
(203, 'AesRx'),
(204, 'Aestus'),
(205, 'Aeterna Zentaris/Aeterna Laboratories'),
(206, 'Aetna'),
(207, 'Afecta'),
(208, 'Afexa'),
(209, 'Affectis Pharma'),
(210, 'Afferent Pharmaceuticals'),
(211, 'Affibody AB'),
(212, 'Affichem'),
(213, 'Affimed Therapeutics'),
(214, 'Affimed'),
(215, 'Affinium Pharma'),
(216, 'AFFiRiS'),
(217, 'Affitech'),
(218, 'Affymax'),
(219, 'Affymetrix'),
(220, 'Afraxis'),
(221, 'AFT Pharma'),
(222, 'AFTS Labs'),
(223, 'Agalimmune'),
(224, 'Agendia'),
(225, 'Agena Bioscience'),
(226, 'AgenDix GmbH'),
(227, 'Agennix'),
(228, 'Agensys'),
(229, 'Agenus/4-Antibody'),
(230, 'Agenus'),
(231, 'Agenus/Antigenics'),
(232, 'AGI Dermatics'),
(233, 'AGI Therapeutics'),
(234, 'Agile Therapeutics'),
(235, 'Agilent Laboratories'),
(236, 'Agilent Technologies'),
(237, 'Agilite'),
(238, 'Agios Pharmaceuticals'),
(239, 'AGIRx'),
(240, 'AGO Germany'),
(241, 'AgonOx'),
(242, 'Agouron'),
(243, 'AgResearch'),
(244, 'AGY Therapeutics'),
(245, 'Ahn-Gook Pharma'),
(246, 'AHRM'),
(247, 'AiCuris'),
(248, 'Aida Pharma'),
(249, 'AIG'),
(250, 'AIKO Biotechnology'),
(251, 'AIM Therapeutics'),
(252, 'Aio-studien-ggmbh'),
(253, 'Air Liquide Healthcare'),
(254, 'Aircast'),
(255, 'Aires Pharma'),
(256, 'aisho Pharmaceutical'),
(257, 'AIT Austrian Institute of Technology'),
(258, 'Aixlie'),
(259, 'AJ Roboscreen'),
(260, 'Ajanta Pharma'),
(261, 'Ajinomoto'),
(262, 'AkaRx'),
(263, 'Akebia'),
(264, 'Akela Pharma/LAB International'),
(265, 'Akesis'),
(266, 'Akili Interactive Labs'),
(267, 'Akinion'),
(268, 'AKL Technologies'),
(269, 'AkPharma'),
(270, 'Akros Pharma'),
(271, 'Akzo Nobel'),
(272, 'Alabama Clinical Therapeutics'),
(273, 'Alacrity Biosciences'),
(274, 'Alantos'),
(275, 'Alaven'),
(276, 'Alavita'),
(277, 'Alba BioPharm Advisors'),
(278, 'Alba Therapeutics'),
(279, 'Albany Molecular Research'),
(280, 'Alberta Health Services'),
(281, 'Albireo Pharma'),
(282, 'Alborz Darou'),
(283, 'Alcedis'),
(284, 'Alchemgen Therapeutics'),
(285, 'Alchemia'),
(286, 'Alcobra'),
(287, 'Alcon'),
(288, 'Alcresta'),
(289, 'Aldagen'),
(290, 'Aldea Pharmaceuticals'),
(291, 'Alder BioPharma'),
(292, 'Aldevron'),
(293, 'Aldo-Union'),
(294, 'Alembic'),
(295, 'Alere'),
(296, 'Alere Technologies'),
(297, 'Alethia Biotherapeutics'),
(298, 'Alexion'),
(299, 'Alexza'),
(300, 'Alfa Wassermann'),
(301, 'Alfacell'),
(302, 'Alfresa'),
(303, 'Algeta'),
(304, 'Algeta/Anticancer Therapeutic Inventions'),
(305, 'AlgiPharma'),
(306, 'Ali Raif'),
(307, 'Alienor Farma'),
(308, 'Alimera'),
(309, 'Alios'),
(310, 'Alize Pharma'),
(311, 'Alize Pathology'),
(312, 'Alizyme'),
(313, 'ALK-Abello'),
(314, 'Alkem Laboratories'),
(315, 'Alkermes'),
(316, 'Allegro Ophthalmics'),
(317, 'Allelix'),
(318, 'Allerbio'),
(319, 'Allergan'),
(320, 'Allergopharma'),
(321, 'Allergy Associates of LaCrosse'),
(322, 'Allergy Therapeutics'),
(323, 'Allermed'),
(324, 'Allgemeines Krankenhaus Viersen GmbH'),
(325, 'Alliance for Paired Donation'),
(326, 'Alliance Life Sciences'),
(327, 'Alliance Pharma'),
(328, 'Alliancells Bioscience'),
(329, 'Alliant Pharmaceuticals'),
(330, 'Allodynic Therapeutics'),
(331, 'Alloksys'),
(332, 'Allon Therapeutics'),
(333, 'Allos'),
(334, 'Allozyne'),
(335, 'Almac Diagnostics'),
(336, 'Almac Discovery'),
(337, 'Almirall'),
(338, 'Alnara'),
(339, 'Alnylam'),
(340, 'Alopexx'),
(341, 'Alpha StatConsult'),
(342, 'AlphaCore Pharma'),
(343, 'AlphaMed'),
(344, 'Alphamed Consulting'),
(345, 'R Systems International'),
(346, 'Alpharma'),
(347, 'AlphaRx'),
(348, 'AlphaVax'),
(349, 'Alseres Pharma/Boston Life Sciences'),
(350, 'American Life Sci Pharmaceuticals'),
(351, 'Alstrom Syndrome'),
(352, 'Alta-Gila'),
(353, 'Altair Therapeutics'),
(354, 'AltaMed Health Services'),
(355, 'ALTANA Pharma'),
(356, 'AltaRex'),
(357, 'Altea Therapeutics'),
(358, 'Alteon'),
(359, 'Alteris Therapeutics'),
(360, 'Althea'),
(361, 'AltheaDx'),
(362, 'Altheos'),
(363, 'AltheRx Pharma'),
(364, 'Altheus Therapeutics'),
(365, 'Altiris Therapeutics'),
(366, 'Altogen Labs'),
(367, 'Altor BioScience'),
(368, 'Altus'),
(369, 'Alvine Pharmaceuticals'),
(370, 'ALZA'),
(371, 'Alzheon'),
(372, 'AM Biotechnologies'),
(373, 'AMAG Pharma/Advanced Magnetics'),
(374, 'AMAG Pharmaceuticals'),
(375, 'Amakem Therapeutics'),
(376, 'Amalyte Pharma'),
(377, 'Amaranth Medical'),
(378, 'Amarantus Bioscience'),
(379, 'Amarillo Biosciences'),
(380, 'Amarin'),
(381, 'Amazon Biotech'),
(382, 'Ambit Biosciences'),
(383, 'Ambrey Genetic Laboratories'),
(384, 'Ambrilia/Procyon Biopharma'),
(385, 'Ambrx'),
(386, 'Ambry Genetics'),
(387, 'AmCyte'),
(388, 'Amdipharm'),
(389, 'AMDL'),
(390, 'America Stem Cell'),
(391, 'American Biopharma Corporation'),
(392, 'American BioScience'),
(393, 'American Pharmaceutical Partners'),
(394, 'Ameriderm Research'),
(395, 'AmeriHealth Caritas'),
(396, 'Amerimmune'),
(397, 'Ameripath'),
(398, 'Ameritox'),
(399, 'Amgen'),
(400, 'Amgen Europe'),
(401, 'Amgen Canada'),
(402, 'Amgen Research Munich'),
(403, 'Amira pharmaceuticals'),
(404, 'AmKor Pharma'),
(405, 'Amneal'),
(406, 'Amnis Corporation'),
(407, 'Amorcyte'),
(408, 'AmorePacific'),
(409, 'Amorfix Life Sciences'),
(410, 'Amorphical'),
(411, 'Amoy Diagnostics'),
(412, 'Amoytop Biotech'),
(413, 'Ampath Lab'),
(414, 'AM-Pharma'),
(415, 'Amphastar'),
(416, 'Amphivena Therapeutics'),
(417, 'Ampio Pharma'),
(418, 'AmpliMed'),
(419, 'Amplimmune'),
(420, 'AmpliPhi Biosciences'),
(421, 'AmpliPhi Biosciences/Targeted Genetics'),
(422, 'Amsterdam Molecular Therapeutics'),
(423, 'AMT'),
(424, 'Amylin'),
(425, 'Amyloidosis Research Consortium'),
(426, 'Anaborex'),
(427, 'Anaconda Pharma'),
(428, 'Anacor'),
(429, 'Anadys'),
(430, 'Anaeropharma Science'),
(431, 'Care UK'),
(432, 'Analgesic Solutions'),
(433, 'Anallergo'),
(434, 'Analysis by Design'),
(435, 'Analysis Group'),
(436, 'Analysta'),
(437, 'Analytic Consulting Solutions'),
(438, 'Analytica International'),
(439, 'AnaMar'),
(440, 'Anapharm'),
(441, 'AnaptysBio'),
(442, 'Anastasia Marie Laboratories'),
(443, 'Anatom-e Information Systems'),
(444, 'Anavex'),
(445, 'Anchen Pharma'),
(446, 'Andarix Pharmaceuticals'),
(447, '23andMe'),
(448, 'Androclus Therapeutics'),
(449, 'AF-Consult Thailand'),
(450, 'Andromeda Biotech'),
(451, 'Andrx'),
(452, 'Anergis'),
(453, 'Anesiva/Corgentech'),
(454, 'Anexon'),
(455, 'Angelini'),
(456, 'AnGes MG'),
(457, 'Angimmune'),
(458, 'Angioblast'),
(459, 'AngioChem'),
(460, 'Angiocrine Bioscience'),
(461, 'Angiogen'),
(462, 'Angiogenix'),
(463, 'Angiolab'),
(464, 'Angion Biomedica'),
(465, 'Angiotech'),
(466, 'Angstrom Pharma'),
(467, 'Anika'),
(468, 'Janvier Labs'),
(469, 'Animas'),
(470, 'Animated Dynamics'),
(471, 'Aniona'),
(472, 'Ann Arbor Pharmacometrics Group'),
(473, 'Anoixis Corporation'),
(474, 'Anolinx'),
(475, 'AnorMED'),
(476, 'Anosys'),
(477, 'ANP Technologies'),
(478, 'AnPac Bio-Medical Science and Technology'),
(479, 'Anpac Bio-Medical Science'),
(480, 'Ansaris'),
(481, 'Ansh Labs'),
(482, 'Antares Pharma'),
(483, 'Anterios'),
(484, 'Anterogen'),
(485, 'Anthem'),
(486, 'Anthera'),
(487, 'Anthony Mills MD'),
(488, 'Anthra Pharma'),
(489, 'Antibe Therapeutics'),
(490, 'Priocam'),
(491, 'Anticancer Biotech (Beijing)'),
(492, 'AntiCancer'),
(493, 'Antigen Laboratories'),
(494, 'Antigen Express'),
(495, 'Antipodean Pharma'),
(496, 'Isis Pharmaceuticals'),
(497, 'Isarna Therapeutics'),
(498, 'Antisoma'),
(499, 'Antitope Ltd.'),
(500, 'Antoxis Limited'),
(501, 'Antoxis Ltd'),
(502, 'Anvyl, LLC, Irvine'),
(503, 'Anza Therapeutics'),
(504, 'Anzamune'),
(505, 'AOI Pharma'),
(506, 'AOP Orphan'),
(507, 'Aoxing Pharma Company'),
(508, 'Apac Biotech'),
(509, 'Apalexo Biotechnologie'),
(510, 'Apceth'),
(511, 'Apceth GmbH & Co.KG'),
(512, 'apceth Biopharma'),
(513, 'Apeiron Biologics'),
(514, 'APEIRON Biologics AG'),
(515, 'Apex Bioscience'),
(516, 'Apex Epidemiology'),
(517, 'Apex Laboratories Pvt.'),
(518, 'Apexigen'),
(519, 'Aphios'),
(520, 'Aphton'),
(521, 'Apimeds'),
(522, 'Apitope'),
(523, 'Apocell'),
(524, 'Apogee Biotechnology'),
(525, 'Apogenix'),
(526, 'Apogenix AG'),
(527, 'Apogepha Arzneimittel'),
(528, 'Apollo Consolidated'),
(529, 'Apollo Life Sciences'),
(530, 'ApoPharma'),
(531, 'Apotex'),
(532, 'Apoxis'),
(533, 'Appistry'),
(534, 'Apple Tree Partners'),
(535, 'Cellular Dynamics International'),
(536, 'Applied BioMath'),
(537, 'Applied Clinical Intelligence'),
(538, 'Applied Genetic Technologies Corporation'),
(539, 'Applied Maths NV'),
(540, 'Applied Molecular Evolution'),
(541, 'Applied Pharma Research'),
(542, 'Taiho Pharmaceutical'),
(543, 'Applied Research Associates'),
(544, 'Genethon'),
(545, 'Appugliese Professional Advisors'),
(546, 'Aprea AB'),
(547, 'Apricus Biosciences'),
(548, 'Aprogen'),
(549, 'Apsen Farmaceutica'),
(550, 'APT Pharma'),
(551, 'Aptalis Pharma/Axcan Pharma'),
(552, 'Aptamera'),
(553, 'Apthera'),
(554, 'Aptium Oncology'),
(555, 'Aptiv Solutions'),
(556, 'Lorus Therapeutics'),
(557, 'Aptose Biosciences'),
(558, 'Aquarius Population Health'),
(559, 'Araclon'),
(560, 'Aragon Pharmaceutical'),
(561, 'Arakis'),
(562, 'Arana Therapeutics'),
(563, 'Arbor Pharma'),
(564, 'Arbor Research'),
(565, 'Arbor Vita'),
(566, 'Tekmira Pharmaceuticals Corporation'),
(567, 'ARCA biopharma'),
(568, 'Archemix'),
(569, 'Arcarios B.V.'),
(570, 'Archer Biosciences'),
(571, 'Cortice Biosciences'),
(572, 'Archer Pharmaceuticals'),
(573, 'ArcherDX'),
(574, 'Archimedes Development Ltd'),
(575, 'Archimedes Pharma US'),
(576, 'Archimedes, Inc.'),
(577, 'Archivel Farma'),
(578, 'Arcion Therapeutics'),
(579, 'Arcturus Therapeutics'),
(580, 'Ardana'),
(581, 'Ardea Biosciences/IntraBiotics'),
(582, 'Ardelyx'),
(583, 'Ardeypharm'),
(584, 'Akron Rubber Development Laboratory'),
(585, 'Gnesis MANLAB'),
(586, 'Arena Pharma'),
(587, 'Arete Therapeutics'),
(588, 'AREVA Med'),
(589, 'Argenes'),
(590, 'Argenomics'),
(591, 'Argenta Discovery'),
(592, 'arGentis Pharma'),
(593, 'Argentum Group'),
(594, 'argenx BVBA'),
(595, 'arGEN-X BV'),
(596, 'Argos Therapeutics'),
(597, 'Argos Therapeutics/Merix Bioscience'),
(598, 'ARGUS GmbH'),
(599, 'Argyll Biotechnologies'),
(600, 'Ariad'),
(601, 'Ariad Pharmaceuticals'),
(602, 'Ariadne Laboratory'),
(603, 'Ariana Pharmaceuticals'),
(604, 'Ariel Pharma'),
(605, 'aRigen'),
(606, 'Arisaph'),
(607, 'Aristo Pharmaceuticals'),
(608, 'Ariston Pharma'),
(609, 'Arisyn'),
(610, 'Ark Therapeutics'),
(611, 'ARMGO'),
(612, 'ARMO BioScience'),
(613, 'Arno Therapeutics'),
(614, 'AROG Pharmaceuticals'),
(615, 'Aromtech'),
(616, 'Aronex'),
(617, 'Aronora'),
(618, 'Aros Pharma'),
(619, 'Arpida'),
(620, 'ArQule'),
(621, 'Array BioPharma'),
(622, 'Array Biostatistics'),
(623, 'Array Pharmaceuticals'),
(624, 'Arresto Biosciences'),
(625, 'Arriani Pharma'),
(626, 'Arrien Pharmaceuticals'),
(627, 'Arriva Pharma'),
(628, 'Arrow Diagnostics'),
(629, 'Arrow Therapeutics'),
(630, 'Artann Laboratories'),
(631, 'Arteaus Therapeutics'),
(632, 'ARTEC'),
(633, 'Artemida Pharma'),
(634, 'Arteriocyte'),
(635, 'Artery Therapeutics'),
(636, 'Artes Medical'),
(637, 'Arthritis & Diabetes Clinic'),
(638, 'Arthrogen'),
(639, 'Artielle ImmunoTherapeutics'),
(640, 'Artisan Pharma'),
(641, 'ARTU Biologicals'),
(642, 'Art Ventive Medical Group'),
(643, 'Arvinas'),
(644, 'ARYx'),
(645, 'Asahi Kasei Pharma'),
(646, 'Asana BioSciences'),
(647, 'Ascend Therapeutics'),
(648, 'Ascendis Pharma'),
(649, 'Ascenta Therapeutics'),
(650, 'Ascentage Pharma'),
(651, 'Asclepius Analytics'),
(652, 'Ash Access Technology'),
(653, 'AstraZeneca'),
(654, 'Aska Pharma'),
(655, 'Asklepion Pharma'),
(656, 'Asklepios BioPharma'),
(657, 'ASL Brescia'),
(658, 'ASLAN Pharma'),
(659, 'ASLAN Pharmaceuticals'),
(660, 'Asmacure'),
(661, 'Asphelia'),
(662, 'Aspreva Pharma'),
(663, 'Aspyrian Therapeutics'),
(664, 'Associated Pathologists Laboratories'),
(665, 'ASTA Medica'),
(666, 'ASTA Medica Oncology'),
(667, 'Astellas Pharma'),
(668, 'Astellas Pharma Europe'),
(669, 'Asterand'),
(670, 'Asterias Biotherapeutics'),
(671, 'Astex Pharma/SuperGen'),
(672, 'Astex Pharmaceutical'),
(673, 'Astion Pharma'),
(674, 'Astra Biotech GmbH'),
(675, 'Astralis'),
(676, 'AstraZeneca China'),
(677, 'AstraZeneca GmbH'),
(678, 'Asubio'),
(679, 'Asuragen'),
(680, 'Atara Biotherapeutics'),
(681, 'Atara Pinta Santa Maria Biotherapeutics'),
(682, 'ATCC'),
(683, 'Athenex'),
(684, 'AtheroGenics'),
(685, 'AtheroNova'),
(686, 'Athersys'),
(687, 'Atlantic Health System'),
(688, 'Atlantic Health Sciences Corporation'),
(689, 'Atlantic Healthcare'),
(690, 'Atlas Data Systems'),
(691, 'ATLAS Medical Research'),
(692, 'Aton Pharma'),
(693, 'Atossa Genetics'),
(694, 'Atox Bio'),
(695, 'Atreca'),
(696, 'Atrin Pharmaceuticals'),
(697, 'Atrium Innovations'),
(698, 'Atrix'),
(699, 'Attenuon'),
(700, 'Atterocor'),
(701, 'Audentes Therapeutics'),
(702, 'Augmentium Pharma Consulting'),
(703, 'Aurigene Discovery Technologies'),
(704, 'Aurobindo Pharma'),
(705, 'Aurolab'),
(706, 'Auron Healthcare'),
(707, 'Aurora Capital'),
(708, 'Aurora Health Care'),
(709, 'Ausio Pharma'),
(710, 'Auspex'),
(711, 'AustinTest'),
(712, 'Australian Cancer Technology'),
(713, 'Austrianova'),
(714, 'Autism Therapeutics'),
(715, 'Autoimmune Technologies'),
(716, 'Autotelic'),
(717, 'Auven Therapeutics'),
(718, 'Auxilium'),
(719, 'Adverum Biotechnologies'),
(720, 'Avalon Pharma'),
(721, 'Avanir'),
(722, 'Avanir Pharmaceuticals'),
(723, 'AVANT Immunotherapeutics'),
(724, 'Avanti Polar Lipids'),
(725, 'Avantogen'),
(726, 'Avantogen Oncology'),
(727, 'AVAX Technologies'),
(728, 'Avaxia Biologics'),
(729, 'Nitto Denko Avecia'),
(730, 'Sanofi - Aventis'),
(731, 'Sanofi Pasteur'),
(732, 'Aveo Pharmaceuticals'),
(733, 'AVEO Pharma'),
(734, 'Areva Pharmaceuticals'),
(735, 'Avexa'),
(736, 'Avexxin'),
(737, 'Avicena'),
(738, 'Avid Radiopharmaceuticals'),
(739, 'Avidex'),
(740, 'Avidia'),
(741, 'Avigen'),
(742, 'AviGenics'),
(743, 'Avila Therapeutics'),
(744, 'Aviles Bio-technology'),
(745, 'Avimex'),
(746, 'Avineuro'),
(747, 'Avipep Pty Ltd'),
(748, 'AVIR Green Hills Biotechnology'),
(749, 'A-Viral'),
(750, 'AVIVA Biosciences'),
(751, 'AVMBioMed'),
(752, 'Avoltus'),
(753, 'Avontec'),
(754, 'Avraham Pharma'),
(755, 'AWD.pharma'),
(756, 'Delete'),
(757, 'Axaron Bioscience'),
(758, 'Axcentua'),
(759, 'Axdev Groupe'),
(760, 'Axelar'),
(761, 'Axelar AB'),
(762, 'Axentis Pharma'),
(763, 'Axio Research, LLC'),
(764, 'Axis Healthcare Consulting Limited'),
(765, 'Axolabs GmbH'),
(766, 'Axonyx'),
(767, 'Axxima Pharma'),
(768, 'axxonis/NeuroBiotec'),
(769, 'Ayugen Biosciences Private Limited'),
(770, 'AZAD Pharma'),
(771, 'Azano Pharma'),
(772, 'Azaya Therapeutics'),
(773, 'Azelon Pharma/Zelos Therapeutics'),
(774, 'Azevan'),
(775, 'Azore'),
(776, 'Azur Pharma'),
(777, '3B Pharmaceuticals GmbH'),
(778, 'B. Braun Melsungen'),
(779, 'Babar Internal Medicine'),
(780, 'Bach Pharma'),
(781, 'Bachem'),
(782, 'Balance Pharma'),
(783, 'Balboa Biosciences'),
(784, 'Banyan Group'),
(785, 'Banyu Pharma'),
(786, 'Baptist Memorial Health Care Corporation'),
(787, 'BaroFold'),
(788, 'Barr Laboratories'),
(789, 'Barrett, Inc.'),
(790, 'Barrier Therapeutics'),
(791, 'BASF Nutrition'),
(792, 'Leidos Biomedical Research'),
(793, 'Basilea'),
(794, 'Basilea Pharmaceutica Ltd.'),
(795, 'Bast Inc. Limited'),
(796, 'Bausch + Lomb'),
(797, 'Bavarian Nordic'),
(798, 'Baxalta'),
(799, 'Baxter'),
(800, 'Bayada Home Health Care'),
(801, 'Bayer'),
(802, 'Bayhill Therapeutics'),
(803, 'Baylor Miraca Genetics Laboratories, LLC'),
(804, 'Bayside Health'),
(805, 'B. Braun Singapore Pte Ltd.'),
(806, 'BD Biosciences'),
(807, 'BD Biosciences, Cedex, France'),
(808, 'Becton Dickinson'),
(809, 'BioDelivery Sciences International'),
(810, 'BEAT BioTherapeutics Corporation'),
(811, 'Beckman Coulter'),
(812, 'Bd Diabetes Care'),
(813, 'Bedford Laboratories'),
(814, 'Beech Tree Labs'),
(815, 'Beigene (Beijing) Co. Ltd,'),
(816, 'Beijing Biostar Technologies'),
(817, 'Beijing Jiansheng Pharmaceutical Industry Limited Company'),
(818, 'Beijing Northland Biotech. Co.'),
(819, 'Beijing Novogene Bioinformatics Technology Co., Ltd,'),
(820, 'Beijing Shenogen Biomedical Co., Ltd'),
(821, 'Beijing Tide Pharma Co.'),
(822, 'Beijing Tongrentang Health-Pharmaceutical Co., Ltd.'),
(823, 'Beijing Wanteer Bio-Pharma Co.'),
(824, 'Beijing Wei Di Kang Tai Medical Equipment Ltd'),
(825, 'Belgian Volition SA'),
(826, 'Bellicum'),
(827, 'Bellicum Pharmaceuticals'),
(828, 'Bellus Health/Neurochem'),
(829, 'Bencard Allergie'),
(830, 'bene pharmaChem'),
(831, 'BENEO GmbH'),
(832, 'Benitec'),
(833, 'Bennett Statistical Consulting'),
(834, 'Bentley Pharma'),
(835, 'Berg'),
(836, 'BergenBio AS'),
(837, 'Bering Limited'),
(838, 'Berlex Canada'),
(839, 'Berlin Heals GmbH'),
(840, 'Berna Biotech'),
(841, 'Berry Consultants'),
(842, 'Bertek Pharma'),
(843, 'Beta Pharma'),
(844, 'BetaCat Pharmaceuticals'),
(845, 'Betta Pharmaceuticals Co., Ltd'),
(846, 'Bevital AS'),
(847, 'Bexel Pharma'),
(848, 'Bexon Clinical Consulting LLC, Montclair, NJ'),
(849, 'Beyer Research'),
(850, 'Beyond Spring'),
(851, 'Bfa-Development'),
(852, 'Bharat Biotech'),
(853, 'Bharat Serums and Vaccines'),
(854, 'BHV Pharma'),
(855, 'Boehringer Ingelheim Pharma GmbH & Co. KG'),
(856, 'Bicycle Therapeutics'),
(857, 'BIND Biosciences'),
(858, 'BIND Therapeutics'),
(859, 'Binex'),
(860, 'Bio Products Laboratory'),
(861, 'Bio Sidus'),
(862, 'Bioaccelerate'),
(863, 'BioActive Labs'),
(864, 'BioActor'),
(865, 'BioAlliance Pharma'),
(866, 'BioArctic Neuroscience'),
(867, 'Bioarctic Neuroscience AB'),
(868, 'BIOARRAY Therapeutics'),
(869, 'BioAssets Development Corporation'),
(870, 'BioAtla'),
(871, 'BioBalance'),
(872, 'A QIAGEN Company, Wolfenb?ttel'),
(873, 'Bioblocks'),
(874, 'BioBridges'),
(875, 'Biocad Biotechnological'),
(876, 'BIOCAD ??Biotechnology company'),
(877, 'BioCancell'),
(878, 'Bio-Cancer Treatment International'),
(879, 'BioCardia'),
(880, 'Biocare Medical'),
(881, 'Biocare'),
(882, 'Biocartis NV'),
(883, 'Biocartis SA'),
(884, 'BioCentury'),
(885, 'Biocept'),
(886, 'Biocept In'),
(887, 'Bioceros BV,'),
(888, 'BioFocus a Charles River Company'),
(889, 'Bioceros B.V.'),
(890, 'Biochem Pharma'),
(891, 'ProQinase GmbH'),
(892, 'BioChemics'),
(893, 'BioCis Pharma'),
(894, 'BioClinica'),
(895, 'Biocodex'),
(896, 'Biocompatible'),
(897, 'Biocon'),
(898, 'Bioconsult GmbH,'),
(899, 'Biocontrol Limited'),
(900, 'Biocrates Life Sciences AG'),
(901, 'BioCryst'),
(902, 'Biodeal Laboratories'),
(903, 'Biodel'),
(904, 'Biodesix'),
(905, 'BioDiem'),
(906, 'BioDiscovery'),
(907, 'BIOENSIS LLC'),
(908, 'Bioenvision'),
(909, 'Bioforce'),
(910, 'BioForm'),
(911, 'Biofrontera'),
(912, 'Biogem'),
(913, 'Biogen'),
(914, 'Biogen Idec/Biogen'),
(915, 'Biogen-Dompe'),
(916, 'BioGeneric Pharma'),
(917, 'BioGeneriX'),
(918, 'BioGenius'),
(919, 'Biogent'),
(920, 'BioGentech'),
(921, 'Bioheart'),
(922, 'BIOHOPE'),
(923, 'Bioiberica'),
(924, 'Bioimmulance'),
(925, 'BioIncept'),
(926, 'Q2 Solutions'),
(927, 'Bioinova'),
(928, 'BioInvent'),
(929, 'Biois Corp.'),
(930, 'Bio-K+'),
(931, 'Bio-Ker'),
(932, 'Biokine'),
(933, 'Biokom'),
(934, 'Biolaxy'),
(935, 'Bioleaders Corp'),
(936, 'Biolex'),
(937, 'BioLife Science'),
(938, 'Biolik'),
(939, 'BioLineRx'),
(940, 'Biolipox'),
(941, 'Biolitec Pharma'),
(942, 'Biological Dynamics'),
(943, 'Biological E Limited'),
(944, 'Biological Mimetics'),
(945, 'Janssen Research & Development, LLC,'),
(946, 'BiologicTx,'),
(947, 'AbbVie GmbH & Co. KG'),
(948, 'FORUM Pharmaceuticals'),
(949, 'ManRos Therapeutics'),
(950, 'Treventis Corporation'),
(951, 'BioMarck'),
(952, 'BioMarin Pharmaceutical'),
(953, 'BioMAS Ltd.'),
(954, 'Biomay'),
(955, 'Biomed Research & Technologies'),
(956, 'BioMed Valley Discoveries'),
(957, 'Detroit Bio Medical Labs'),
(958, 'Turner Broadcasting System'),
(959, 'Lifeliver Co'),
(960, 'Biomedicine Group'),
(961, 'BioMedicines'),
(962, 'Biomedics Japan'),
(963, 'Biomedicum Genomics Ltd'),
(964, 'bioMerieux'),
(965, 'bioMrieux (Shanghai) Co.,Ltd'),
(966, 'Biomet'),
(967, 'BioMimetic Therapeutics'),
(968, 'Biomira'),
(969, 'bioMmune Technologies'),
(970, 'Biomodels LLC'),
(971, 'Biomodifying LLC'),
(972, 'BioMS'),
(973, 'BiondVax'),
(974, 'BioNet-Asia'),
(975, 'Bioniche'),
(976, 'Bionomics'),
(977, 'Bionor Immuno AS'),
(978, 'Bionor Pharma ASA'),
(979, 'Bionor Pharma/Nutri Pharma ASA'),
(980, 'Bionorica Research'),
(981, 'BioNovion B.V.'),
(982, 'Bionovo'),
(983, 'BioNTech AG'),
(984, 'BioNTech Diagnostics GmbH'),
(985, 'BioNTech RNA Pharmaceuticals GmbH'),
(986, 'Bio-Nucleonics'),
(987, 'BioNumerik'),
(988, 'BIOP AG'),
(989, 'BioPartners GmbH'),
(990, 'Bio-Path'),
(991, 'Biopeutics'),
(992, 'BioPharma Consulting Services, LLC'),
(993, 'Dong-A Pharm. Co. Ltd.'),
(994, 'NOVO NORDISKA/S'),
(995, 'Biopharmagen Corp'),
(996, 'Biopolis S.L.'),
(997, 'Bioprocess Capital Ventures'),
(998, 'BIOPROJET'),
(999, 'Biopure'),
(1000, 'BIOQUAL'),
(1001, 'Bio-Rad Laboratories K.K.'),
(1002, 'Bio-Rad Laboratories,'),
(1003, 'BioRankings'),
(1004, 'Bio-Rad Laboratories'),
(1005, 'Biorex Research and Development Company'),
(1006, 'BioRexis'),
(1007, 'BioSante'),
(1008, 'Biosceptre (Aust) Pty Ltd'),
(1009, 'BioScience Slovakia, Ltd.'),
(1010, 'LGC Biosearch Technologies'),
(1011, 'BioSense Technologies'),
(1012, 'Biosense Webster'),
(1013, 'Biosensor Tools'),
(1014, 'Biosensors Europe SA'),
(1015, 'BioServe Biotechnologies, Ltd.'),
(1016, 'Bio Sidus Sa'),
(1017, 'Biosite'),
(1018, 'Biospective'),
(1019, 'BioSphere Medical'),
(1020, 'BioSpherix, Ltd.'),
(1021, 'BioSpyder Technologies'),
(1022, 'Biostat International'),
(1023, 'Biostat Solutions'),
(1024, 'Biostatistics ??Amgen'),
(1025, 'Biostatistics Consultant,'),
(1026, 'GlaxoSmithKline Pharmaceuticals Limited'),
(1027, 'Biostatistics Wissenschaftlicher Service Pharma GmbH'),
(1028, 'Cubist Pharmaceuticals'),
(1029, 'EMMES Corporation'),
(1030, 'Roche Products Limited'),
(1031, 'Janssen Research and Development,'),
(1032, 'Biostratum'),
(1033, 'Biosuccess Biotech'),
(1034, 'biosyn Arzneimittel'),
(1035, 'Biosynex'),
(1036, 'Biosynexus'),
(1037, 'Bio-Synthesis'),
(1038, 'Biota Holdings'),
(1039, 'Biotec Pharmacon'),
(1040, 'Biotech Equity Partners'),
(1041, 'Biotech Holdings'),
(1042, 'Biotech Pharma'),
(1043, 'Biotech Start-Up Management'),
(1044, 'BioTech Tools SA'),
(1045, 'Biotechnology Incubation Center'),
(1046, 'Aliquot LLC'),
(1047, 'Biotekna'),
(1048, 'BioTelemetry Research (formerly Cardiocore)'),
(1049, 'Biotest'),
(1050, 'Biothera'),
(1051, 'bioTheranostics'),
(1052, 'Biotie'),
(1053, 'BioTime'),
(1054, 'Bioton'),
(1055, 'Biotoscana'),
(1056, 'Biotoxtech'),
(1057, 'BioTrion'),
(1058, 'Biotron Limited'),
(1059, 'Biotronik'),
(1060, 'Biovail'),
(1061, 'BioValve Technologies'),
(1062, 'BioVascular'),
(1063, 'BIO-VED'),
(1064, 'Bioven'),
(1065, 'Bio Ventrix'),
(1066, 'Biovest International'),
(1067, 'BioVex'),
(1068, 'BioVinc'),
(1069, 'Biovitrum'),
(1070, 'BioWa'),
(1071, 'Biowest Therapeutics'),
(1072, 'Bioxcel Branford'),
(1073, 'BioXell'),
(1074, 'Bioxyne/Probiomics'),
(1075, 'Yi new Societe Generale (Beijing) Technology'),
(1076, 'BiPar'),
(1077, 'Birdie Biopharmaceuticals'),
(1078, 'BiRDS Pharma'),
(1079, 'Birmingham Laboratories'),
(1080, 'Birmingham Pediatric Associates'),
(1081, 'bitop'),
(1082, 'Bit Zesty'),
(1083, 'Bium'),
(1084, 'Blackmores'),
(1085, 'Blaze Bioscience'),
(1086, 'Blend Therapeutics'),
(1087, 'Blenderhouse'),
(1088, 'BLIS Technologies'),
(1089, 'Heidelberg Engineering GmbH'),
(1090, 'BLP Consulting'),
(1091, 'Blue Note Pharma'),
(1092, 'Bluebird Bio'),
(1093, 'Blueprint Medicines'),
(1094, 'JBS Science'),
(1095, 'BMP Sunstone'),
(1096, 'BMS, Lawrenceville'),
(1097, 'HELIOS Kliniken'),
(1098, 'BN ImmunoTherapeutics'),
(1099, 'Boehringer Ingelheim Corporation'),
(1100, 'Boehringer Ingelheim'),
(1101, 'Boehringer Ingelheim Taiwan'),
(1102, 'Boehringer Mannheim'),
(1103, 'Boiron'),
(1104, 'Bolder BioPATH'),
(1105, 'Bon Secours Hospital'),
(1106, 'Bone Care International'),
(1107, 'Bone Index Finland'),
(1108, 'Bone Medical'),
(1109, 'Bone Therapeutics'),
(1110, 'Boneca'),
(1111, 'Booster Shot Media'),
(1112, 'Boots Healthcare International'),
(1113, 'BORAD'),
(1114, 'Boreal Genomics'),
(1115, 'Borow Consulting Group'),
(1116, 'Boryung Pharma'),
(1117, 'Boston Biomedical'),
(1118, 'Boston Health Economics'),
(1119, 'Boston Scientific'),
(1120, 'Boston Scientific Corporatio'),
(1121, 'Boston Therapeutics'),
(1122, 'Bostwick Laboratories'),
(1123, 'Bostwick Therapeutics'),
(1124, 'Botanic Century'),
(1125, 'BOWS Pharma'),
(1126, 'BPS Intl,'),
(1127, 'Bracco'),
(1128, 'Bracket Global'),
(1129, 'Brackets'),
(1130, 'Bradley Pharma'),
(1131, 'Bradmer'),
(1132, 'Brain Matters Researc'),
(1133, 'Brain Resource'),
(1134, 'BrainCells'),
(1135, 'BrainStorm Cell Therapeutics'),
(1136, 'Braintree Laboratories'),
(1137, 'Brane Discovery'),
(1138, 'Breakthrough Therapeutics'),
(1139, 'BREONICS'),
(1140, 'BresaGen'),
(1141, 'BriaCell Therapeutics Corp'),
(1142, 'Bridge BioResearch'),
(1143, 'Bristol-Myers Squibb'),
(1144, 'Bristol-Myers Squibb FZ-LLC'),
(1145, 'Bristol-Myers Squibb GmbH & Co. KGaA'),
(1146, 'Bristol-Myers Squibb Pte Ltd'),
(1147, 'Britannia Pharma'),
(1148, 'British American Hospital'),
(1149, 'British Biotech'),
(1150, 'BRN Science'),
(1151, 'Broadvector'),
(1152, 'BRTI Life Sciences'),
(1153, 'BruCells'),
(1154, 'Hospital St. Marienstift Magdeburg GmbH'),
(1155, 'BSP Pharma'),
(1156, 'BT Group'),
(1157, 'BTG'),
(1158, 'BTG International'),
(1159, 'BTG PLC'),
(1160, 'BTS Tissue Typing'),
(1161, 'Bucher & Christian Consulting'),
(1162, 'Buffalo BioLabs'),
(1163, 'Buhl Oncology'),
(1164, 'BUKWANG PHARM.CO.'),
(1165, 'Bukwang Pharma'),
(1166, 'Burke Pharma'),
(1167, 'International Health Management Associates'),
(1168, 'Byk Gulden'),
(1169, 'BZL Biologics'),
(1170, 'C&O Pharma'),
(1171, 'C2N Diagnostics'),
(1172, 'Cabernet Pharmaceuticals'),
(1173, 'Cabrellis'),
(1174, 'Cadence Pharma'),
(1175, 'Cadila Healthcare Limited,'),
(1176, 'Cadila Laboratories'),
(1177, 'Caduceus Information Systems'),
(1178, 'Cahaba Pharma'),
(1179, 'Cicatelli Associate'),
(1180, 'Caladrius Bioscience'),
(1181, 'Calando/Insert Therapeutics'),
(1182, 'CalciMedica'),
(1183, 'Caleco Pharma'),
(1184, 'California Family Health Council'),
(1185, 'California Neuroscience Research Medical Group'),
(1186, 'Calimmune'),
(1187, 'Calistoga Pharma'),
(1188, 'Calithera Biosciences'),
(1189, 'Calitor Sciences'),
(1190, 'Calixa Therapeutics'),
(1191, 'Callisto Pharma'),
(1192, 'Calosyn Pharma'),
(1193, 'Calpis'),
(1194, 'Calyx Therapeutics'),
(1195, 'Calzada Limited'),
(1196, 'Cambridge Cognition'),
(1197, 'Cambridge Laboratories'),
(1198, 'Cambridge Theranostics'),
(1199, 'Camelina'),
(1200, 'Camurus AB'),
(1201, 'CanBas'),
(1202, 'Cancer Advances'),
(1203, 'Cancer Care Center'),
(1204, 'Cancer Communications'),
(1205, 'Cancer Genetics'),
(1206, 'Cancer Healthcare Associates'),
(1207, 'Cancer Prevention Pharma'),
(1208, 'Cancer Research Technology'),
(1209, 'Cancer Solutions Co.'),
(1210, 'Cancer Targeted Technologies'),
(1211, 'Cancer Therapeutics Innovation Group'),
(1212, 'CancerVax Corporation'),
(1213, 'Canfite'),
(1214, 'Cangene'),
(1215, 'Canhelp Genomics'),
(1216, 'Canon'),
(1217, 'Canopus BioPharma'),
(1218, 'Cantabria Farmaceutica'),
(1219, 'Cantex Pharmaceuticals'),
(1220, 'Canyon Pharma'),
(1221, 'Capital Biosciences'),
(1222, 'Capnia'),
(1223, 'Capricor'),
(1224, 'Capstone Therapeutics'),
(1225, 'Cara Therapeutics'),
(1226, 'Carbomed'),
(1227, 'Carbylan'),
(1228, 'CardiAmit'),
(1229, 'Cardio3 BioSciences'),
(1230, 'CardioDx'),
(1231, 'Cardiokine'),
(1232, 'Cardiome'),
(1233, 'CardioNova'),
(1234, 'CardioPep'),
(1235, 'Cardiorentis'),
(1236, 'CardioVascular BioTherapeutics/Cardio Vascular Genetic Engineering'),
(1237, 'Cardiovascular Systems'),
(1238, 'Cardioxyl'),
(1239, 'Cardium'),
(1240, 'CareDx'),
(1241, 'CAREFIRST'),
(1242, 'Carevive Systems'),
(1243, 'Caris Diagnostics'),
(1244, 'Caris Life Sciences'),
(1245, 'Carlsson Research'),
(1246, 'Carmenta HealthInnovations PLC'),
(1247, 'CarnaBio USA'),
(1248, 'Carol B. White & Associates'),
(1249, 'Carpal Pain Solutions'),
(1250, 'Cary Pharma'),
(1251, 'Cascade'),
(1252, 'Castle Biosciences'),
(1253, 'Catabasis'),
(1254, 'Catalent Pharma Solution'),
(1255, 'Catalloid Products'),
(1256, 'Catalysis'),
(1257, 'Catalyst Medical Consulting'),
(1258, 'Catalyst Pharma Partners'),
(1259, 'Catel Network'),
(1260, 'Cavion'),
(1261, 'Cavit Sciences'),
(1262, 'CBA Pharma'),
(1263, 'Cbio'),
(1264, 'CBPartners'),
(1265, 'CBS Squared'),
(1266, 'CBSET'),
(1267, 'cCAM Biotherapeutics'),
(1268, 'CCB Elba test Sponsor'),
(1269, 'CCHERS'),
(1270, 'SC Compa SA'),
(1271, 'CCS Associates'),
(1272, 'CD Pharma India'),
(1273, 'CDG Therapeutics'),
(1274, 'CDO Foodsphere'),
(1275, 'CE Outcomes LLC'),
(1276, 'Cebix'),
(1277, 'Cedar Associates LLC'),
(1278, 'CEDRES CHU Treichville'),
(1279, 'CeGaT'),
(1280, 'Celator Pharmaceuticals'),
(1281, 'Celcuity LLC'),
(1282, 'Celek Pharmaceuticals'),
(1283, 'Celera Corporation'),
(1284, 'Celera'),
(1285, 'Celestial Biologicals'),
(1286, 'Celestial Pharma'),
(1287, 'Celgene'),
(1288, 'Cell Genesys'),
(1289, 'Cell IDx'),
(1290, 'Cell Medica'),
(1291, 'Cell Medicine'),
(1292, 'Cell Pathways'),
(1293, 'Cell Pro Danube Gmbh'),
(1294, 'Cell Signaling Technology'),
(1295, 'Cell Therapeutics'),
(1296, 'Cell Transplants International'),
(1297, 'CellAct Pharma'),
(1298, 'CellAct Pharma GmbH'),
(1299, 'Celladon'),
(1300, 'Cellanyx Diagnostics'),
(1301, 'Cellaria Biosciences'),
(1302, 'Cellceutix'),
(1303, 'CellCure'),
(1304, 'Celldex Therapeutics'),
(1305, 'Cellecta'),
(1306, 'Cellectar'),
(1307, 'Cellectis'),
(1308, 'Cellegy'),
(1309, 'Cellerant Therapeutics'),
(1310, 'Cellerix'),
(1311, 'Celleron'),
(1312, 'Cellex Patient Treatment GmbH'),
(1313, 'Cellgate'),
(1314, 'CellGenix'),
(1315, 'CellMed'),
(1316, 'Cell-Medicine'),
(1317, 'Cellmid/Medical Therapies'),
(1318, 'Cellonis Biotechnologies'),
(1319, 'CellPath Therapeuthics'),
(1320, 'Cellphire'),
(1321, 'CellSievo Private Limited'),
(1322, 'Celltech'),
(1323, 'Celltran'),
(1324, 'CellTrend GmbH'),
(1325, 'Celltrion'),
(1326, 'Celltrion Healthcare'),
(1327, 'Cellular Nanomed'),
(1328, 'Cellular Therapeutics'),
(1329, 'Cellworks Group'),
(1330, 'Cellworks Research India'),
(1331, 'Cellzome'),
(1332, 'Celmed Biosciences'),
(1333, 'Celon Pharma'),
(1334, 'Celprogen'),
(1335, 'CEL-SCI'),
(1336, 'Celsee Diagnostics'),
(1337, 'Celsion'),
(1338, 'Celsus'),
(1339, 'Celtaxsys'),
(1340, 'Celtic Pharma'),
(1341, 'Celyad'),
(1342, 'Cempra'),
(1343, 'CeNeRx'),
(1344, 'CeNeS'),
(1345, 'Centaur'),
(1346, 'Centelion'),
(1347, 'Center for Breast Care'),
(1348, 'Laboratory Corporation of America'),
(1349, 'Center for Molecular Medicine and Immunology/Garden State Cancer Center and Immunomedics'),
(1350, 'Mednax'),
(1351, 'Quintiles'),
(1352, 'Centocor - Janssen Biotech'),
(1353, 'Janssen Research & Development LLC'),
(1354, 'Hamamatsu Photonics K.K.'),
(1355, 'Central Texas Neurology Consultants'),
(1356, 'Centrose'),
(1357, 'PeopleBio'),
(1358, 'Cephalon'),
(1359, 'Cepheid'),
(1360, 'Ceptaris Therapeutics/Yaupon Therapeutics'),
(1361, 'Ception Therapeutics'),
(1362, 'Ceragenix'),
(1363, 'Cerecor'),
(1364, 'Ceregene'),
(1365, 'Cerenis'),
(1366, 'Cerep'),
(1367, 'Ceres Oncology'),
(1368, 'CereSpir'),
(1369, 'Cerevast Therapeutics'),
(1370, 'Cereve'),
(1371, 'Cerexa'),
(1372, 'Cergentis B.V.'),
(1373, 'Cerilliant Corporation'),
(1374, 'Cerimon'),
(1375, 'Cerner Corporation World Head Quarters (WHQ)'),
(1376, 'Cerner ?sterreich GmbH'),
(1377, 'Cerora,'),
(1378, 'Cerovene'),
(1379, 'CerRx'),
(1380, 'Cerulean Pharma'),
(1381, 'Cerus'),
(1382, 'Cerylid Biosciences'),
(1383, 'Cesca Therapeutics'),
(1384, 'Cetara Life Sciences'),
(1385, 'Cetero'),
(1386, 'CFD Research Corporation'),
(1387, 'CG Therapeutics'),
(1388, 'CGG-Klinik GmbH'),
(1389, 'Surplus General Viel'),
(1390, 'Chakshu'),
(1391, 'Champions Biotechnology'),
(1392, 'Champions Oncology'),
(1393, 'Champlin Technologies'),
(1394, 'Changchun Baike'),
(1395, 'Changchun Changsheng Life Sciences'),
(1396, 'Changchun Huayang High-tech'),
(1397, 'ChanRx'),
(1398, 'Charak Pharma'),
(1399, 'Charles River Laboratories'),
(1400, 'Charleston Laboratories'),
(1401, 'CharlestonPharma'),
(1402, 'Chase Pharma'),
(1403, 'Checkmate Pharmaceuticals'),
(1404, 'Chegg'),
(1405, 'Connexios Life Science'),
(1406, 'Chelsea Therapeutics'),
(1407, 'Chem Tech Research Incorporation'),
(1408, 'ChemGenex'),
(1409, 'ChemoCentryx'),
(1410, 'Chemokine'),
(1411, 'CHEMO Romikin S.A.'),
(1412, 'Chengdu Kanghong'),
(1413, 'Chiasma'),
(1414, 'Chiesi'),
(1415, 'Child Health Corporation of America'),
(1416, 'Janssen Pharmaceuticals'),
(1417, 'Chimeric Therapies'),
(1418, 'Chimerix'),
(1419, 'China Biologic Products'),
(1420, 'China Biopharma'),
(1421, 'China Medical System'),
(1422, 'China Pharma'),
(1423, 'China Shenghuo Pharma'),
(1424, 'ChiRhoClin'),
(1425, 'Chiron'),
(1426, 'Choice Pharma'),
(1427, 'Chong Kun Dang Pharmaceuticals'),
(1428, 'Chongqing Jiachen'),
(1429, 'Chr. Hansen'),
(1430, 'Chroma Therapeutics'),
(1431, 'ChromoTek'),
(1432, 'Chronix Biomedical,'),
(1433, 'ChronTech Pharma AB/Tripep AB'),
(1434, 'Chrysalis BioTechnology'),
(1435, 'Chrysalis Biotherapeutics'),
(1436, 'Chugai Pharmaceutical'),
(1437, 'Chugai Pharmabody Research'),
(1438, 'Ciba-Geigy'),
(1439, 'CIBIC'),
(1440, 'Cielo Therapeutics'),
(1441, 'CigArrest Pty Ltd'),
(1442, 'Cigna'),
(1443, 'Cilag GmbH'),
(1444, 'CIMAB'),
(1445, 'CIMYM BioSciences'),
(1446, 'Cincinnati Hematology Oncology'),
(1447, 'Cinkate'),
(1448, 'CinnaGen'),
(1449, 'IMHealthScience'),
(1450, 'Cipher Pharma'),
(1451, 'Cipla'),
(1452, 'Circ Pharma'),
(1453, 'Circassia Limited'),
(1454, 'Circulogene Theranostics'),
(1455, 'Cita Neuro Pharma'),
(1456, 'Citius Pharma'),
(1457, 'Citrine Technologies'),
(1458, 'Civitas Therapeutics'),
(1459, 'CJ Cheiljedang'),
(1460, 'CJSC BIOCAD'),
(1461, 'CK Consulting'),
(1462, 'CK Life Sciences'),
(1463, 'Clarassance'),
(1464, 'Clarient Diagnostic Services'),
(1465, 'Clarient'),
(1466, 'Claritas Genomics'),
(1467, 'Clarus Therapeutics'),
(1468, 'Clavis Pharma'),
(1469, 'CLC bio'),
(1470, 'Clearbridge Biomedics'),
(1471, 'Clearside Biomedical'),
(1472, 'Cleave Biosciences'),
(1473, 'Clera'),
(1474, 'Cleveland BioLabs'),
(1475, 'ClinAssess GmbH'),
(1476, 'Clinical Cancer Research'),
(1477, 'Dong-A ST Co., Ltd.,'),
(1478, 'GlaxoSmithKline Pharmaceuticals Limited.'),
(1479, 'Nestec Ltd'),
(1480, 'Associates of Cape Cod'),
(1481, 'Kinesis Pharma B.V.'),
(1482, 'Pendar Medical LLC'),
(1483, 'QUE Oncology'),
(1484, 'Clinical Diagnostic Strategies, LLC'),
(1485, 'Clinical Pathology Service'),
(1486, 'Clinical Persona'),
(1487, 'Pfizer'),
(1488, 'Janssen Research & Development'),
(1489, 'Merck KGaA'),
(1490, 'Neurocode AG'),
(1491, 'QdotPharma'),
(1492, 'Singapore Health Services Pte Ltd,'),
(1493, 'CRST Ltd.'),
(1494, 'CareFusion'),
(1495, 'Steigerwald Arzneimittelwerk GmbH'),
(1496, 'Hanmi Pharmaceutical'),
(1497, 'Clinical Research Consultant, Del Mar'),
(1498, 'AcariaHealth,'),
(1499, 'Clinical Tools'),
(1500, 'Clinical Trials of Texas'),
(1501, 'Clinilabs'),
(1502, 'CliniPharma'),
(1503, 'Clinomics'),
(1504, 'Biologics Consulting'),
(1505, 'ClinRes Experts, LLC'),
(1506, 'ClinStat GmbH'),
(1507, 'Clintara, LLC'),
(1508, 'CLL Pharma'),
(1509, 'Clovis Oncology'),
(1510, 'Clontech Laboratories'),
(1511, 'Clopton Clinic of Jonesboro'),
(1512, 'Closure Medical Corporation'),
(1513, 'CM&D Pharma'),
(1514, 'CMI India'),
(1515, 'CMP Therapeutics'),
(1516, 'CNN'),
(1517, 'AbbVie Deutschland GmbH'),
(1518, 'Hoffmann-La Roche'),
(1519, 'CNS Therapeutics'),
(1520, 'CNSBio'),
(1521, 'Co KG, Biberach, Germany'),
(1522, 'Co KG'),
(1523, 'Co Ltd'),
(1524, 'Co. KG'),
(1525, 'Co., Ltd'),
(1526, 'COARE Biotechnology'),
(1527, 'Coastal Hospice'),
(1528, 'Cobalis'),
(1529, 'Cobra Therapeutics'),
(1530, 'CoDa Therapeutics'),
(1531, 'Cofactor Genomics'),
(1532, 'CoGenesys'),
(1533, 'Cogentus'),
(1534, 'Cognetix'),
(1535, 'Cognicept'),
(1536, 'Cognigen Corporation'),
(1537, 'Cognis'),
(1538, 'Cognition Pharma'),
(1539, 'Motac Neuroscience'),
(1540, 'Cognoptix'),
(1541, 'ColBar'),
(1542, 'Colby Pharma'),
(1543, 'Cold Genesys'),
(1544, 'Coley Pharma Group'),
(1545, 'Collabrx'),
(1546, 'CollaGenex'),
(1547, 'Collateral Therapeutics'),
(1548, 'Collegium Pharmaceutical'),
(1549, 'Collgard'),
(1550, 'CoLucid Pharma'),
(1551, 'CombiMatrix'),
(1552, 'CoMentis/Athenagen'),
(1553, 'Alcyomics Ltd'),
(1554, 'Compass Biotechnologies/Cyplasin Biomedical'),
(1555, 'Compellis'),
(1556, 'Compendia Bioscience'),
(1557, 'Complix N.V'),
(1558, 'Comprehensive Health Insights'),
(1559, 'In Silico Biosciences'),
(1560, 'Conatus'),
(1561, 'CoNCERT Pharma'),
(1562, 'Concit Pharma'),
(1563, 'Concordia Pharma'),
(1564, 'Concortis Biotherapeutics'),
(1565, 'Confluent Surgical'),
(1566, 'Conforma Therapeutics'),
(1567, 'ConjuChem'),
(1568, 'ConjuGon'),
(1569, 'Conkwest'),
(1570, 'Connetics'),
(1571, 'Consorzio Oncotech'),
(1572, 'Constab Pharma'),
(1573, 'Constellation Pharmaceuticals'),
(1574, 'Constellation Wines'),
(1575, 'Vigilant Biosciences'),
(1576, 'eResearchTechnology'),
(1577, 'Contextive Research'),
(1578, 'Continuum Health Partners'),
(1579, 'Control Delivery Systems'),
(1580, 'Contura'),
(1581, 'Convergence Pharmaceuticals'),
(1582, 'CONVIDIA clinical research GmbH'),
(1583, 'Cook MyoSite'),
(1584, 'Copernicus Therapeutics'),
(1585, 'Corautus Genetics'),
(1586, 'Corcept Therapeutics'),
(1587, 'Cordex Pharma'),
(1588, 'Cordis'),
(1589, 'CoreMed'),
(1590, 'Corestem'),
(1591, 'Coria'),
(1592, 'Corimmun'),
(1593, 'Corium'),
(1594, 'Corixa'),
(1595, 'Corline Systems'),
(1596, 'CorMedix'),
(1597, 'Cornerstone Pharmaceuticals'),
(1598, 'Cornerstone Research Group'),
(1599, 'Chiesi USA'),
(1600, 'Coronado Biosciences'),
(1601, 'Corporate Technology Development'),
(1602, 'Cortendo'),
(1603, 'Cortex Pharma'),
(1604, 'Corthera'),
(1605, 'Corthera/BAS Medical'),
(1606, 'Cortria'),
(1607, 'Corus Pharma'),
(1608, 'Corvas'),
(1609, 'Coserics'),
(1610, 'Cosmo Bioscience'),
(1611, 'Cosmo Pharma'),
(1612, 'Cotherix/Exhale Therapeutics'),
(1613, 'Cougar Biotechnology'),
(1614, 'Covagen AG'),
(1615, 'Covance'),
(1616, 'Covidien/Tyco Healthcare'),
(1617, 'CovX'),
(1618, 'Cox Pharma'),
(1619, 'CPEX Pharma'),
(1620, 'C-Pharma'),
(1621, 'Creabilis'),
(1622, 'CreaGene'),
(1623, 'Creative Biolabs'),
(1624, 'Creative Micro Designs'),
(1625, 'Creatv Microtech'),
(1626, 'Creme Global'),
(1627, 'Crinos SpA'),
(1628, 'Critical Pharma'),
(1629, 'Critical Therapeutics'),
(1630, 'CritiTech'),
(1631, 'Crofoot Research'),
(1632, 'Crohnology.com'),
(1633, 'CromaPharma'),
(1634, 'Crospon Limited'),
(1635, 'Crown Bioscience'),
(1636, 'Crucell'),
(1637, 'CrystalGenomics'),
(1638, 'CSL Behring'),
(1639, 'CSL Limited'),
(1640, 'CSL Ltd'),
(1641, 'CSPC-NBP Pharma'),
(1642, 'CTC Communications Corporation'),
(1643, 'CTI Clinical Trial and Consulting Services'),
(1644, 'CTI Clinical Trial and Consulting'),
(1645, 'CTI Life Sciences Fund'),
(1646, 'CTK Consults'),
(1647, 'CTL ImmunoTherapies'),
(1648, 'Cubist Pharma'),
(1649, 'Cumberland Pharma'),
(1650, 'Cumbre Pharma'),
(1651, 'Cura Biotech'),
(1652, 'Curacyte'),
(1653, 'CuraGen'),
(1654, 'Curalogic'),
(1655, 'Curasan'),
(1656, 'Curatek'),
(1657, 'Curaxis/Voyager Pharma'),
(1658, 'CureDM'),
(1659, 'Curemark'),
(1660, 'CureTech'),
(1661, 'Curetis GmbH'),
(1662, 'CureVac'),
(1663, 'Curidium'),
(1664, 'Curis'),
(1665, 'GlaxoSmithKline'),
(1666, 'CV Technologies'),
(1667, 'CV Therapeutics'),
(1668, 'CVie Therapeutics'),
(1669, 'Cvpath Institute'),
(1670, 'cxpartners'),
(1671, 'CXR Biosciences'),
(1672, 'Cyanotech'),
(1673, 'Cyathus Exquirere'),
(1674, 'Cyberonics'),
(1675, 'Cyclacel'),
(1676, 'CyDex'),
(1677, 'Cylene'),
(1678, 'Cynapsus Therapeutics/Cannasat'),
(1679, 'Cynvenio Biosystems'),
(1680, 'Cypress Bioscience'),
(1681, 'Cyrenaic Pharma'),
(1682, 'Cystemix'),
(1683, 'Cytavis Biopharma'),
(1684, 'Cytel'),
(1685, 'Cytelligen'),
(1686, 'Cytheris'),
(1687, 'CytImmune'),
(1688, 'Cyto Pulse'),
(1689, 'Cytochroma'),
(1690, 'CytoDyn'),
(1691, 'Cytogel'),
(1692, 'Cytogen'),
(1693, 'Cytokine PharmaSciences'),
(1694, 'Cytokinetics'),
(1695, 'Cytomedix'),
(1696, 'CytomX Therapeutics'),
(1697, 'Cytonix LLC'),
(1698, 'Cytopeutics'),
(1699, 'CytoPharm'),
(1700, 'Cytopia'),
(1701, 'Cytori Therapeutics'),
(1702, 'Cytos Biotechnology'),
(1703, 'Cytosystems'),
(1704, 'CytoTest'),
(1705, 'CytoVac'),
(1706, 'Cytox'),
(1707, 'Cytran'),
(1708, 'CytRx'),
(1709, 'D Co., Ltd,'),
(1710, 'D Systems'),
(1711, 'd.s.h. statistical services GmbH'),
(1712, 'D16 Pharma'),
(1713, 'd3 Medicine'),
(1714, 'Dabur Pharma'),
(1715, 'Dabur'),
(1716, 'DAC Research'),
(1717, 'DAEHWA Pharmaceutical'),
(1718, 'Daewon Pharm'),
(1719, 'Daewoong'),
(1720, 'Dafra Pharma International'),
(1721, 'Daihan Pharmaceuticals'),
(1722, 'Daiichi Sankyo'),
(1723, 'Daiichi-Suntory Pharma'),
(1724, 'DIC Corporation'),
(1725, 'Dainippon Sumitomo'),
(1726, 'Dako'),
(1727, 'Dako/Agilent Technologies'),
(1728, 'DanDrit'),
(1729, 'DanioLabs'),
(1730, 'Danisco'),
(1731, 'Danube Pharma'),
(1732, 'Dar Pharma'),
(1733, 'DARA BioSciences'),
(1734, 'DarPharma'),
(1735, 'Dart NeuroScience'),
(1736, 'Dasan Medichem'),
(1737, 'Data Reduction LLC'),
(1738, 'DATA VISION SYSTEM'),
(1739, 'Dava Oncology, L.P.'),
(1740, 'Daval International'),
(1741, 'David Norris Consulting'),
(1742, 'Data Business Per?'),
(1743, 'DBV Technologies'),
(1744, 'DCPrime'),
(1745, 'DCPrime B.V.'),
(1746, 'Debiopharm'),
(1747, 'Deciphera'),
(1748, 'Deciphera Pharmaceuticals'),
(1749, 'Decision Development'),
(1750, 'DecisionQ Corporation'),
(1751, 'deCODE genetics'),
(1752, 'Decoy Biosystems'),
(1753, 'DEKK-TEC'),
(1754, 'Dekkun'),
(1755, 'Dekkun Corporation'),
(1756, 'Del Mar Pharma'),
(1757, 'DelMar Pharmaceuticals'),
(1758, 'Delcath Systems'),
(1759, 'Delenex AG'),
(1760, 'Delphi Bioscience B.V.'),
(1761, 'DelSite/Carrington Laboratories'),
(1762, 'Delta-Fly Pharma'),
(1763, 'Deltanoid'),
(1764, 'Demegen'),
(1765, 'Dendreon'),
(1766, 'Dendreon Corporation'),
(1767, 'Denka'),
(1768, 'Denka Seiken'),
(1769, 'Gastro I. s.r.o., Presov'),
(1770, 'HPL microbiological laboratories'),
(1771, 'Biohit HealthCare'),
(1772, 'SNP Genetics'),
(1773, 'Jiangsu HengRui Medicine Co.'),
(1774, 'Ipsen'),
(1775, 'Kaiser Permanente'),
(1776, 'Hornetcon Biotechnology Company'),
(1777, 'Depomed'),
(1778, 'DePuy Mitek'),
(1779, 'Derma Sciences'),
(1780, 'DermaGen AB'),
(1781, 'Dermik'),
(1782, 'DermiPsor'),
(1783, 'Desitin Arzneimittel'),
(1784, 'Destiny Pharma'),
(1785, 'DeTOURE, LLC'),
(1786, 'Detroit R&d'),
(1787, 'Kyowa Hakko Kirin'),
(1788, 'Cognition Therapeutics'),
(1789, 'Developmental Therapeutics'),
(1790, 'DeVilbiss Healthcare'),
(1791, 'Dexa Medica'),
(1792, 'Dexcel Pharma'),
(1793, 'DexTech Medical'),
(1794, 'Dey'),
(1795, 'DGI Clinical'),
(1796, 'Dharma Biomedical'),
(1797, 'DHP Korea'),
(1798, 'Dia-B Tech'),
(1799, 'Diabetology'),
(1800, 'Diacarta'),
(1801, 'Diaceutics'),
(1802, 'Diadem Ltd'),
(1803, 'diaDexus'),
(1804, 'DiagCor Bioscience'),
(1805, 'DiagnoCure'),
(1806, 'DiagNodus'),
(1807, 'Diagnostic Pathology Medical Group'),
(1808, 'Diagnostic Photonics'),
(1809, 'Amarantus BioScience Holdings'),
(1810, 'DiaKine'),
(1811, 'DIAKO Bremen'),
(1812, 'Diakonieclinic Rotenburg (W?mme) gGmbH'),
(1813, 'Diakron'),
(1814, 'DiaMedica'),
(1815, 'DiamiR'),
(1816, 'Diamyd Medical'),
(1817, 'Dianon Systems'),
(1818, 'Diartis Pharma'),
(1819, 'Diasome'),
(1820, 'DiaSorin'),
(1821, 'Diatech Oncology'),
(1822, 'Diatech Pharmacogenetics S.R.L.'),
(1823, 'Diatos'),
(1824, 'Dicerna Pharmaceuticals'),
(1825, 'Diffusion Pharmaceuticals'),
(1826, 'DifluMed Pharmaceuticals'),
(1827, 'Digestive Care'),
(1828, 'Digital Biology Center, Bio-Rad Laboratorie'),
(1829, 'Digna Biotech'),
(1830, 'Dilts and Partners'),
(1831, 'DiObex'),
(1832, 'Dipexium'),
(1833, 'Direct Therapeutics'),
(1834, 'Directed Genomics'),
(1835, 'Medical Pharmacies Group Limited'),
(1836, 'DiscGenics'),
(1837, 'Tolero Pharmaceuticals'),
(1838, 'Discovery Genomics'),
(1839, 'Windtree Therapeutics'),
(1840, 'ONO PHARMACEUTICAL'),
(1841, 'Janssen'),
(1842, 'Disease Pathways'),
(1843, 'Disneyworld'),
(1844, 'Diurnal Limited'),
(1845, 'Diurnal Group'),
(1846, 'Alltech'),
(1847, 'Intermountain Healthcare'),
(1848, 'TaiyoKagaku.Co'),
(1849, 'Fundacja DKMS'),
(1850, 'DNA Chip Research'),
(1851, 'DNA Direct'),
(1852, 'DNA Electronics'),
(1853, 'DNA Link'),
(1854, 'DNA Therapeutics'),
(1855, 'ATUM'),
(1856, '(Note) DNA link'),
(1857, 'DNAVEC'),
(1858, 'Kiwee Health, LLC, Gainesville'),
(1859, 'Merck Sharp & Dohme (China)'),
(1860, 'Dohmen'),
(1861, 'Dolon Limited'),
(1862, 'DOLPHIN TEST SPONSOR'),
(1863, 'Domain Therapeutics/Faust Pharma'),
(1864, 'Dompe'),
(1865, 'DoNatur'),
(1866, 'Dong Sung'),
(1867, 'Dong Wha'),
(1868, 'Dong-A Pharmaceutical'),
(1869, 'Dong-A Socio-Group'),
(1870, 'Dongkook'),
(1871, 'Donor Alliance'),
(1872, 'Dorr & Associates'),
(1873, 'Douglas Labs'),
(1874, 'DOV Pharma'),
(1875, 'Dow Pharma'),
(1876, 'DP Clinical'),
(1877, 'D-Pharm'),
(1878, 'Vavrusova Consulting s.r.o'),
(1879, 'Dr. Falk Pharma'),
(1880, 'Dr. R. Pfleger GmbH'),
(1881, 'Dr. Reddys Laboratories'),
(1882, 'Dragon Pharma'),
(1883, 'Drais Pharma'),
(1884, 'DreamPharma'),
(1885, 'Driver Group'),
(1886, 'Drogsan'),
(1887, 'DROIA'),
(1888, 'Drossapharm'),
(1889, 'Sumitomo Dainippon Pharma'),
(1890, 'Therapure Biopharma'),
(1891, 'Sanofi Aventis'),
(1892, 'DrugAbuse Sciences'),
(1893, 'DSM Food Specialties'),
(1894, 'Diamond Trading Company, Botswana'),
(1895, 'Du Pont'),
(1896, 'Duck Flats Pharma'),
(1897, 'Duckworth Pathology Group'),
(1898, 'Duopharma'),
(1899, 'Dupont'),
(1900, 'Dupont Pharmaceuticals'),
(1901, 'Duramed Pharmaceuticals'),
(1902, 'Durata Therapeutics'),
(1903, 'DURECT'),
(1904, 'DUSA Pharma'),
(1905, 'Duska Therapeutics'),
(1906, 'Dyax'),
(1907, 'Dynamis Skin Science'),
(1908, 'Dynavax'),
(1909, 'Dynogen'),
(1910, 'DynPort'),
(1911, 'EA Genomics'),
(1912, 'Eagle Pharmaceuticals'),
(1913, 'Eastern Biotech'),
(1914, 'Eastern Health'),
(1915, 'Ebewe Neuro Pharma'),
(1916, 'Ebewe Pharma'),
(1917, 'ECbiotech'),
(1918, 'Echo Pharma'),
(1919, 'Echotech'),
(1920, 'Ecopia'),
(1921, 'EDAP Technomed'),
(1922, 'Edison Pharmaceuticals'),
(1923, 'Editas Medicine'),
(1924, 'Edmond Pharma'),
(1925, 'EDP Biotech'),
(1926, 'Edusa Pharma'),
(1927, 'Edwards Lifesciences'),
(1928, 'EEC Bio-tech'),
(1929, 'Effective Pharma'),
(1930, 'Efficas'),
(1931, 'EffRx'),
(1932, 'Egalet'),
(1933, 'EGEN'),
(1934, 'EGEN/Expression Genetics'),
(1935, 'Eiger BioPharmaceuticals'),
(1936, 'EIP Pharma'),
(1937, 'Eisai'),
(1938, 'EKF Molecular Diagnostics'),
(1939, 'EKR Therapeutics'),
(1940, 'Elan Drug Delivery/Elan'),
(1941, 'Elan Pharmaceutical'),
(1942, 'Elara Pharmaceuticals'),
(1943, 'Elcelyx'),
(1944, 'Elder Pharma'),
(1945, 'Electromedical Products International'),
(1946, 'EMOL Health'),
(1947, 'Eleison Pharma'),
(1948, 'Eleos'),
(1949, 'Elevation Pharma'),
(1950, 'Eli Lilly'),
(1951, 'Eli Lilly Interamerica'),
(1952, 'Elite Pharma'),
(1953, 'Elixir Medical Corporate Headquarters'),
(1954, 'Elixir Pharma'),
(1955, 'Elkhart Group'),
(1956, 'Elorac'),
(1957, 'Elpen'),
(1958, 'Elusys Therapeutics'),
(1959, 'Elysia Group'),
(1960, 'EMB Statistical Solutions'),
(1961, 'European Molecular Biology Laboratory(EMBL)'),
(1962, 'Embria'),
(1963, 'Emcure'),
(1964, 'EMD Lexigen Research Center'),
(1965, 'EMD Millipore'),
(1966, 'EMD Serono'),
(1967, 'EMEA - Janssen Pharmaceuticals'),
(1968, 'Emergent BioSolutions'),
(1969, 'Emergent BioSolutions/BioPort'),
(1970, 'emergentec biodevelopment GmbH'),
(1971, 'EMET Pharma'),
(1972, 'EmipiriQA'),
(1973, 'Emisphere Technologies'),
(1974, 'Emmes Canada'),
(1975, 'Emotional Brain BV'),
(1976, 'Emotra'),
(1977, 'Emphycorp'),
(1978, 'Empire Genomics'),
(1979, 'Enanta'),
(1980, 'Encapsula NanoSciences'),
(1981, 'Enceladus Pharmaceuticals'),
(1982, 'Encelle'),
(1983, 'Encore Pharma'),
(1984, 'Encysive'),
(1985, 'Endo and Metab Consultants'),
(1986, 'Endo Pharmaceuticals'),
(1987, 'Endoceutics'),
(1988, 'Endocyte'),
(1989, 'EndoRheum Consulting'),
(1990, 'Endotis Pharma'),
(1991, 'Endotools therapeutics'),
(1992, 'Endovasc'),
(1993, 'ENEA'),
(1994, 'enGene'),
(1995, 'EngMab'),
(1996, 'Enhance Biotech'),
(1997, 'Enhance Life Sciences'),
(1998, 'ENKAM'),
(1999, 'Enlivex Therapeutics/Tolarex'),
(2000, 'eNos Pharma'),
(2001, 'Entera Bio'),
(2002, 'Entera Health'),
(2003, 'Enterologics'),
(2004, 'Entheogen Corporation'),
(2005, 'Entos Pharmaceutical'),
(2006, 'EntreChem'),
(2007, 'EntreMed'),
(2008, 'Enumeral Biomedical'),
(2009, 'Envision Scientific'),
(2010, 'EnVivo'),
(2011, 'Enzo Biochem'),
(2012, 'Enzon Pharmaceuticals'),
(2013, 'Enzychem Lifesciences'),
(2014, 'EnzymeRx'),
(2015, 'Enzymotec'),
(2016, 'Epeius Biotechnologies'),
(2017, 'Epic Sciences'),
(2018, 'Epic Systems Corporation'),
(2019, 'EpicentRx'),
(2020, 'EpiCept'),
(2021, 'Epidemico'),
(2022, 'EpidStat'),
(2023, 'Epigen Therapeutics'),
(2024, 'EpigenDx'),
(2025, 'Epigenesis');
INSERT INTO `organizations` (`id`, `name`) VALUES
(2026, 'Epigenomics'),
(2027, 'Epigentek'),
(2028, 'Epiliver International'),
(2029, 'EpimedX'),
(2030, 'Epimmune'),
(2031, 'Epiontis GmbH'),
(2032, 'Epiphany Biosciences'),
(2033, 'Epi-Q'),
(2034, 'Episciences'),
(2035, 'EpiSource'),
(2036, 'Epistem'),
(2037, 'Epitech International'),
(2038, 'Epitome Pharma'),
(2039, 'Epitomics'),
(2040, 'Epivax'),
(2041, 'Epizyme'),
(2042, 'EPO GmbH'),
(2043, 'Equidyne Systems'),
(2044, 'Equispharm'),
(2045, 'ErgoNex'),
(2046, 'Erimos/Biocure Medical'),
(2047, 'EryDel'),
(2048, 'ERYtech'),
(2049, 'ERYTECH Pharma'),
(2050, 'Esanex'),
(2051, 'ESBATech'),
(2052, 'ESP Pharma'),
(2053, 'Esperance Pharma'),
(2054, 'Esperance Pharmaceuticals'),
(2055, 'Esperion Therapeutics'),
(2056, 'Esprit Pharma'),
(2057, 'ESSA'),
(2058, 'Essentialis'),
(2059, 'Essex Chemical Corporation'),
(2060, 'Essex Association Management'),
(2061, 'Essex Pharma'),
(2062, 'Estee Lauder'),
(2063, 'Estetra'),
(2064, 'ESTEVE'),
(2065, 'Eternity Bioscience'),
(2066, 'e-Therapeutics'),
(2067, 'Ethical Oncology Science'),
(2068, 'Ethicon'),
(2069, 'Ethris GmbH'),
(2070, 'Ethypharm'),
(2071, 'Etubics'),
(2072, 'Etubics Corporation'),
(2073, 'Eucodis'),
(2074, 'EUFETS GmbH'),
(2075, 'Eunoe'),
(2076, 'Eurand'),
(2077, 'Eureka Therapeutics'),
(2078, 'Eurocine Vaccines'),
(2079, 'Euroimmun'),
(2080, 'EUROIMMUN Medizinische Labordiagnostika AG'),
(2081, 'EUSA Pharma'),
(2082, 'Euthymics'),
(2083, 'Eutropics'),
(2084, 'Eutropics Pharmaceuticals'),
(2085, 'ev3'),
(2086, 'EVER Neuro Pharma'),
(2087, 'Evercyte GmbH'),
(2088, 'Everest Clinical Research'),
(2089, 'Evestra'),
(2090, 'Evicom'),
(2091, 'Sanofi'),
(2092, 'Evidera'),
(2093, 'eviti'),
(2094, 'Evofem'),
(2095, 'Evoke Pharma'),
(2096, 'Evolutec'),
(2097, 'Evolva'),
(2098, 'EvoRx Technologies'),
(2099, 'Evotec'),
(2100, 'Exact Sciences'),
(2101, 'Exagen Diagnostics'),
(2102, 'eXcorLab GmbH'),
(2103, 'ZERO TO THREE'),
(2104, 'Exelixis'),
(2105, 'Eximias'),
(2106, 'Exiqon A/S'),
(2107, 'Exl Services'),
(2108, 'Exonhit'),
(2109, 'Exosome Diagnostics'),
(2110, 'Exoxemis'),
(2111, 'Expanscience'),
(2112, 'Experimental Therapeutics Centre'),
(2113, 'Genentech'),
(2114, 'Galapagos SASU'),
(2115, 'Exponent'),
(2116, 'Exponential Biotherapies'),
(2117, 'Expression Pathology'),
(2118, 'Exprimo NV'),
(2119, 'Exsulin Corp./Kinexum Metabolics'),
(2120, 'EyeGate'),
(2121, 'Eyetech'),
(2122, 'EZLife BioSciTech'),
(2123, 'Roche'),
(2124, 'FAB Pharma'),
(2125, 'Fabre-Kramer Pharma'),
(2126, 'Fachpraxis'),
(2127, 'FACT Trial Group'),
(2128, 'Faes Farma'),
(2129, 'Fahy Gurteen Labs'),
(2130, 'Falco Biosystems'),
(2131, 'Farmacija'),
(2132, 'Farmigea'),
(2133, 'Farmoquimica'),
(2134, 'Fate Therapeutics'),
(2135, 'Faustus Forschungs Company'),
(2136, 'Favrille'),
(2137, 'FC Richardson Consulting'),
(2138, 'FCB-Pharmicell'),
(2139, 'MolMo Services'),
(2140, 'FemmePharma'),
(2141, 'Femta Pharma'),
(2142, 'Femtogenix'),
(2143, 'Ferndale Laboratories'),
(2144, 'Ferozsons Laboratories'),
(2145, 'Ferring'),
(2146, 'Ferring Arzneimittel GmbH'),
(2147, 'Ferring International Center'),
(2148, 'Ferring Pharmaceuticals'),
(2149, 'Ferro Pfanstiehl Laboratories'),
(2150, 'Ferrosan'),
(2151, 'Fertin Pharma'),
(2152, 'FeRx'),
(2153, 'Fibrex Medical'),
(2154, 'Fibrocell Science'),
(2155, 'FibroGen'),
(2156, 'Fidia Advanced Biopolymers/Fidia'),
(2157, 'Fina Biotech'),
(2158, 'Finnegan Consulting'),
(2159, 'FINOX'),
(2160, 'First Horizon Pharma'),
(2161, 'Fisciano'),
(2162, 'FIT Biotech'),
(2163, 'Five Prime Therapeutics'),
(2164, 'Five3 Genomics'),
(2165, 'FivePrime Therapeutics'),
(2166, 'FK Biotec'),
(2167, 'FKD Therapeutics'),
(2168, 'FKx'),
(2169, 'FLAG Therapeutics'),
(2170, 'Flagship Biosciences'),
(2171, 'Flamel Technologies'),
(2172, 'FlatIron Health'),
(2173, 'Fleury Medicina e Sa?de'),
(2174, 'Flexion Therapeutics'),
(2175, 'Flexpharm'),
(2176, 'FLX Bio'),
(2177, 'FlowMetric'),
(2178, 'FLUIDDA nv'),
(2179, 'Fluidigm Corporation'),
(2180, 'Fluoresprobe Sciences'),
(2181, 'Fluorinov Pharma'),
(2182, 'Fmc Biopolymer AS'),
(2183, 'Foundation Medicine'),
(2184, 'Foamix'),
(2185, 'Focus Surgery'),
(2186, 'Forbes Medi-Tech'),
(2187, 'Foreland Pharma'),
(2188, 'Forest Laboratories'),
(2189, 'Forma Therapeutics'),
(2190, 'Formerly of GSK'),
(2191, 'Formation Biologics'),
(2192, 'Piramal Enterprises'),
(2193, 'Eisai Limited'),
(2194, 'Response Genetics'),
(2195, 'Teva Pharmaceutical Industries'),
(2196, 'Fornix BioSciences'),
(2197, 'For-Robin'),
(2198, 'ForSight Vision4'),
(2199, 'Forticell Bioscience'),
(2200, 'FortuneRock'),
(2201, 'Forty Seven'),
(2202, 'Forward Pharma'),
(2203, 'Fougera'),
(2204, 'Fought Consulting'),
(2205, 'Fournier'),
(2206, 'Fovea Pharma'),
(2207, 'FoxHollow Technologies'),
(2208, 'Franklin Pharmaceutical Consulting'),
(2209, 'Frederick National Laboratory for Cancer Research Leidos Biomedical Research'),
(2210, 'Fresenius Biotech'),
(2211, 'Fresenius Kabi'),
(2212, 'Fresenius-Biotech'),
(2213, 'Friedman Consulting'),
(2214, 'Fritsche Consulting Services'),
(2215, 'Fritz Stephan GmbH'),
(2216, 'Frontier Biotechnologies'),
(2217, 'Frontier Science'),
(2218, 'FUCH ??bioMrieux Laboratory'),
(2219, 'Fuji Pharma Valley'),
(2220, 'Fuji Yakuhin Co Ltd'),
(2221, 'Fujian Cosunter Pharma'),
(2222, 'Fujian Longhua Pharma'),
(2223, 'Fujifilm Pharma'),
(2224, 'FUJIFILM RI Pharma'),
(2225, 'FUJIFILM Visualsonics'),
(2226, 'Fujimoto Pharma'),
(2227, 'Fujirebio Diagnostics AB'),
(2228, 'Fujirebio Diagnostics'),
(2229, 'Fujirebio Europe'),
(2230, 'Fujirebio U.S.'),
(2231, 'Fujisawa'),
(2232, 'Fujitsu Limited'),
(2233, 'Fujitsu Systems East Limited'),
(2234, 'Fulcrum Analytics'),
(2235, 'Fulcrum Pharma'),
(2236, 'Fulford India'),
(2237, 'Fulgent Therapeutics'),
(2238, 'FumaPharm'),
(2239, 'Functional Genetics'),
(2240, 'PDXen Biosystem'),
(2241, 'Functional Neuromodulation'),
(2242, 'Funxional'),
(2243, 'Furiex'),
(2244, 'Fuso Pharma Industries'),
(2245, 'FusoGen'),
(2246, 'Future Therapies'),
(2247, 'Futures Institute'),
(2248, 'FyMed'),
(2249, 'G D Searle'),
(2250, 'G&G Science'),
(2251, 'G1 Therapeutics'),
(2252, 'G2 Therapies'),
(2253, 'GA Generic Assays GmbH'),
(2254, 'Gador SA'),
(2255, 'Gaia BioPharma'),
(2256, 'Galapagos NV'),
(2257, 'Galaxy Biotech LLC'),
(2258, 'Galaxy Pharma'),
(2259, 'Galderma'),
(2260, 'Galderma S.A.'),
(2261, 'Galectin Therapeutics/Pro-Pharma'),
(2262, 'Galen Limited'),
(2263, 'Galena Biopharma'),
(2264, 'Galena Biopharma/RXi Pharma'),
(2265, 'Galera Therapeutics'),
(2266, 'Galleon Pharmaceuticals'),
(2267, 'Galmed GmbH'),
(2268, 'Galmed Medical Research'),
(2269, 'Gamamabs Pharma'),
(2270, 'Gamida Cell'),
(2271, 'GammaCan'),
(2272, 'Ganeden Biotech'),
(2273, 'Ganymed'),
(2274, 'Gardant Pharma'),
(2275, 'Garden State Cancer Center'),
(2276, 'Garnet BioTherapeutics/Neuronyx'),
(2277, 'Gastroenterology Associates'),
(2278, 'Gastroenterology Consultants of Laredo'),
(2279, 'Gastroenterology Consultants'),
(2280, 'Gastrointestinal Associates'),
(2281, 'Gauss Surgical'),
(2282, 'GB Therapeutics'),
(2283, 'GDL Consulting'),
(2284, 'GE Global Research'),
(2285, 'GE Healthcare Life Science'),
(2286, 'GE Healthcare/Amersham International'),
(2287, 'Gebro Pharma'),
(2288, 'Gedeon Richter'),
(2289, 'Geference'),
(2290, 'Gelesis'),
(2291, 'GELTAMO'),
(2292, 'Gem Pharma'),
(2293, 'Gem Pharmaceuticals'),
(2294, 'GemacBio'),
(2295, 'Gemin X'),
(2296, 'Gemini Group'),
(2297, 'GEMoaB Monoclonals GmbH'),
(2298, 'GemVax'),
(2299, 'Genaderm'),
(2300, 'Genaera'),
(2301, 'Genaissance'),
(2302, 'Gene Arrays'),
(2303, 'Gene Signal'),
(2304, 'Asklepios Biopharmaceuticals'),
(2305, 'Gene Centric Diagnostics'),
(2306, 'Genection'),
(2307, 'GeneCure'),
(2308, 'GeneDiagnostics'),
(2309, 'GeneDx'),
(2310, 'GeneFerm'),
(2311, 'Genelabs'),
(2312, 'Genelux'),
(2313, 'GeneMax'),
(2314, 'Genencor'),
(2315, 'GenenDesign'),
(2316, 'Genenetech'),
(2317, 'Genenews'),
(2318, 'GenEpria Consulting'),
(2319, 'General Musculoskeletal Imaging'),
(2320, 'Generativity Solutions'),
(2321, 'Generex Biotechnology'),
(2322, 'Generon (Shanghai) Corporation'),
(2323, 'Genervon'),
(2324, 'GeneRx+'),
(2325, 'GeneScience Pharma'),
(2326, 'Geneseeq Technology'),
(2327, 'GeneSegues Therapeutics'),
(2328, 'Genesis Biopharma'),
(2329, 'Genesis Research & Development Corporation Limited'),
(2330, 'Genetech'),
(2331, 'Genetic Development Corporation'),
(2332, 'Genetic Immunity'),
(2333, 'Genetic SpA'),
(2334, 'GeneticLab'),
(2335, 'Genetics Development Corporation'),
(2336, 'Genetics Institute'),
(2337, 'GeNeuro'),
(2338, 'GENEWIZ'),
(2339, 'Genexine'),
(2340, 'Genfit'),
(2341, 'GENimmune'),
(2342, 'Genisphere LLC'),
(2343, 'Genitope'),
(2344, 'Genix Pharma'),
(2345, 'Genizon BioSciences'),
(2346, 'GenKyoTex'),
(2347, 'Genmab'),
(2348, 'Genmab A/S'),
(2349, 'Genmab BV'),
(2350, 'Gennova BioPharma'),
(2351, 'Geno Pharmaceuticals'),
(2352, 'GenoLac'),
(2353, 'Genomatix'),
(2354, 'European Molecular Biology Laboratory'),
(2355, 'WuXi AppTec (Shanghai)'),
(2356, 'GenoMed'),
(2357, 'GenomeDx Biosciences'),
(2358, 'Genomic Health'),
(2359, 'Dainippon Sumitomo Pharma'),
(2360, 'Genomic Systems'),
(2361, 'Genomictree'),
(2362, 'Genopole'),
(2363, 'Genosaber Biotech'),
(2364, 'Genotypic Technology'),
(2365, 'Genova BioTech'),
(2366, 'Genovate Biotechnology'),
(2367, 'Genovax'),
(2368, 'GenPhar'),
(2369, 'Genpharm'),
(2370, 'Genprex/Convergen LifeSciences'),
(2371, 'GenSpera'),
(2372, 'Genta'),
(2373, 'Genticel'),
(2374, 'Gentium S.p.A'),
(2375, 'Genus Oncology'),
(2376, 'GenVec'),
(2377, 'Genzyme'),
(2378, 'GeoPharma'),
(2379, 'GeoVax'),
(2380, 'Geron'),
(2381, 'Gerontion Research'),
(2382, 'Getz Pharma'),
(2383, 'GfK'),
(2384, 'GI Associates'),
(2385, 'GI View Ltd'),
(2386, 'Giaconda Ltd.'),
(2387, 'GIFT Counseling Center for Wellness'),
(2388, 'Gilead Sciences'),
(2389, 'GILUPI GmbH'),
(2390, 'Gincare INT\'L ENT'),
(2391, 'Giuliani S.p.A.'),
(2392, 'GKM New Pharma'),
(2393, 'GL PharmTech'),
(2394, 'GLab Pathology Center'),
(2395, 'Glactone Pharma'),
(2396, 'Glasgow Memory Clinic'),
(2397, 'Glaukos'),
(2398, 'Glaxo Wellcome'),
(2399, 'GlaxoSmithKline Research and Development'),
(2400, 'Glenmark'),
(2401, 'Glenmark Generics'),
(2402, 'GLG Pharma'),
(2403, 'Gliatech'),
(2404, 'Glide Pharma'),
(2405, 'Gliknik'),
(2406, 'Lundbeck'),
(2407, 'Shimadzu Corporation'),
(2408, 'Merck Serono Pharmaceutical R&D'),
(2409, 'Global Biotech'),
(2410, 'Global BioTherapeutics'),
(2411, 'Global Blood Therapeutics'),
(2412, 'Janssen Global Services'),
(2413, 'Novartis Pharmaceuticals Corporation'),
(2414, 'Global Oncology'),
(2415, 'Eli Lilly and Company'),
(2416, 'Global-Infusions and Aspiration Systems'),
(2417, 'GlobeImmune'),
(2418, 'Gloucester Pharma'),
(2419, 'Glycadia/Exocell'),
(2420, 'GlycaNova'),
(2421, 'GlycoGenesys'),
(2422, 'GlycoMimetics'),
(2423, 'GlycoMira Therapeutics'),
(2424, 'Glycostem Therapeutics'),
(2425, 'Glycotope'),
(2426, 'Glycotope GmbH'),
(2427, 'GlycoVaxyn'),
(2428, 'Proinnovera GmbH'),
(2429, 'GMP Endotherapeutics'),
(2430, 'GNI Pharma'),
(2431, 'Gn?bila'),
(2432, 'Goemar Laboratories'),
(2433, 'Golden Biotechnology Corporation'),
(2434, 'Google Life Sciences'),
(2435, 'GORTEC'),
(2436, 'GORTEC-GETTEC'),
(2437, 'Gesellschaftf Onkologische Studien (GOSPL), Troidorf'),
(2438, 'GP Pharm'),
(2439, 'GPC Biotech'),
(2440, 'Graceway Pharma'),
(2441, 'Gradalis'),
(2442, 'Grannus Biosciences'),
(2443, 'Green Cross'),
(2444, 'Green Cross Genome'),
(2445, 'Green Signal Bio Pharma'),
(2446, 'GreenPeptide'),
(2447, 'Greenwich Therapeutics'),
(2448, 'Greer Laboratories'),
(2449, 'Grifols'),
(2450, 'Grindex'),
(2451, 'Grunenthal GmbH'),
(2452, 'Gr?nenthal GmbH'),
(2453, 'Grupo Uriach'),
(2454, 'Grupo Vita'),
(2455, 'GSK Ophthalmology'),
(2456, 'GSO Gesellschaft Studienmanagement Onkologie'),
(2457, 'GTC Biotherapeutics'),
(2458, 'GTx'),
(2459, 'GTx Incorporated'),
(2460, 'Guangdong Zhongsheng Pharmaceutical'),
(2461, 'Guangzhou Doublle Bio-products'),
(2462, 'Guangzhou Pharmaceuticals'),
(2463, 'Guardant Health'),
(2464, 'Guerbet'),
(2465, 'Guidant'),
(2466, 'Guilford Pharmaceuticals'),
(2467, 'Guizhou Yibai Pharmaceutical'),
(2468, 'Gulf Pharma Industries/Julphar'),
(2469, 'GVK Biosciences'),
(2470, 'GW Pharmaceuticals'),
(2471, 'Gynecologic Oncology Associates'),
(2472, 'H G Pars Laboratories'),
(2473, 'H. Lundbeck A / S'),
(2474, 'HaemaCon Ltd'),
(2475, 'Hainan Changan International Pharmaceutical'),
(2476, 'HAJAP'),
(2477, 'Hakuaikai Medical Corp'),
(2478, 'HAL Allergy'),
(2479, 'Halcygen'),
(2480, 'Halozyme Therapeutics'),
(2481, 'Hamad Medical Corporation'),
(2482, 'Hamamatsu Photonics'),
(2483, 'Hamri Co.'),
(2484, 'Han Kook Shin Yak'),
(2485, 'Hana Biosciences'),
(2486, 'HanAll'),
(2487, 'HANDOK Pharma'),
(2488, 'European Automobile Manufacturers Association'),
(2489, 'Hangzhou CancerProbe Biotechnology Company'),
(2490, 'Hangzhou DAC Biotech Co Ltd'),
(2491, 'Hangzhou Jiuyuan'),
(2492, 'Hangzhou Polar Gene Company'),
(2493, 'HanLim Pharm'),
(2494, 'Hanmi Pharma'),
(2495, 'Hansoh Pharmaceutical'),
(2496, 'Hanul Medizin'),
(2497, 'Hapten Pharma'),
(2498, 'Haptoguard'),
(2499, 'Harbor BioSciences/Hollis-Eden'),
(2500, 'Harkness Pharma'),
(2501, 'Harmon Hill Consulting'),
(2502, 'HARP Pharma Consulting'),
(2503, 'Harris Insights & Analytics'),
(2504, 'Harvest Moon Pharma'),
(2505, 'Hawaii Biotech'),
(2506, 'Hayashibara Co.'),
(2507, 'Hays Pharma Consulting'),
(2508, 'HCD Economics'),
(2509, 'HealthCare Global Enterprises'),
(2510, 'HDB Biosciences Co Ltd,'),
(2511, 'HealOr'),
(2512, 'Joanneum Research'),
(2513, 'Lockheed Martin'),
(2514, 'Health Care Service Corporation'),
(2515, 'Health Data Specialists Ltd'),
(2516, 'Health Diagnostic Laboratory'),
(2517, 'Health Discovery'),
(2518, 'Janssen Pharmaceutical'),
(2519, 'Health Outcomes Consulting'),
(2520, 'HealthPartners'),
(2521, 'Health ResearchTx'),
(2522, 'Health Services Consulting Corporation'),
(2523, 'Healthcare & Strategy Consultant'),
(2524, 'Healthcare Decisions'),
(2525, 'Healthcare Global LTD'),
(2526, 'Healthcare Ventures Focus Companies'),
(2527, 'Health Core'),
(2528, 'HealthHel'),
(2529, 'HealthStat Consulting'),
(2530, 'HealthTell'),
(2531, 'Heartland Research Associates'),
(2532, 'Heat Biologics'),
(2533, 'Healthcare Pharmaceutical Limited'),
(2534, 'Hebei Tangshan Steel and Iron Company'),
(2535, 'Heidelberg Pharma'),
(2536, 'Helicon Therapeutics'),
(2537, 'Helix BioMedix'),
(2538, 'Helix BioPharma'),
(2539, 'Helperby Therapeutics'),
(2540, 'Helsana Group'),
(2541, 'Helsinn Healthcare'),
(2542, 'Helsinn Healthcare SA'),
(2543, 'Helsinn Therapeutics'),
(2544, 'Helsinn Therapeutics (US)'),
(2545, 'Hematology Oncology Consultants'),
(2546, 'HemaQuest'),
(2547, 'Hematologics'),
(2548, 'Hematology & Oncology of Dayton'),
(2549, 'Hematology-Oncology Consultants'),
(2550, 'HemCon'),
(2551, 'Hemedex'),
(2552, 'HeMemics Biotechnologies'),
(2553, 'Hemispherx Biopharma'),
(2554, 'Hemodynamic Therapeutics'),
(2555, 'Hengrui Pharmacy'),
(2556, 'Henogen'),
(2557, 'Henry M. Jackson Foundation for the Advancement of Military Medicine'),
(2558, 'Hepasome Pharma'),
(2559, 'Herber Biotech'),
(2560, 'Hermes Biosciences'),
(2561, 'Heron Health'),
(2562, 'Heron Therapeutics/A.P. Pharma'),
(2563, 'Hetero Labs'),
(2564, 'Hexal'),
(2565, 'Hexor'),
(2566, 'High Point Pharmaceuticals'),
(2567, 'Highline Research Advisors,'),
(2568, 'Hill Dermaceuticals'),
(2569, 'Hilton Pharma'),
(2570, 'HIMformatics,'),
(2571, 'Hisamitsu Pharma'),
(2572, 'Histogen'),
(2573, 'Neuroscience Associates'),
(2574, 'Historx'),
(2575, 'HistoTox Labs'),
(2576, 'Hitachi Chemical Company'),
(2577, 'Hitachi Chemical Research Center'),
(2578, 'Hithru Analytics LLC'),
(2579, 'Hive Design & Consultancy'),
(2580, 'Hoechst-Roussel'),
(2581, 'Hoffmann-La Roche Limited'),
(2582, 'Hollis-Eden'),
(2583, 'Hologic'),
(2584, 'HolyStone Healthcare'),
(2585, 'HomeoTherapy'),
(2586, 'Hope Pharma'),
(2587, 'Horizon Bioadvance'),
(2588, 'Horizon Pharma'),
(2589, 'Horizon Therapeutics'),
(2590, 'Hormos Medical'),
(2591, 'Horphag'),
(2592, 'Hospira'),
(2593, 'HRA Pharma'),
(2594, 'HTCR Consulting,'),
(2595, 'HTG Molecular Diagnostics'),
(2596, 'Hualan Biological'),
(2597, 'Hudson Health Sciences'),
(2598, 'Human Genome Sciences'),
(2599, 'GSK Vaccines'),
(2600, 'Human Metabolome'),
(2601, 'Human Stem Cells Institute JSC'),
(2602, 'Humana'),
(2603, 'Humanetics'),
(2604, 'Hunter Immunology'),
(2605, 'Hunter-Fleming'),
(2606, 'Hutchison MediPharma Limited'),
(2607, 'Hutchison MediPharma'),
(2608, 'HUYA'),
(2609, 'H Y Biopharma'),
(2610, 'Hybridyne Imaging Technologies'),
(2611, 'Hybrigenics'),
(2612, 'Hydra Biosciences'),
(2613, 'Hygeianey Bioscience'),
(2614, 'Hypnion'),
(2615, 'i Sciences'),
(2616, 'i/oTrak E-Z Document Services'),
(2617, 'i3 Research Ltd'),
(2618, 'i3 Innovus'),
(2619, 'International Association of Designers (IAD)'),
(2620, 'IASO Pharma/ Pacific Beach BioSciences'),
(2621, 'IBA Molecular'),
(2622, 'IBC Generium/NauchtechStroy Plus'),
(2623, 'IBC Pharmaceuticals'),
(2624, 'IBD Column Therapies International'),
(2625, 'IBD Network'),
(2626, 'iBioPharma'),
(2627, 'IBM'),
(2628, 'Ibris'),
(2629, 'Icagen'),
(2630, 'iCardiac Technologies'),
(2631, 'ICERA Consulting'),
(2632, 'iCeutica'),
(2633, 'ICF'),
(2634, 'Ichor Medical Systems'),
(2635, 'IC-MedTech'),
(2636, 'iCo Therapeutics'),
(2637, 'Icon Bioscience'),
(2638, 'ICON'),
(2639, 'Icon Laboratories'),
(2640, 'ICON plc'),
(2641, 'Icon Development Solutions'),
(2642, 'Iconic Therapeutics'),
(2643, 'ICOS'),
(2644, 'ID Biomedical'),
(2645, 'IDAC Theranostics'),
(2646, 'Idexx Laboratories'),
(2647, 'IDEA AG'),
(2648, 'Idealab'),
(2649, 'Idenix'),
(2650, 'Idera Pharmaceuticals'),
(2651, 'iDialog'),
(2652, 'IDM'),
(2653, 'Idun'),
(2654, 'IgDraSol'),
(2655, 'igeneon'),
(2656, 'IGENZ'),
(2657, 'IGF Oncology'),
(2658, 'IGI'),
(2659, 'Ignyta'),
(2660, 'IHI Corporation'),
(2661, 'Global Group'),
(2662, 'Ikano Therapeutics/Intranasal Therapeutics'),
(2663, 'Ikaria'),
(2664, 'Il Dong'),
(2665, 'ILEX Oncology'),
(2666, 'ILJIN Life Science'),
(2667, 'Pathology, Inc.'),
(2668, 'Illumina Cambridge'),
(2669, 'Illumina'),
(2670, 'ILYANG'),
(2671, 'Ilypsa'),
(2672, 'IM HealthScience'),
(2673, 'Image IQ'),
(2674, 'Imagenetix'),
(2675, 'ImaginAb'),
(2676, 'Imaging Endpoints'),
(2677, 'IXICO'),
(2678, 'Imanis Life Sciences'),
(2679, 'ImaRx Therapeutics'),
(2680, 'ImaSight'),
(2681, 'ImClone'),
(2682, 'ImClone Systems'),
(2683, 'IMED'),
(2684, 'Immafarma'),
(2685, 'immatics'),
(2686, 'IMMD'),
(2687, 'Immensity Consulting'),
(2688, 'Immodulon'),
(2689, 'Immodulon Therapeutics'),
(2690, 'Immtech'),
(2691, 'Immune Cell Therapy'),
(2692, 'Immune Control'),
(2693, 'Immune Design'),
(2694, 'Immune Network'),
(2695, 'Immune Pharma'),
(2696, 'Immune Regulation Limited'),
(2697, 'Immune System Therapeutics'),
(2698, 'Immune Targeting Systems'),
(2699, 'Immune Technologies and Medicine'),
(2700, 'Immune Tolerance Network'),
(2701, 'ImmuneCarta'),
(2702, 'Immuneering Corporation'),
(2703, 'ImmuneRegen'),
(2704, 'ImmuneWorks'),
(2705, 'Immunex'),
(2706, 'ImmuneXcite'),
(2707, 'Immungene'),
(2708, 'Immunicon'),
(2709, 'Immunicum'),
(2710, 'Immunitor'),
(2711, 'Immunity Pharma'),
(2712, 'ImmunoBiology Limited'),
(2713, 'ImmunoCellular Therapeutics'),
(2714, 'Immunocore'),
(2715, 'IDS Ltd'),
(2716, 'ImmunoFrontier'),
(2717, 'ImmunoGen'),
(2718, 'Immunogenex'),
(2719, 'Mapp Biopharmaceutical'),
(2720, 'Immunome'),
(2721, 'Immunomedics'),
(2722, 'Immunomic'),
(2723, 'ImmunoMod'),
(2724, 'Immunotec'),
(2725, 'Immunotech Laboratories'),
(2726, 'Immunotope'),
(2727, 'Immunovaccine'),
(2728, 'Immunovative Therapies'),
(2729, 'Immunsystem AB'),
(2730, 'ImmuPharma'),
(2731, 'Immuron/Anadis'),
(2732, 'Immusoft Corporation'),
(2733, 'Immusol'),
(2734, 'Immutep'),
(2735, 'ImmvaRx'),
(2736, 'IMPACT Therapeutics'),
(2737, 'Impacts'),
(2738, 'IMPAX Laboratories'),
(2739, 'Implicit Bioscience'),
(2740, 'improveRX'),
(2741, 'ImQuest'),
(2742, 'IMS Health'),
(2743, 'IMS Health Canada'),
(2744, 'IMS'),
(2745, 'IMS Solutions Pvt Ltd'),
(2746, 'Information Management Services'),
(2747, 'ImVisioN'),
(2748, 'In Silico Solutions'),
(2749, 'INB Biotechnologies'),
(2750, 'INC Research'),
(2751, 'Incara Pharma'),
(2752, 'IncellDx'),
(2753, 'Incell Dx'),
(2754, 'Incozen Therapeutics'),
(2755, 'Incuron'),
(2756, 'Incyte Corporation'),
(2757, 'Indena'),
(2758, 'Independence Blue Cross'),
(2759, 'Independent Pharmaceutical'),
(2760, 'Indevus'),
(2761, 'InDex Pharma'),
(2762, 'InDex Pharmaceuticals AB'),
(2763, 'Indiana Hemophilia and Thrombosis Center'),
(2764, 'Indigene'),
(2765, 'Indigo Pharma/Milford Sound Sciences'),
(2766, 'Indivumed GmbH'),
(2767, 'INDS'),
(2768, 'Ind-Swift'),
(2769, 'Indus Biotech'),
(2770, 'INEOS Healthcare/INEOS Silicas'),
(2771, 'Inex Pharma'),
(2772, 'InfectoPharm'),
(2773, 'Infinity Pharmaceuticals'),
(2774, 'Inflabloc'),
(2775, 'InflaRx'),
(2776, 'Inflazyme'),
(2777, 'Inflection Biosciences'),
(2778, 'Inflexxion'),
(2779, 'Infopeople'),
(2780, 'Inform Genomics'),
(2781, 'Quest Diagnostics'),
(2782, 'Infraredx'),
(2783, 'ING Bank N.V'),
(2784, 'QIAGEN Redwood City'),
(2785, 'Inhale Therapeutic Systems'),
(2786, 'Inhibikase'),
(2787, 'Inhibitex'),
(2788, 'Inimex'),
(2789, 'Inivata Limited,'),
(2790, 'Inivata Ltd'),
(2791, 'Injex'),
(2792, 'InKine'),
(2793, 'Innapharma'),
(2794, 'Innate Immunotherapeutics/Virionyx'),
(2795, 'Innate Pharma'),
(2796, 'InnaVirVax'),
(2797, 'Innocell'),
(2798, 'Innocoll'),
(2799, 'Innocrin Pharmaceuticals'),
(2800, 'Innodia'),
(2801, 'Innogene Kalbiotech'),
(2802, 'Innogenetics'),
(2803, 'Innoheart Pte Ltd'),
(2804, 'Innopharma'),
(2805, 'InnoPharmax'),
(2806, 'Innotech International'),
(2807, 'Innova Biosciences'),
(2808, 'innoVactiv/Oceanova Biotechnologies'),
(2809, 'Innovascreen'),
(2810, 'Innovata plc/ML Laboratories'),
(2811, 'Innovate Oncology'),
(2812, 'Innovive Pharma'),
(2813, 'INO Therapeutics'),
(2814, 'Inostics GmbH'),
(2815, 'Inotek'),
(2816, 'Inova Diagnostics'),
(2817, 'Inovio Pharmaceuticals'),
(2818, 'InQpharm'),
(2819, 'Insight Research Group'),
(2820, 'InSightec-TxSonics'),
(2821, 'Insilicos'),
(2822, 'InSite Vision'),
(2823, 'InskeepDMPK, LLC'),
(2824, 'Insmed'),
(2825, 'Inspiration BioPharma'),
(2826, 'Inspire Pharma'),
(2827, 'Institut Biochimique SA'),
(2828, 'INSYS Therapeutics'),
(2829, 'Intarcia Therapeutics'),
(2830, 'Intas Pharma'),
(2831, 'Intas Biopharmaceuticals'),
(2832, 'Intec Pharma'),
(2833, 'Integrated BioPharma'),
(2834, 'Integrated Therapeutic Solutions'),
(2835, 'Integrative Therapeutics'),
(2836, 'Janssen Research and Development'),
(2837, 'InteKrin'),
(2838, 'IntelGenx'),
(2839, 'Intellect Neurosciences'),
(2840, 'IntelliCell'),
(2841, 'Intellikine'),
(2842, 'Intellipharmaceutics'),
(2843, 'Intendis'),
(2844, 'Intercell'),
(2845, 'Intercept Pharma'),
(2846, 'Intercytex'),
(2847, 'Interferon Sciences'),
(2848, 'InterMune'),
(2849, 'Mayo Clinic'),
(2850, 'International Medical Corporation'),
(2851, 'International Organization for Migration'),
(2852, 'Interneuron'),
(2853, 'Intersero'),
(2854, 'InterVivo Solutions'),
(2855, 'Intracel'),
(2856, 'Intra-Cellular Therapies'),
(2857, 'Intrexon'),
(2858, 'IntrinsiQ, LLC'),
(2859, 'Introgen Therapeutics'),
(2860, 'Invamed Pharma'),
(2861, 'InVasc'),
(2862, 'Invent Farma'),
(2863, 'Inventia Healthcare'),
(2864, 'inVentiv Health'),
(2865, 'Inveresk Research Group'),
(2866, 'Inverseon'),
(2867, 'Invictus Oncology'),
(2868, 'Invion Limited'),
(2869, 'Inviragen'),
(2870, 'INVITAE'),
(2871, 'Invitrox'),
(2872, 'Invivis Pharmaceuticals'),
(2873, 'In-Vivo Science'),
(2874, 'InvivoGen Therapeutics'),
(2875, 'Invivoscribe Technologies'),
(2876, 'Invivoscribe'),
(2877, 'Io Therapeutics'),
(2878, 'Iomai'),
(2879, 'iOMEDICO AG'),
(2880, 'IOmet Pharma'),
(2881, 'Ion Channel Innovations'),
(2882, 'Ipca'),
(2883, 'Ips Therapeutiqus'),
(2884, 'Ipsen Biopharmaceuticals'),
(2885, 'IPSEN Bioscience'),
(2886, 'Ipsen/Biomeasure'),
(2887, 'Ipsos Healthcare'),
(2888, 'iRhythm Technologies'),
(2889, 'Iroko'),
(2890, 'Iron Therapeutics (UK)'),
(2891, 'Ironwood Pharma/Microbia'),
(2892, 'Ironwood Pharmaceuticals'),
(2893, 'IRX Therapeutics'),
(2894, 'ISA Pharma'),
(2895, 'Isarna Therapeutics GmbH'),
(2896, 'Ischemix'),
(2897, 'Isconova'),
(2898, 'ISDIN'),
(2899, 'Isifer'),
(2900, 'Isis Pharma'),
(2901, 'ISK Ltd'),
(2902, 'Islet Sciences'),
(2903, 'ISM Therapeutics'),
(2904, 'Isolagen'),
(2905, 'Isotechnika'),
(2906, 'ISP Vincience'),
(2907, 'ISPG Technologies India'),
(2908, 'Issar Pharma'),
(2909, 'IST GmbH'),
(2910, 'ISTA Pharma'),
(2911, 'ISTO Technologies'),
(2912, 'Isu Abxis'),
(2913, 'Italfarmaco'),
(2914, 'iTeos Therapeutics SA'),
(2915, 'iThera Medical GmbH'),
(2916, 'ItherX'),
(2917, 'ITR'),
(2918, 'IVAX'),
(2919, 'Ivy Life Sciences'),
(2920, 'IX Biopharma'),
(2921, 'IXICO Ltd,'),
(2922, 'Izun Pharma'),
(2923, 'J Cotton Consultancy'),
(2924, 'J&JPRD'),
(2925, 'Jackson Oncology Associates'),
(2926, 'Jacobus Pharma'),
(2927, 'JADO Technologies'),
(2928, 'Jaleva'),
(2929, 'James R Berenson Inc'),
(2930, 'Janssen Alzheimer Immunotherapy'),
(2931, 'Janssen Biologics B.V'),
(2932, 'Janssen Biotech'),
(2933, 'Janssen Canada'),
(2934, 'Janssen-Cilag'),
(2935, 'Janssen Diagnostics'),
(2936, 'Janssen Scientific Affairs'),
(2937, 'Janssen Therapeutics'),
(2938, 'Janus Pharmaceuticals'),
(2939, 'Japan Immunoresearch Laboratories'),
(2940, 'Japan Tobacco'),
(2941, 'Jasco Pharmaceuticals'),
(2942, 'Javelin Pharma'),
(2943, 'Jazz Pharma'),
(2944, 'Jazz Pharmaceuticals'),
(2945, 'JB Medical Ltd'),
(2946, 'JBNI'),
(2947, 'JCOM'),
(2948, 'JCR Pharma'),
(2949, 'JCR Pharmaceuticals'),
(2950, 'JDS Pharma'),
(2951, 'Jeil Pharmaceutical'),
(2952, 'Jeil-Kirin Pharmaceutical'),
(2953, 'Jelfa'),
(2954, 'Jenapharm'),
(2955, 'Jenburkt Pharmaceuticals'),
(2956, 'Jenken'),
(2957, 'JenLab GmbH'),
(2958, 'Jennerex'),
(2959, 'Jennerex Biotherapeutics'),
(2960, 'Jerini AG'),
(2961, 'Jerini Ophthalmic'),
(2962, 'Jiangsu Aosaikang'),
(2963, 'Jiangsu Chiatai Qingjiang Pharmaceutical'),
(2964, 'Jiangsu Furui Pharma'),
(2965, 'Jiangsu Hansen'),
(2966, 'Jiangsu Hansoh Pharmaceutical Group'),
(2967, 'Jiangsu Hengrui Medicine'),
(2968, 'Jiangsu Lianhuan'),
(2969, 'Jiangsu Nhwa Pharma'),
(2970, 'JIMRO'),
(2971, 'Jina Pharma'),
(2972, 'Jina Pharmaceuticals'),
(2973, 'JK Biostatistics AB'),
(2974, 'JK Consulting'),
(2975, 'John Snow Research and Training Institute'),
(2976, 'Johnson & Johnson'),
(2977, 'Johnson & Johnson Medical (China)'),
(2978, 'Johnson Matthey'),
(2979, 'Jon Oliner Consulting'),
(2980, 'Jounce Therapeutics'),
(2981, 'J-Pharma'),
(2982, 'PJSC Pharmstandard-Biolek'),
(2983, 'Farmak JSC'),
(2984, 'Valenta Pharm JSC'),
(2985, 'JSL Consulting and Associates'),
(2986, 'JSS Medical Research India Private Limited'),
(2987, 'JSS Medical Research'),
(2988, 'Jubilant Biosys Limited'),
(2989, 'Jubilant Innovation'),
(2990, 'Juno Therapeutic'),
(2991, 'J?rgens and Botha'),
(2992, 'Juvantia Pharma'),
(2993, 'Juvaris'),
(2994, 'Juvenon'),
(2995, 'Juventas Therapeutics'),
(2996, 'JW Consulting'),
(2997, 'JW Pharma/Choongwae Pharma'),
(2998, 'JW PHARMACEUTICAL CORP'),
(2999, 'JW Theriac Pharmaceutical'),
(3000, 'Kadmon'),
(3001, 'Kadmus'),
(3002, 'KAEL-GemVax'),
(3003, 'Kai Fu Biotech'),
(3004, 'KAI Pharma'),
(3005, 'Kainos Medicine'),
(3006, 'Kaken'),
(3007, 'Kaketsuken'),
(3008, 'Kalo'),
(3009, 'Kalidex'),
(3010, 'Kali-Duphar Pharma'),
(3011, 'KaloBios'),
(3012, 'Kalypsys'),
(3013, 'Kamada'),
(3014, 'Kracie Pharma'),
(3015, 'Kancera AB'),
(3016, 'Kaneka Corporation'),
(3017, 'KangLaiTe'),
(3018, 'Kanglaite U.S.A.'),
(3019, 'Kanisa Pharma'),
(3020, 'Kanpai Therapeutics'),
(3021, 'Tsumura'),
(3022, 'Kansas City Cancer Centers'),
(3023, 'Kantar Health'),
(3024, 'KantarHealth'),
(3025, 'Kao Corporation'),
(3026, 'Karo Bio'),
(3027, 'Karyopharm Therapeutics'),
(3028, 'Karyopharm Europe GmbH'),
(3029, 'Kasiak Research'),
(3030, 'Kath. Marienkrankenhaus GmbH'),
(3031, 'Kedem Pharma/Global Health Ventures'),
(3032, 'Kedrion'),
(3033, 'Kemia'),
(3034, 'Kemin Pharma'),
(3035, 'KemPharm'),
(3036, 'Kendle International'),
(3037, 'Kendrick Farmaceutica'),
(3038, 'Kenta Biotech'),
(3039, 'Kenwood Therapeutics'),
(3040, 'KeraCure'),
(3041, 'Kerecis'),
(3042, 'Keryx'),
(3043, 'Keryx Biopharmaceuticals'),
(3044, 'KetoCytonyx'),
(3045, 'kevin test'),
(3046, 'KEW Group'),
(3047, 'Key Pharma'),
(3048, 'KeyNeurotek Pharmaceuticals'),
(3049, 'Keystone Biomedical'),
(3050, 'Immuneering'),
(3051, 'Khandelwal Laboratories'),
(3052, 'Kiadis'),
(3053, 'Kibow'),
(3054, 'Kilitch'),
(3055, 'Kind Consumer'),
(3056, 'Kinderbuik&co'),
(3057, 'KinDex'),
(3058, 'KineMed'),
(3059, 'Kinesic Sport Lab'),
(3060, 'Kineta'),
(3061, 'Kinex Pharmaceuticals'),
(3062, 'King Pharma'),
(3063, 'Kinogea'),
(3064, 'Kirax Corporation/Tigris Pharma'),
(3065, 'Kirin Company'),
(3066, 'Kyowa Kirin Pharmaceutical Development'),
(3067, 'Kiromic'),
(3068, 'Kissei Pharmaceuticals'),
(3069, 'Kite Pharma'),
(3070, 'KIYATEC'),
(3071, 'KMK Consulting'),
(3072, 'Knoll Pharma'),
(3073, 'Knopp Biosciences'),
(3074, 'Koiwai Dairy Products'),
(3075, 'Kolltan Pharmaceuticals'),
(3076, 'Kolon'),
(3077, 'Kona Medical'),
(3078, 'Konica Minolta'),
(3079, 'Koronis'),
(3080, 'Kos Pharma'),
(3081, 'Kosan Biosciences'),
(3082, 'Kotobuki Pharma'),
(3083, 'Kowa Pharma'),
(3084, 'KPS Biotechnology'),
(3085, 'Kramer Consulting'),
(3086, 'Kremers Urban'),
(3087, 'Krenitsky'),
(3088, 'Kringle Pharma'),
(3089, 'Krka'),
(3090, 'KuDOS Pharmaceuticals'),
(3091, 'Kuhnil Pharm'),
(3092, 'Kureha'),
(3093, 'Kuros'),
(3094, 'KV Pharmaceutical'),
(3095, 'Kwizda'),
(3096, 'Kymos'),
(3097, 'KYORIN Pharmaceutical'),
(3098, 'Kyosei Pharmaceutical'),
(3099, 'Kyowa Kirin Pharmaceutical'),
(3100, 'Kyusai'),
(3101, 'L Meltzer CNS Consulting'),
(3102, 'Ls Biopath'),
(3103, 'La Jolla Pharma Company'),
(3104, 'La Jolla Pharmaceutical Company'),
(3105, 'Labceutics'),
(3106, 'LabConnect'),
(3107, 'LabCorp Clinical Trials'),
(3108, 'LabCorp'),
(3109, 'Labinca Argentina'),
(3110, 'Labopharm'),
(3111, 'Laboratoires Carilene'),
(3112, 'Laboratoires Genevrier'),
(3113, 'Laboratoires IPRAD'),
(3114, 'Laboratoires Mayoly Spindler'),
(3115, 'Laboratoires SMB'),
(3116, 'Laboratoires Thea'),
(3117, 'Laboratorio Chile'),
(3118, 'Laboratorio Elea'),
(3119, 'ELEA'),
(3120, 'Laboratorio Farmacologico Milanese'),
(3121, 'Laboratorio Ferrer'),
(3122, 'Laboratorios Baldacci'),
(3123, 'Laboratorios Colombia'),
(3124, 'Laboratorios LETI'),
(3125, 'Laboratorios Liconsa'),
(3126, 'Laboratorios Liomont'),
(3127, 'Laboratorios Ordesa'),
(3128, 'Laboratorios Phoenix'),
(3129, 'Laboratorios Pisa'),
(3130, 'Laboratorios Silanes'),
(3131, 'Laboratorios Vita'),
(3132, 'Laborie Medical Technologies'),
(3133, 'LaborMed'),
(3134, 'LabPMM GmbH'),
(3135, 'LABS Inc'),
(3136, 'Labtec GmbH'),
(3137, 'Lacer SA'),
(3138, 'Lafon Laboratories'),
(3139, 'Laila Impex'),
(3140, 'Laila Pharmaceuticals'),
(3141, 'Lakewood-Amedex'),
(3142, 'LAL Clinica'),
(3143, 'Lallemand Pharma'),
(3144, 'Lambda Therapeutic Research'),
(3145, 'Lamdasoft'),
(3146, 'Lancet Laboratories'),
(3147, 'LaneLabs'),
(3148, 'Lantibio'),
(3149, 'Lap & P Consultants BV'),
(3150, 'Laphal Developpemen'),
(3151, 'Large Scale Biology'),
(3152, 'Laser Analtyica'),
(3153, 'Laser Detect Systems'),
(3154, 'Laurantis Pharma'),
(3155, 'Lavin Consulting'),
(3156, 'Lavipharm'),
(3157, 'Lawley Pharma'),
(3158, 'Laxdale'),
(3159, 'Layton BioScience'),
(3160, 'Lazarus Therapeutics'),
(3161, 'LB Biostatistics'),
(3162, 'LC Sciences'),
(3163, 'LCA Pharma'),
(3164, 'Lead Discovery Center GmbH'),
(3165, 'Lead Lab'),
(3166, 'Leaf Healthcare'),
(3167, 'LeanTaaS'),
(3168, 'Learn and Confirm'),
(3169, 'Learner Research Institute'),
(3170, 'Lederle Laboratories'),
(3171, 'Lee\'s Pharmaceutical'),
(3172, 'Lee\'s Pharmaceutical Holdings'),
(3173, 'LegoChem'),
(3174, 'Leica Biosystems'),
(3175, 'Leidos-Frederick'),
(3176, 'Leiras'),
(3177, 'Leitner Pharma'),
(3178, 'Lenticular Research Group'),
(3179, 'Lentigen'),
(3180, 'Leo Pharma'),
(3181, 'Leo Pharma GmbH'),
(3182, 'Lescarden'),
(3183, 'Leuchemix'),
(3184, 'Leukocare AG'),
(3185, 'Lexicon Pharmaceuticals'),
(3186, 'LFB'),
(3187, 'LG Life Sciences'),
(3188, 'Liangrun Biomedical Technology'),
(3189, 'Liaoning Chengda Biotechnology'),
(3190, 'Libbs'),
(3191, 'Lichtwer Pharma'),
(3192, 'LI-COR Biosciences'),
(3193, 'LIDDS AB'),
(3194, 'NAGASE & CO.'),
(3195, 'Life Research Technologies'),
(3196, 'Life Science Pharmaceuticals'),
(3197, 'Life Technologies'),
(3198, 'Life Technologies/ Thermofisher'),
(3199, 'LifeCell'),
(3200, 'Lifeline Technologies'),
(3201, 'LifeSequencing'),
(3202, 'LifeSource Biomedical Services LLC'),
(3203, 'LifeTime Pharma'),
(3204, 'Ligand'),
(3205, 'Ligandis GbR'),
(3206, 'Light Consulting'),
(3207, 'Light Sciences'),
(3208, 'Lightlake Therapeutics'),
(3209, 'LighTopTech Corp'),
(3210, 'Likarda, LLC'),
(3211, 'Lilly Deutschland'),
(3212, 'Lilly Europe'),
(3213, 'Lilly ICOS'),
(3214, 'Lilly Oncology'),
(3215, 'Lilly Research Centre'),
(3216, 'Lilly Suzhou Pharmaceutical'),
(3217, 'Lilly-NUS Center for Clinical Pharmacology'),
(3218, 'Limbach'),
(3219, 'Limerick BioPharma'),
(3220, 'Linden Oncology Limited'),
(3221, 'Link Medicine'),
(3222, 'Lion Biotechnologies'),
(3223, 'Lion Corporation'),
(3224, 'Lionex Diagnostics & Therapeutics'),
(3225, 'Lipella'),
(3226, 'Lipid Therapeutics'),
(3227, 'LiPlasome'),
(3228, 'Liplasome Pharma ApS'),
(3229, 'Lipocine'),
(3230, 'LipoMedics'),
(3231, 'Lipomedix Pharmaceuticals'),
(3232, 'Liponex'),
(3233, 'LipoNova'),
(3234, 'Lipotek'),
(3235, 'Liquid Genomics'),
(3236, 'Liquidia'),
(3237, 'ittle Sparrows Technologies'),
(3238, 'Liverpool Clinical Laboratories'),
(3239, 'Living Cell Technologies'),
(3240, 'Livzon Pharma Group'),
(3241, 'Lixte'),
(3242, 'Lixte Biotech Holdings'),
(3243, 'Locus Pharma'),
(3244, 'Lofarma'),
(3245, 'Logan Natural Products'),
(3246, 'Logical Therapeutics'),
(3247, 'LondonPharma'),
(3248, 'Long Key Consulting'),
(3249, 'Longstreth & Associates'),
(3250, 'Lonza'),
(3251, 'Lotus Clinical Research'),
(3252, 'Lotus Pharma'),
(3253, 'Loxo Oncology'),
(3254, 'Lpath'),
(3255, 'LSK BioPartners'),
(3256, 'Ltd, Ibaraki'),
(3257, 'Ebihara Lumber'),
(3258, 'PMOD Technologies'),
(3259, 'LTKfarma'),
(3260, 'LTS Lohman Therapie-Systeme'),
(3261, 'Luitpold'),
(3262, 'Lumavita'),
(3263, 'Lumenis'),
(3264, 'Lumicell'),
(3265, 'Luminant Biosciences'),
(3266, 'Luminex Corporation'),
(3267, 'Lumosity'),
(3268, 'Lunamed'),
(3269, 'Lundbeck LLC'),
(3270, 'LUNGevity Foundation'),
(3271, 'Lupin'),
(3272, 'Lux Biosciences'),
(3273, 'Lytix'),
(3274, 'Lytix Biopharma'),
(3275, 'iCuerious Research Services'),
(3276, 'M2Gen'),
(3277, 'MabQuest SA'),
(3278, 'MabVax Therapeutics'),
(3279, 'MacroChem'),
(3280, 'Macrogen'),
(3281, 'MacroGenics'),
(3282, 'MacroMed'),
(3283, 'Macrostat'),
(3284, 'MacuCLEAR'),
(3285, 'MacuSight'),
(3286, 'Madaus'),
(3287, 'Madeira Therapeutics'),
(3288, 'Madeleine Pharma'),
(3289, 'Madrigal Pharma'),
(3290, 'Madronish LLC'),
(3291, 'Magellan Rx Management'),
(3292, 'MagForce Nanotechnologies'),
(3293, 'Magna Pharma'),
(3294, 'MAJARO InfoSystems'),
(3295, 'Mallinckrodt Pharmaceuticals'),
(3296, 'Neurodyn Life Science'),
(3297, 'Xcyton Diagnostics'),
(3298, 'MannKind'),
(3299, 'Manpower'),
(3300, 'Mantecorp'),
(3301, 'MAP Pharma'),
(3302, 'Mapi Consultancy'),
(3303, 'Mapi Group'),
(3304, 'Mapi'),
(3305, 'Marcadia Biotech'),
(3306, 'Marco Polo Pharma'),
(3307, 'Marcor'),
(3308, 'Marie Curie CellEurope'),
(3309, 'Marillion Pharma'),
(3310, 'Marina Biotech'),
(3311, 'Marinomed'),
(3312, 'Marinus'),
(3313, 'Marnac'),
(3314, 'Marsala Biotech'),
(3315, 'Marshall Edwards/MEI Pharma'),
(3316, 'Martek Biosciences'),
(3317, 'Martens Beheer, B.V.'),
(3318, 'Martin and Associates Consulting'),
(3319, 'Maruho'),
(3320, 'Maruishi Pharma'),
(3321, 'Mary Kay'),
(3322, 'Massachusetts Prostate Cancer Coalition'),
(3323, 'MassBiologics'),
(3324, 'Savara'),
(3325, 'Mast Therapeutics'),
(3326, 'MAT Biopharma'),
(3327, 'Materia Medica'),
(3328, 'Matrix Laboratories'),
(3329, 'Matrix Pharma'),
(3330, 'MaxCyte'),
(3331, 'Maxim Pharma'),
(3332, 'Max Planck Innovation GmbH'),
(3333, 'Maxygen'),
(3334, 'Mayne Pharma'),
(3335, 'Mazal Plant Pharma'),
(3336, 'Mazence'),
(3337, 'McKesson Pharmaceutical Solutions'),
(3338, 'McNeil Consumer'),
(3339, 'Microsoft Certified Solutions Associate (MCSA)'),
(3340, 'MDC Partners'),
(3341, 'MDG Global Systems'),
(3342, 'MDR Global Systems'),
(3343, 'MDRNA'),
(3344, 'MDxHealth'),
(3345, 'Meabco'),
(3346, 'Mead Johnson Nutrition'),
(3347, 'Mead Johnson'),
(3348, 'Mead Johnson Pediatric Nutrition Institute'),
(3349, 'Mebiopharm'),
(3350, 'MED Institute'),
(3351, 'Meda'),
(3352, 'Meda Pharma'),
(3353, 'Medafor'),
(3354, 'Medarex'),
(3355, 'MedAvante'),
(3356, 'Medco Health Solutions'),
(3357, 'MedDRA'),
(3358, 'Medesis'),
(3359, 'Medestea'),
(3360, 'Medeus Pharma'),
(3361, 'medgen.at GmbH'),
(3362, 'Medgenics'),
(3363, 'MedGenome'),
(3364, 'MediBIC'),
(3365, 'Medicago'),
(3366, 'MSD'),
(3367, 'Medical Co. LTA Hakata Clinic'),
(3368, 'Nord-Tr?ndelag Hospital Trust'),
(3369, 'Lundbeck Canada'),
(3370, 'Medical Enzymes'),
(3371, 'Arthrolab'),
(3372, 'Heidelberg Engineering'),
(3373, 'Medical Tactile'),
(3374, 'Medical Toukei Co'),
(3375, 'Medice'),
(3376, 'Medicinal Chemistry Pharmaceuticals, Co., Ltd'),
(3377, 'Medicines360'),
(3378, 'MediciNova'),
(3379, 'Medicis'),
(3380, 'Medicor Research'),
(3381, 'Medicure'),
(3382, 'Medicus Economics'),
(3383, 'Medigen Biotechnology'),
(3384, 'MediGene'),
(3385, 'Medigreen'),
(3386, 'MediHerb'),
(3387, 'MedImageMetric'),
(3388, 'MedImmune'),
(3389, 'MedImmune/Cambridge Antibody Technology'),
(3390, 'Medinet'),
(3391, 'Medinox'),
(3392, 'Mediolanum farmaceutici'),
(3393, 'MediPharm Biotech'),
(3394, 'Medipost'),
(3395, 'Mediprojekt, spol. S R.o.'),
(3396, 'Mediquest Research Group'),
(3397, 'MediQuest Therapeutics'),
(3398, 'Medis Tunisia'),
(3399, 'MediSapiens'),
(3400, 'medistat GmbH'),
(3401, 'Medistem'),
(3402, 'Meditech Research'),
(3403, 'Meditope Biosciences'),
(3404, 'Meditor Pharma'),
(3405, 'Meditrina'),
(3406, 'MediVas'),
(3407, 'Medivation'),
(3408, 'Medivir'),
(3409, 'Medivo'),
(3410, 'MedKinetic'),
(3411, 'Medlab'),
(3412, 'Medley'),
(3413, 'Medley Pharmaceuticals'),
(3414, 'Medpace'),
(3415, 'MedPointe'),
(3416, 'Medqia LLC'),
(3417, 'Medreich'),
(3418, 'Medscape Education'),
(3419, 'Medscape'),
(3420, 'Medsearch'),
(3421, 'Medsintez'),
(3422, 'Medtronic'),
(3423, 'Medwell Capital'),
(3424, 'Medy-Tox'),
(3425, 'Meiji Seika'),
(3426, 'MeKo Laser Material Processing'),
(3427, 'Meldex International'),
(3428, 'Melema Pharma GmbH'),
(3429, 'Melior Pharma'),
(3430, '3M Deutschland | Membranes'),
(3431, 'Memgen'),
(3432, 'Memory Pharma'),
(3433, 'MenoGeniX'),
(3434, 'Menssana Research'),
(3435, 'Mentor Corporation'),
(3436, 'Mepha'),
(3437, 'Mera Pharma'),
(3438, 'Merck'),
(3439, 'Merck Group'),
(3440, 'Merck Research Laboratories'),
(3441, 'Merck Research Labs'),
(3442, 'Merck Serono'),
(3443, 'Merck Serono GmbH'),
(3444, 'Merck Sharp & Dohme'),
(3445, 'Merck & Co.'),
(3446, 'Merck & Co'),
(3447, 'Merckle'),
(3448, 'Merckle Biotec GmbH'),
(3449, 'TEVA GmbH'),
(3450, 'Mercy Clinic Oklahoma Communities'),
(3451, 'Meristem Therapeutics'),
(3452, 'Merit Medical'),
(3453, 'MerLion Pharma'),
(3454, 'Merrimack Pharmaceutical'),
(3455, 'Merrimack Pharma'),
(3456, 'Merrion Pharma'),
(3457, 'Mersana'),
(3458, 'Mersana Therapeutics'),
(3459, 'Merus N.V.'),
(3460, 'Merz'),
(3461, 'Meso Scale Diagnostics'),
(3462, 'Mesoblast'),
(3463, 'MESTRA Consulting'),
(3464, 'Metabasis Therapeutics'),
(3465, 'Metabolex'),
(3466, 'Metabolic Pharma'),
(3467, 'Metabolic Solutions Development'),
(3468, 'Metabolomic Technologies Inc'),
(3469, 'Metabolon'),
(3470, 'Metabolous Pharma'),
(3471, 'Metagenics'),
(3472, 'Meta-iq ApS'),
(3473, 'Metairie Oncologist'),
(3474, 'Metamark Genetics'),
(3475, 'MetaMax'),
(3476, 'Metanomics Health GmbH'),
(3477, 'Metaphore'),
(3478, 'Metares e.V'),
(3479, 'MetaStat'),
(3480, 'Metastatix'),
(3481, 'METAvivor Research and Support'),
(3482, 'MethylGene'),
(3483, 'Metis Associates'),
(3484, 'Metropolitian Onc Consultants'),
(3485, 'Mexican Cooperative Leukemia Group'),
(3486, 'Meyer Pharma'),
(3487, 'MeyerZall Laboratories'),
(3488, 'MGI Pharma'),
(3489, 'Michael Kurman Consulting'),
(3490, 'Michigan Healthcare Professionals'),
(3491, 'Micro Labs'),
(3492, 'Microbio'),
(3493, 'Fimlab Laboratoriot Ltd,'),
(3494, 'MicroBiome Therapeutics'),
(3495, 'Microbiotix'),
(3496, 'MicroDiag Biomedicine Ltd'),
(3497, 'MicroDose Technologies'),
(3498, 'MicroDose Therapeutx'),
(3499, 'Micromet'),
(3500, 'Micropathology Ltd'),
(3501, 'Microscience'),
(3502, 'Microsoft Corporation'),
(3503, 'MicuRx'),
(3504, 'Mid Atlantic Pharmatech Consultants'),
(3505, 'HE&M'),
(3506, 'Mid-Atlantic Geriatric Association'),
(3507, 'MiddleBrook Pharma'),
(3508, 'Hematology Inc'),
(3509, 'MIGENIX/Micrologix Biotech'),
(3510, 'Miikana'),
(3511, 'MIKA Pharma'),
(3512, 'Mikovits Consulting'),
(3513, 'Millennium'),
(3514, 'Millennium Pharmaceuticals'),
(3515, 'Millennix'),
(3516, 'Milliman'),
(3517, 'Milsing'),
(3518, 'Miltenyi Biotec GmbH'),
(3519, 'Mimetogen'),
(3520, 'Minapharm'),
(3521, 'Ministry of Health, Saudi Arabia'),
(3522, 'MinoGuard'),
(3523, 'Minophagen Pharma'),
(3524, 'Minster Pharma'),
(3525, 'Mipharm'),
(3526, 'Philips Research, Global Headquarters'),
(3527, 'Mirati Therapeutics'),
(3528, 'MIRAX Co, Ltd'),
(3529, 'Mirimus'),
(3530, 'Mirna Therapeutics'),
(3531, 'Mishima Food'),
(3532, 'Mission Pathology Consultants'),
(3533, 'MISSION Therapeutics'),
(3534, 'Mistral Pharma'),
(3535, 'Mitchell Pharmaceutical Consulting'),
(3536, 'Mithra Pharma'),
(3537, 'Mithridion'),
(3538, 'MitoKor'),
(3539, 'Mitovie'),
(3540, 'Mitra Biotech'),
(3541, 'Mitralign'),
(3542, 'Mitsubishi Chemical Medience Corporation'),
(3543, 'Mitsubishi Tanabe Pharma'),
(3544, 'Mistui Knowledge Industry'),
(3545, 'Mitsui Norin'),
(3546, 'Miyarisan Pharmacentical'),
(3547, 'MJ Biopharm'),
(3548, 'Mjp Risk Assessment'),
(3549, 'MMR Information Systems'),
(3550, 'MMRGlobal'),
(3551, 'Molecular Neuroimaging'),
(3552, 'Moberg Derma'),
(3553, 'Mochida'),
(3554, 'PI Inc'),
(3555, 'Model Answers'),
(3556, 'Modern Biosciences'),
(3557, 'Modigene'),
(3558, 'Mogam Biotechnology Institute'),
(3559, 'Molbox Llc'),
(3560, 'Moleac'),
(3561, 'Molecular Devices'),
(3562, 'Molecular Health'),
(3563, 'Molecular Imaging'),
(3564, 'Molecular Insight'),
(3565, 'Molecular MD Corporation'),
(3566, 'Molecular Partners'),
(3567, 'Molecular Pharmaceutics'),
(3568, 'Molecular Pharmacology'),
(3569, 'Molecular Response'),
(3570, 'Molecular Targeting Technologies'),
(3571, 'Molecular Templates'),
(3572, 'Molecular Therapeutics'),
(3573, 'Molecular Therapy'),
(3574, 'Molecular Transfer'),
(3575, 'MolecularHealth,'),
(3576, 'MolecularMD'),
(3577, 'Molecules For Health'),
(3578, 'Molmed'),
(3579, 'Mologen'),
(3580, 'Molteni Farmaceutici'),
(3581, 'Momenta Pharmaceuticals'),
(3582, 'Momentum Research'),
(3583, 'Momotaro-Gene'),
(3584, 'mondoBIOTECH'),
(3585, 'MonoSol Rx'),
(3586, 'Monsea s.r.o'),
(3587, 'Morishita Jintan'),
(3588, 'MorphoSys'),
(3589, 'Morphotek'),
(3590, 'Morria'),
(3591, 'Mortara Instrument'),
(3592, 'Morvus Technology'),
(3593, 'Mosaiques GmbH'),
(3594, 'Movetis'),
(3595, 'Mpex Pharma'),
(3596, 'MPI Research'),
(3597, 'MPD Foundation'),
(3598, 'MRD Co.'),
(3599, 'M\'s Science'),
(3600, 'MSD China Holding Co.'),
(3601, 'MSD Europe'),
(3602, 'MSD K.K.'),
(3603, 'MSD Pharmaceuticals India Private Limited'),
(3604, 'Mt Cook Pharma/Mount Cook Biosciences'),
(3605, 'Mu Sigma'),
(3606, 'Mucosis'),
(3607, 'Mueller Medical'),
(3608, 'Multi Gene Vascular Systems'),
(3609, 'MultiCell Technologies'),
(3610, 'Multigene Diagnostics'),
(3611, 'multimmune'),
(3612, 'Multiplicom N.V.'),
(3613, 'Mundipharma'),
(3614, 'Mundipharma Pte'),
(3615, 'Munich Biotech'),
(3616, 'Muro Pharma'),
(3617, 'Mutual Pharma'),
(3618, 'Mycenax'),
(3619, 'Mylan'),
(3620, 'Mymetics'),
(3621, 'Myogen'),
(3622, 'Myotec'),
(3623, 'MyRAQA'),
(3624, 'Myrexis'),
(3625, 'Myrexis/Myriad Pharma'),
(3626, 'Myriad Genetics'),
(3627, 'Mytech'),
(3628, 'Mytogen'),
(3629, 'Myung-In Pharma'),
(3630, 'MyungMoon Pharma'),
(3631, 'N.V. Perricone'),
(3632, 'VeriFax Corporation'),
(3633, 'N30 Pharma'),
(3634, 'Nabi BioPharma'),
(3635, 'Nabriva'),
(3636, 'Nadler Pharma Associates'),
(3637, 'Nafees Consulting'),
(3638, 'NAMSA'),
(3639, 'Nang Kuang Pharma'),
(3640, 'Nanjing Aosaikang Medicinal Group'),
(3641, 'Nanjing Luye Sike Pharma'),
(3642, 'Nanjing Sike Pharma'),
(3643, 'Nano Terra'),
(3644, 'Nano Valent Phamaceuticals'),
(3645, 'Nano 3D Biosciences'),
(3646, 'NanoBio'),
(3647, 'NANOBIOTEC'),
(3648, 'Nanobiotix'),
(3649, 'NanoCarrier'),
(3650, 'NanoLab'),
(3651, 'Nanoprobes'),
(3652, 'Nanospectra'),
(3653, 'Nanostring Technologies'),
(3654, 'Nanotherapeutics'),
(3655, 'Nanovector srl'),
(3656, 'NantBioScience'),
(3657, 'NantHealth'),
(3658, 'NantKwest'),
(3659, 'NantOmics'),
(3660, 'NantWorks'),
(3661, 'Napo Pharma'),
(3662, 'Napp Pharma'),
(3663, 'Narhex'),
(3664, 'Naryx Pharma/SinusPharma'),
(3665, 'Nascent Pharma'),
(3666, 'Nashai Biotech'),
(3667, 'Nastech Pharma'),
(3668, 'NasVax'),
(3669, 'Natco Pharma'),
(3670, 'Natera'),
(3671, 'National Biological'),
(3672, 'National Development and Research Institutes'),
(3673, 'Nativis'),
(3674, 'Naurex'),
(3675, 'Nautilus Biotech'),
(3676, 'Navidea Biopharmaceuticals'),
(3677, 'Navigant Consulting'),
(3678, 'Navya Network'),
(3679, 'NB Therapeutics'),
(3680, 'NCRI Breast Clinical Studies Group'),
(3681, 'Nearmedic Plus'),
(3682, 'Nectid'),
(3683, 'Negma'),
(3684, 'Nektar Therapeutics'),
(3685, 'NEMA Research'),
(3686, 'Neocodex'),
(3687, 'Neocutis'),
(3688, 'Neodiagnostic Research'),
(3689, 'Neogenix'),
(3690, 'NeoGenomics'),
(3691, 'Neometrix Consulting'),
(3692, 'NeoPharm'),
(3693, 'NeoRx'),
(3694, 'Neose Technologies'),
(3695, 'NeoStem'),
(3696, 'NeoStrata'),
(3697, 'Neotropix'),
(3698, 'Neovacs'),
(3699, 'NeoVista'),
(3700, 'NephroGenex'),
(3701, 'Over the Counter Services (OTC) - Boursa Kuwait'),
(3702, 'Nephropath'),
(3703, 'NephRx'),
(3704, 'Neptune Technologies & Bioressources'),
(3705, 'Nereus Pharmaceuticals'),
(3706, 'Nerveda'),
(3707, 'Nerviano Medical Sciences'),
(3708, 'Nestl Health Science'),
(3709, 'Molecular Biomarkers'),
(3710, 'Nestle Nutrition'),
(3711, 'Nestl Nutrition North America'),
(3712, 'Nestle Research Center'),
(3713, 'Neth. Transl. Res. Center B.V.'),
(3714, 'Neuralstem'),
(3715, 'Neuraltus Pharma'),
(3716, 'NeurAxon'),
(3717, 'Neurelis'),
(3718, 'Neuren Pharma'),
(3719, 'Neurex'),
(3720, 'Neurim'),
(3721, 'Neuro Bioscience'),
(3722, 'Neuro3d'),
(3723, 'Neurobiological Technologies'),
(3724, 'Neurocare'),
(3725, 'NeuroCog Trials'),
(3726, 'Neurocrine Biosciences'),
(3727, 'NeuroDerm'),
(3728, 'NeuroDiscovery'),
(3729, 'Neurodyn'),
(3730, 'Neurogen'),
(3731, 'NeuroGeneration'),
(3732, 'NeuroGenomeX'),
(3733, 'NeurogesX'),
(3734, 'Neurognostics'),
(3735, 'NeuroHealing Pharma'),
(3736, 'Neuro-Hitech'),
(3737, 'Neurokos'),
(3738, 'Neurological Foundation'),
(3739, 'Neurologix'),
(3740, 'Neuromed'),
(3741, 'Neuron Therapeutics'),
(3742, 'Neuronex'),
(3743, 'NeuroNova'),
(3744, 'Neuropharm'),
(3745, 'Neuropharma'),
(3746, 'QPS Austria'),
(3747, 'NeuroProof GmbH'),
(3748, 'Kessler Foundation'),
(3749, 'Fairfax'),
(3750, 'NeuroScience Pharma'),
(3751, 'Atuka'),
(3752, 'AXON Neuroscience SE'),
(3753, 'MOTAC'),
(3754, 'Renovo Neural'),
(3755, 'Jackson Laboratory'),
(3756, 'NeuroScios'),
(3757, 'NeuroSearch'),
(3758, 'NeuroSolutions'),
(3759, 'Neuro Summum'),
(3760, 'Neurotech'),
(3761, 'Neurotez'),
(3762, 'NeuroTrax'),
(3763, 'Neuro-Trials Research'),
(3764, 'NeuroTronik'),
(3765, 'Neurotune'),
(3766, 'NeuroVive'),
(3767, 'Neusentis'),
(3768, 'NeuTec Pharma'),
(3769, 'Neutrogena'),
(3770, 'Nevro'),
(3771, 'New England Research Institutes'),
(3772, 'New River Pharma'),
(3773, 'New York Hematology-Oncology'),
(3774, 'NewBiotics'),
(3775, 'Newfields'),
(3776, 'NewLink Genetics'),
(3777, 'Newron'),
(3778, 'NewSouth Innovations'),
(3779, 'Newtree. Co., Ltd'),
(3780, 'NewVac'),
(3781, 'NexBio'),
(3782, 'Nexcelom Bioscience'),
(3783, 'Nexcura'),
(3784, 'Nexigen GmbH'),
(3785, 'NexMed USA'),
(3786, 'Next Pharma'),
(3787, 'NextBio'),
(3788, 'NextWave Pharma'),
(3789, 'Nexus Pharma'),
(3790, 'Nexus Surgical Associates'),
(3791, 'N-Gene'),
(3792, 'Niadyne Development'),
(3793, 'Nicar Laboratories'),
(3794, 'Niche Pharma'),
(3795, 'Niche Science & Technology'),
(3796, 'Nichi-Iko'),
(3797, 'Nichimo'),
(3798, 'Niconovum'),
(3799, 'Nicox'),
(3800, 'Nielsen Consumer Insights'),
(3801, 'Nihon Medi-Physics'),
(3802, 'Nihon Pharma Industry'),
(3803, 'Niiki Pharma'),
(3804, 'Nikken Chemicals'),
(3805, 'Nile Therapeutics'),
(3806, 'Nippon Boehringer Ingelheim'),
(3807, 'Nippon Chemiphar'),
(3808, 'Nippon Kayaku'),
(3809, 'Nippon Roche'),
(3810, 'Nippon Shinyaku'),
(3811, 'Nissan Chemical Industries'),
(3812, 'Nitec Pharma'),
(3813, 'Nitric Bio'),
(3814, 'Nitric Solutions'),
(3815, 'NitroMed'),
(3816, 'NitrOSystems'),
(3817, 'Nitrox'),
(3818, 'Nitto Boseki'),
(3819, 'Nittobo Medical'),
(3820, 'Nizhpharm'),
(3821, 'NKBio'),
(3822, 'NMS Labs'),
(3823, 'Nobelpharma'),
(3824, 'Nobex'),
(3825, 'Nobilon'),
(3826, 'NOD Pharma'),
(3827, 'Nodality'),
(3828, 'N-Of-One'),
(3829, 'Baxalta Innovations'),
(3830, 'NoNO'),
(3831, 'Nordic Bioscience'),
(3832, 'Nordic Society of Gynaecological Oncology'),
(3833, 'Norgine'),
(3834, 'NormOxys'),
(3835, 'Norpharma'),
(3836, 'Norpro Light Systems Incorporation'),
(3837, 'NorthBay Neonatology Associates'),
(3838, 'Northeast Indiana Research'),
(3839, 'Northern Therapeutics'),
(3840, 'Northlake International'),
(3841, 'Beijing Northland Biotech'),
(3842, 'Northrop Grumman Corporation'),
(3843, 'Northwest Biotherapeutics'),
(3844, 'Northwest NCORP'),
(3845, 'Norwell'),
(3846, 'Norwood Abbey'),
(3847, 'Norwood Immunology'),
(3848, 'Noscira'),
(3849, 'NOVA Research Company'),
(3850, 'NovaBay'),
(3851, 'NovaBiotics'),
(3852, 'NovaCardia'),
(3853, 'Novacea'),
(3854, 'Novacta'),
(3855, 'NovaDel Pharma'),
(3856, 'NovaDigm'),
(3857, 'Novagali'),
(3858, 'NovaLead'),
(3859, 'NovAliX SAS'),
(3860, 'NovaMed Pharma'),
(3861, 'Novartis'),
(3862, 'Novartis Asia Pacific Pharmaceuticals Pte'),
(3863, 'NovaRx'),
(3864, 'NovaRx Corporation'),
(3865, 'Novasep'),
(3866, 'NovaTarg Therapeutics'),
(3867, 'Novavax'),
(3868, 'Novel BioSpectrum'),
(3869, 'Novel Health Strategies'),
(3870, 'Novella Clinical'),
(3871, 'NovellusDx'),
(3872, 'Novelos Therapeutics'),
(3873, 'Noven'),
(3874, 'Novexel'),
(3875, 'NovImmune'),
(3876, 'Novo Nordisk'),
(3877, 'Novocell'),
(3878, 'Novocure'),
(3879, 'Novogen'),
(3880, 'Novolytics'),
(3881, 'NovoNordisk'),
(3882, 'Novosys Health'),
(3883, 'Novotech'),
(3884, 'Novozymes'),
(3885, 'Novozymes GroPep'),
(3886, 'Novuspharma'),
(3887, 'NOX technologies'),
(3888, 'NOXXON Pharm'),
(3889, 'NOXXON Pharma N.V.'),
(3890, 'NPIL Research & Development'),
(3891, 'NPM Pharma'),
(3892, 'NPS Allelix'),
(3893, 'NPS Pharmaceuticals'),
(3894, 'NS Pharma'),
(3895, 'NsGene'),
(3896, 'NSK Statistical Solutions'),
(3897, 'NT Life Sciences'),
(3898, 'Nu Skin'),
(3899, 'NuCana'),
(3900, 'Nucitec'),
(3901, 'Nuclea Biotechnologies/Oncogene Science'),
(3902, 'Nucleonics'),
(3903, 'Nucryst'),
(3904, 'Nuelle'),
(3905, 'Nueva Vida'),
(3906, 'Numira'),
(3907, 'Nuon Therapeutics'),
(3908, 'NuPathe'),
(3909, 'Nurel Therapeutics'),
(3910, 'Nuron Biotech'),
(3911, 'Nursing Professor'),
(3912, 'NuRx Pharma'),
(3913, 'Nutra Pharma'),
(3914, 'Nutricia'),
(3915, 'Nutricia USA'),
(3916, 'Nutrilite'),
(3917, 'Nutrition Care Pharma'),
(3918, 'TAIYO KAGAKU CO LTD'),
(3919, 'Nutrition21'),
(3920, 'Nuvelo'),
(3921, 'Nuventa Pharma Sciences'),
(3922, 'Nuventra'),
(3923, 'Nuvera Biosciences'),
(3924, 'Nuvilex'),
(3925, 'Nuvo Research/Dimethaid Research'),
(3926, 'NuvOx Pharma LLC'),
(3927, 'Nventa/Stressgen'),
(3928, 'Nycomed'),
(3929, 'Nyken'),
(3930, 'Nymox Pharma'),
(3931, 'Nyxis Neurotherapies'),
(3932, 'Polytec Products Corporation'),
(3933, 'OAG Interventional Pain Consultants'),
(3934, 'Oakwood Laboratories'),
(3935, 'Oasmia'),
(3936, 'Obagi Medical'),
(3937, 'Obecure'),
(3938, 'OBI Pharma'),
(3939, 'Obio Pharma'),
(3940, 'Eternit'),
(3941, 'OcellO B.V.'),
(3942, 'Ocera Therapeutics'),
(3943, 'Octagen'),
(3944, 'Octapharma'),
(3945, 'OctoPlus'),
(3946, 'Ocular Therapeutix'),
(3947, 'Oculex'),
(3948, 'Oculis'),
(3949, 'Oculus Innovative'),
(3950, 'OCULUS Optikger?te GmbH'),
(3951, 'OCuSOFT'),
(3952, 'Ocuspecto Oy'),
(3953, 'Odyssey Pharma'),
(3954, 'Ohm Laboratories'),
(3955, 'Ohmx'),
(3956, 'Ohr Pharma'),
(3957, 'Okairos'),
(3958, 'Oligomerix'),
(3959, 'OM Pharma'),
(3960, 'Omeros'),
(3961, 'Omni Bio Pharma'),
(3962, 'Omninvest'),
(3963, 'Omniox'),
(3964, 'Omnitura'),
(3965, 'OmniVision GmbH'),
(3966, 'Atlantic Laboratories'),
(3967, 'Omrix'),
(3968, 'Omthera'),
(3969, 'Onc Alliance'),
(3970, 'Onc Analytics'),
(3971, 'Oncare Hawaii'),
(3972, 'Oncbiomune'),
(3973, 'oncgnostics GmbH'),
(3974, 'Oncobiomed'),
(3975, 'Oncoceutics'),
(3976, 'Oncocidex'),
(3977, 'OncoCyte Corporation'),
(3978, 'OncoDNA'),
(3979, 'Oncoethix'),
(3980, 'OncoFluor'),
(3981, 'Oncogene Science'),
(3982, 'Oncogenesis Corporation'),
(3983, 'OncoGenex Pharmaceuticals'),
(3984, 'Oncolix'),
(3985, 'Oncologianova GmbH Gesellschaft f?r Innovationen in der Onkologie'),
(3986, 'OncoLogic Consulting, LLC'),
(3987, 'Oncology Analytics'),
(3988, 'WuXi PharmaTech'),
(3989, 'Oncology Consortia of Criterium'),
(3990, 'Quintiles IMS Holdings'),
(3991, 'Oncolys BioPharma'),
(3992, 'Oncolytics Biotech'),
(3993, 'Oncomatrix'),
(3994, 'OncoMed Pharmaceuticals'),
(3995, 'Onconostics Technologies'),
(3996, 'Onconova Therapeutics'),
(3997, 'Oncopep'),
(3998, 'Oncopeptides'),
(3999, 'OncoPlexDx'),
(4000, 'Oncos Therapeutics'),
(4001, 'Oncoscience'),
(4002, 'Oncoscience AG'),
(4003, 'OncoSec'),
(4004, 'OncoSec Medical'),
(4005, 'OncoTab'),
(4006, 'OnTarget Chemistry AB'),
(4007, 'Oncotech'),
(4008, 'Oncotelic'),
(4009, 'Oncotest GmbH'),
(4010, 'Teva Pharmeceuticals'),
(4011, 'OncoTherapeutics'),
(4012, 'OncoTherapy Science'),
(4013, 'Oncothyreon'),
(4014, 'Oncovir'),
(4015, 'OncoVista');
INSERT INTO `organizations` (`id`, `name`) VALUES
(4016, 'Oncozyme Pharma'),
(4017, 'OneLegacy'),
(4018, 'Oneness Biotech'),
(4019, 'Onkotrakt AG'),
(4020, 'Onkovis'),
(4021, 'Only for Children Pharma'),
(4022, 'Ono Pharma'),
(4023, 'On-Q-ity'),
(4024, 'Onset Dermatologics'),
(4025, 'Onset Therapeutics'),
(4026, 'Ontochem IT Solutions GmbH'),
(4027, 'Ontogen'),
(4028, 'Onxeo'),
(4029, 'Onyvax Limited'),
(4030, 'Onyx Pharmaceuticals'),
(4031, 'OPAL Therapeutics'),
(4032, 'OpAns'),
(4033, 'OpenAnalytics'),
(4034, 'OpenBiome'),
(4035, 'OpenQ'),
(4036, 'Opexa Therapeutics'),
(4037, 'OphthaliX'),
(4038, 'Ophthalmology Discovery Performance Unit'),
(4039, 'Ophthotech'),
(4040, 'Ophthy-DS'),
(4041, 'OPK Biotech'),
(4042, 'OPKO Health'),
(4043, 'Opko Biologics'),
(4044, 'OPKO Diagnostics'),
(4045, 'Opocrin'),
(4046, 'Opsona'),
(4047, 'Optimal Data Analysis'),
(4048, 'Optimata'),
(4049, 'Optimer Pharma'),
(4050, 'Optimer Pharmaceuticals'),
(4051, 'Optimum Therapeutics'),
(4052, 'OptiNose'),
(4053, 'Optum'),
(4054, 'OptumInsight'),
(4055, 'Opus Science'),
(4056, 'Ora Bio'),
(4057, 'Oracle Biosciences'),
(4058, 'OracleBio Limited'),
(4059, 'Oragenics'),
(4060, 'Oralance Pharma'),
(4061, 'Oramed'),
(4062, 'OraPharma'),
(4063, 'Orban Biotech'),
(4064, 'Orbimed'),
(4065, 'Orbsen Therapeutics'),
(4066, 'ORCA Therapeutics'),
(4067, 'Orchard Healthcare Research'),
(4068, 'Orchestra Therapeutics/Immune Response'),
(4069, 'Orchid Chemicals & Pharma'),
(4070, 'Ordesa Laboratories'),
(4071, 'Ore Pharmaceuticals'),
(4072, 'Orexigen Therapeutics'),
(4073, 'Orexo'),
(4074, 'Organogenesis'),
(4075, 'Organon'),
(4076, 'ORGENTEC Diagnostika'),
(4077, 'Oriel Therapeutics'),
(4078, 'Orient Europharma'),
(4079, 'Orient Pharma'),
(4080, 'Oriflame'),
(4081, 'Origene Technologies'),
(4082, 'Orin Pharma'),
(4083, 'Orion Corporation'),
(4084, 'Orion Pharma'),
(4085, 'Orphan Australia'),
(4086, 'Orphan Europe, SARL'),
(4087, 'Orphan Medical'),
(4088, 'Ortec International'),
(4089, 'Ortho Biotech'),
(4090, 'Ortho Dermatologics'),
(4091, 'OrthoBiotech Oncology Research and Development'),
(4092, 'Orthogen'),
(4093, 'OrthoLogic'),
(4094, 'Ortho-McNeill'),
(4095, 'OrthoNeutrogena'),
(4096, 'Orthovita'),
(4097, 'ORx Pharma'),
(4098, 'Oryx'),
(4099, 'Oryzon Genomics'),
(4100, 'Oscient'),
(4101, 'Oscotec'),
(4102, 'Osel'),
(4103, 'OSF Health Care'),
(4104, 'Oshadi Drug Administration'),
(4105, 'OSI Pharmaceuticals'),
(4106, 'Osiris Therapeutics'),
(4107, 'Osmotica'),
(4108, 'OsteoCorp'),
(4109, 'Osteologix'),
(4110, 'Otsuka Pharmaceutical'),
(4111, 'Osvah Pharma'),
(4112, 'Othera Pharmaceuticals'),
(4113, 'Otorhinolaryngology'),
(4114, 'Outcome Sciences'),
(4115, 'Outcome/Quintiles'),
(4116, 'Outcomes Insights'),
(4117, 'Outcomes Research Solutions'),
(4118, 'Outcomes Research'),
(4119, 'OvaMed'),
(4120, 'Ovation Pharma'),
(4121, 'Oxagen'),
(4122, 'Oxford Biodynamics'),
(4123, 'Oxford BioMedica'),
(4124, 'Oxford BioTherapeutics'),
(4125, 'Oxford Outcomes an ICON PLC Company'),
(4126, 'Oxford Outcomes'),
(4127, 'OXiGENE'),
(4128, 'OXIS'),
(4129, 'OXO Chemie'),
(4130, 'OxOnc Development'),
(4131, 'Oxxon Therapeutics'),
(4132, 'Oxygen Biotherapeutics/Synthetic Blood International'),
(4133, 'OxyPharma'),
(4134, 'Ozmosis Research'),
(4135, 'P Less Than'),
(4136, 'P&D Pharmaceutical'),
(4137, 'Pacific Biosciences'),
(4138, 'Pacific Corp'),
(4139, 'Pacific Therapeutics'),
(4140, 'PacificPharma'),
(4141, 'Pacira/SkyePharma'),
(4142, 'Paddock Laboratories'),
(4143, 'Pain Therapeutics'),
(4144, 'PainReform'),
(4145, 'PAION'),
(4146, 'Paladin Labs'),
(4147, 'Palatin Technologies'),
(4148, 'Palau Pharma'),
(4149, 'Palindrome Liaisons Consultants'),
(4150, 'Parc'),
(4151, 'Paloma Pharma'),
(4152, 'PamGene International BV'),
(4153, 'Pamlab'),
(4154, 'Panacea Biotec'),
(4155, 'Panacea Pharmaceuticals'),
(4156, 'Panacor'),
(4157, 'Panacos'),
(4158, 'PANAGENE'),
(4159, 'Panagin'),
(4160, 'PanGenetics'),
(4161, 'Pangenomics'),
(4162, 'Panion & BF Biotech'),
(4163, 'PanOptica'),
(4164, 'Pantarhei Bioscience'),
(4165, 'Pantec Biosolutions'),
(4166, 'Par Pharmaceutical'),
(4167, 'Paradigm Diagnostics'),
(4168, 'Paradigm Shift Therapeutics'),
(4169, 'Paragon Bioservices'),
(4170, 'Parapharm'),
(4171, 'Paras Biopharmaceuticals Finland'),
(4172, 'Paratek Pharma'),
(4173, 'PAREXEL'),
(4174, 'PAREXEL International'),
(4175, 'PARI Pharma'),
(4176, 'ParinGenix'),
(4177, 'Parion Sciences'),
(4178, 'Parke-Davis'),
(4179, 'Pharmaceutical, Co.,'),
(4180, 'Parsortix,'),
(4181, 'Particle Sciences'),
(4182, 'Partnership for Health Analytic Research'),
(4183, 'Pathcare Laboratories'),
(4184, 'Pathfinder International'),
(4185, 'Pathgroup'),
(4186, 'Pathology Consultants'),
(4187, 'Pathology Experts GmbH'),
(4188, 'Fimlab Laboratoriot'),
(4189, 'Pathway Diagnostics'),
(4190, 'Pathway Genomics'),
(4191, 'Pathway Therapeutics'),
(4192, 'Pathwork Diagnostics'),
(4193, 'PatientCrossroads'),
(4194, 'PatientsLikeMe'),
(4195, 'Patrys'),
(4196, 'Patton Medical'),
(4197, 'Paxman Coolers'),
(4198, 'PaxVax'),
(4199, 'Thompson Homes'),
(4200, 'Pediatric Anes'),
(4201, 'Pediatric Care Inc'),
(4202, 'QuintilesIMS'),
(4203, 'Three Lower Counties Community Services'),
(4204, 'Pediatrix Medical Group'),
(4205, 'Pellucid Advantage'),
(4206, 'Peloton'),
(4207, 'Pendar Medical'),
(4208, 'Pentabase ApS'),
(4209, 'Pentapharm'),
(4210, 'Pentara Corporation'),
(4211, 'Penumbra'),
(4212, 'Penwest'),
(4213, 'Pepgen'),
(4214, 'Peplin Limited'),
(4215, 'Pepscan B.V'),
(4216, 'Pepscan Therapeutics'),
(4217, 'Pepscan Therapeutics B.V.'),
(4218, 'PepTcell'),
(4219, 'Peptech'),
(4220, 'PeptiMed'),
(4221, 'Peptimmune'),
(4222, 'Pepto'),
(4223, 'PEPTONIC Medical'),
(4224, 'Peptron'),
(4225, 'Perceptive Informatics'),
(4226, 'PerceptMX'),
(4227, 'Peregrine Pharmaceuticals'),
(4228, 'PerfAction'),
(4229, 'Pergamum'),
(4230, 'PeriCor'),
(4231, 'PeriRx'),
(4232, 'PerkinElmer'),
(4233, 'Perlecan Pharma'),
(4234, 'Perrigo'),
(4235, 'Perscitus Biosciences'),
(4236, 'Personal Genome Diagnostic'),
(4237, 'Personalis'),
(4238, 'Personalized Cancer Medcn'),
(4239, 'Personalized Cancer Therapy'),
(4240, 'Personalized Sci'),
(4241, 'PersonalizeDx'),
(4242, 'Perstorp'),
(4243, 'Pervasis'),
(4244, 'Petrovax'),
(4245, 'PETTAC-1'),
(4246, 'Pevion'),
(4247, 'Pfizer AB'),
(4248, 'pH Associates'),
(4249, 'PH&T'),
(4250, 'Phage Pharma/Phage Biotechnology'),
(4251, 'Zeltia'),
(4252, 'Pharis Biotec'),
(4253, 'Pharm East'),
(4254, 'PCG Clinical Services AB'),
(4255, 'Pharma Foods International'),
(4256, 'Pharma Integra Limited'),
(4257, 'Sun Pharmaceutical Industries'),
(4258, 'Pharma Mar SA'),
(4259, 'Pharma Nord'),
(4260, 'Pharma Two B'),
(4261, 'Pharma Valley Center'),
(4262, 'PharmAbcine'),
(4263, 'PharmaBlood'),
(4264, 'Pharmaceutical and Health Care Consultation'),
(4265, 'Fujifilm'),
(4266, 'Pharmaceutical Development Integrators'),
(4267, 'Dimension Therapeutics'),
(4268, 'Nipponkayaku'),
(4269, 'Pharmaceuticals and Medical Devices Agency'),
(4270, 'Pharmacia'),
(4271, 'Pharmaclon'),
(4272, 'Grupo Ferrer Internacional'),
(4273, 'Pharmacology Consultants'),
(4274, 'Pharmacopeia'),
(4275, 'Pharmacosmos'),
(4276, 'European Medicines Agency'),
(4277, 'Pharmacyclics'),
(4278, 'PharmaDerm'),
(4279, 'PharmaEngine'),
(4280, 'PharmaEssentia'),
(4281, 'PharmaFacts'),
(4282, 'Pharmagene'),
(4283, 'Pharmagenesis'),
(4284, 'Pharmaleads'),
(4285, 'PharmaMar'),
(4286, 'Pharmanest'),
(4287, 'PharmaNet'),
(4288, 'Pharmanet i3'),
(4289, 'PharmaNet Development Group'),
(4290, 'PharmaNeuroBoost'),
(4291, 'Pharmanutra'),
(4292, 'Pharmaplaz'),
(4293, 'Pharmaron'),
(4294, 'Pharmascience'),
(4295, 'PharmaSeq'),
(4296, 'Pharmasset'),
(4297, 'PharmaStat'),
(4298, 'Pharmatech Oncology'),
(4299, 'Pharmatelligence'),
(4300, 'Pharmatest Services'),
(4301, 'Pharmathen'),
(4302, 'Pharmavite'),
(4303, 'Pharmaxis'),
(4304, 'Pharmed'),
(4305, 'Pharmena'),
(4306, 'Pharmerit BV'),
(4307, 'PharmEste'),
(4308, 'PharmEvo'),
(4309, 'Pharmexa'),
(4310, 'Pharmicell'),
(4311, 'Pharming Group'),
(4312, 'Pharming Technologies NV'),
(4313, 'Pharminox'),
(4314, 'Pharmion Corporation'),
(4315, 'Pharmos'),
(4316, 'Pharm-Sintez'),
(4317, 'Pharmstandard'),
(4318, 'Pharmsynthez'),
(4319, 'PharPoint Research'),
(4320, 'Cetara Corporation'),
(4321, 'Corporation Pharsight Canada'),
(4322, 'Phase 2 Discovery/P2D Bioscience'),
(4323, 'PhaseBio'),
(4324, 'Phenomenome Discoveries'),
(4325, 'Phenomix'),
(4326, 'Pherin Pharma'),
(4327, 'Phico Therapeutics'),
(4328, 'Philip Morris'),
(4329, 'Uxbridge'),
(4330, 'HomeHealthcare Solutions'),
(4331, 'Philips Corporation'),
(4332, 'Philips Research Europe'),
(4333, 'Philips Technologie GmbH'),
(4334, 'Philogen'),
(4335, 'Phi-Medics Ltd'),
(4336, 'Phoenix Interventional'),
(4337, 'Phoenix Pharmacologics'),
(4338, 'Phosphagenics'),
(4339, 'Phosphate Therapeutics'),
(4340, 'PhotoCure'),
(4341, 'PhotoMedex'),
(4342, 'Photonamic GmbH'),
(4343, 'Photopharmica'),
(4344, 'PHT Consulting Services'),
(4345, 'PHusis Therapeutics'),
(4346, 'Phynova'),
(4347, 'Physician Resource Management'),
(4348, 'Physicians Pharma'),
(4349, 'Physiomics'),
(4350, 'PhytoCeutica'),
(4351, 'PhytoHealth Corporation'),
(4352, 'Phytomedics'),
(4353, 'Phytopharm'),
(4354, 'Phytotox SA'),
(4355, 'Pianowski & Pianowski LTDA'),
(4356, 'Pieris AG'),
(4357, 'Pierre Fabre'),
(4358, 'Pilot Therapeutics'),
(4359, 'Primera'),
(4360, 'PIN Pharma'),
(4361, 'Pinnacle Pharma'),
(4362, 'Pinnacle Technology'),
(4363, 'Pioneer Surgical'),
(4364, 'Pipex Pharma'),
(4365, 'Pique Therapeutics'),
(4366, 'PIQUR Therapeutics AG'),
(4367, 'Piramal Healthcare'),
(4368, 'Piramal Healthcare/Nicholas Piramal India'),
(4369, 'Piramal Imaging GmbH'),
(4370, 'Piramal Life Sciences Ltd'),
(4371, 'PIVINA Consulting'),
(4372, 'PK Consultant,'),
(4373, 'PK Noonan Pharmaceutical Consulting'),
(4374, 'PLANTON'),
(4375, 'PlasmidFactory GmbH & Co. KG'),
(4376, 'PLC Medical Systems'),
(4377, 'PledPharma'),
(4378, 'Plethora Solutions'),
(4379, 'Plexxikon'),
(4380, 'Pliva'),
(4381, 'Pluristem'),
(4382, 'PLx Pharma'),
(4383, 'PMG Pharm'),
(4384, 'PMK Consulting'),
(4385, 'PNP Therapeutics'),
(4386, 'Point Therapeutics'),
(4387, 'Polaris'),
(4388, 'Polaris Group'),
(4389, 'Polichem'),
(4390, 'Policy Analysis'),
(4391, 'Polifarma'),
(4392, 'Polydex'),
(4393, 'Polymed Therapeutics'),
(4394, 'PolyMedix'),
(4395, 'Polymun Scientific'),
(4396, 'Polynoma'),
(4397, 'Polyphenon Pharma'),
(4398, 'Polyphor'),
(4399, 'Poniard Pharma'),
(4400, 'PopTest Oncology'),
(4401, 'Porta Clinica'),
(4402, 'Portola Pharmaceuticals'),
(4403, 'Potentia Pharma'),
(4404, 'Potomac Pharma'),
(4405, 'PowderJect'),
(4406, 'PowderMed'),
(4407, 'Poxel Pharma'),
(4408, 'POZEN'),
(4409, 'PPD'),
(4410, 'PR Pharma'),
(4411, 'PRA Health Sciences'),
(4412, 'Praecis'),
(4413, 'Prairie Cardiovascular Consultants'),
(4414, 'Prana Biotechnology'),
(4415, 'PRB Pharma'),
(4416, 'Precise Biopharma'),
(4417, 'Precision NanoSystems'),
(4418, 'Precision Therapeutics'),
(4419, 'Neuro Phage Pharmaceuticals'),
(4420, 'Precog'),
(4421, 'Precos'),
(4422, 'Predicine'),
(4423, 'PregLem'),
(4424, 'Prelude Corporation,'),
(4425, 'Premera Blue Cross'),
(4426, 'Premier Health Research Center'),
(4427, 'Premier Health Partners'),
(4428, 'Premier'),
(4429, 'Premier Research Group Limited'),
(4430, 'Premiere Oncology'),
(4431, 'Presage Biosciences'),
(4432, 'Presidio Pharma'),
(4433, 'Prestwick Pharma'),
(4434, 'Pret Therapeutics'),
(4435, 'PricewaterhouseCoopers'),
(4436, 'Prima BioMed'),
(4437, 'Primecore consulting'),
(4438, 'Primus Pharma'),
(4439, 'RadMD'),
(4440, 'Principia Biopharma'),
(4441, 'PRISM BioLab'),
(4442, 'Prism Pharma'),
(4443, 'PRMA Consulting'),
(4444, 'Proacta'),
(4445, 'SciQuus Oncology'),
(4446, 'PRO - ACTINA'),
(4447, 'Probiodrug'),
(4448, 'Probiomed'),
(4449, 'Procertus Biopharm'),
(4450, 'VGXI'),
(4451, 'Procris Pharma'),
(4452, 'Procter & Gamble'),
(4453, 'Procter & Gamble India'),
(4454, 'Procyrion'),
(4455, 'ProCyte'),
(4456, 'Prodimed S.A.'),
(4457, 'IBL International GmbH'),
(4458, 'ProEthic'),
(4459, 'Profectus Biosciences'),
(4460, 'Boots Norge As'),
(4461, 'ProFibrix'),
(4462, 'Proge Farm'),
(4463, 'Progen Pharma'),
(4464, 'Progenics Pharmaceuticals'),
(4465, 'Progenity'),
(4466, 'Progenra'),
(4467, 'Madipen'),
(4468, 'Prohealth Care Associates'),
(4469, 'Project Data Sphere'),
(4470, 'Projections Research'),
(4471, 'Prolexys'),
(4472, 'Proliant'),
(4473, 'Prolong Pharmaceuticals'),
(4474, 'Prolor Biotech'),
(4475, 'ProlX'),
(4476, 'Promedior'),
(4477, 'Promega Bio Sciences'),
(4478, 'Promega'),
(4479, 'Prometheon Pharma'),
(4480, 'Prometheus Lab'),
(4481, 'Prometheus Laboratories'),
(4482, 'ProMetic'),
(4483, 'PROMETRIKA'),
(4484, 'Promics'),
(4485, 'Promigen Life Sciences'),
(4486, 'Promius Pharma'),
(4487, 'ProNAi'),
(4488, 'ProNAi Therapeutics'),
(4489, 'Pronova'),
(4490, 'Proove Biosciences'),
(4491, 'Propagenix'),
(4492, 'Capita Property & infrastructure'),
(4493, 'ProPhase'),
(4494, 'Proprius Pharma'),
(4495, 'ProQR Therapeutics'),
(4496, 'Proreo Pharma'),
(4497, 'Prosidion'),
(4498, 'ProSkelia'),
(4499, 'Prospect Therapeutics'),
(4500, 'Prostate Oncology Specialists'),
(4501, 'ProStrakan'),
(4502, 'ProtAffin'),
(4503, 'Protalex'),
(4504, 'Protalix'),
(4505, 'Protea Biosciences Group'),
(4506, 'Protein Sciences'),
(4507, 'Protein Therapeutics'),
(4508, 'Protemix'),
(4509, 'Proteo Biotech'),
(4510, 'Proteolix'),
(4511, 'Proteome Sciences'),
(4512, 'Proteon Therapeutics'),
(4513, 'ProteoTech'),
(4514, 'Proteovista'),
(4515, 'Proteros Biostructures GmbH'),
(4516, 'Proteus Digital Health'),
(4517, 'Protez Pharma'),
(4518, 'Protgen'),
(4519, 'Prothena Biosciences'),
(4520, 'Prothena Corp'),
(4521, 'ProThera'),
(4522, 'Protherics'),
(4523, 'Protiva'),
(4524, 'Protobios LLC'),
(4525, 'Provalis'),
(4526, 'Provectus Biopharmaceuticals'),
(4527, 'Provenance BioPharma'),
(4528, 'Provesica'),
(4529, 'Provexis'),
(4530, 'Provid Pharmaceutical'),
(4531, 'Provista Diagnostics'),
(4532, 'Proximagen'),
(4533, 'PSI CRO AG'),
(4534, 'PsiOxus Therapeutics'),
(4535, 'pSivida'),
(4536, 'Psychology Consultants'),
(4537, 'Psyadon'),
(4538, 'Danuvius Klinik GmbH'),
(4539, 'PsychoGenics'),
(4540, 'Psynapse Ltd.'),
(4541, 'Lorimer Enterprises'),
(4542, 'Pulmagen'),
(4543, 'Pulmatrix'),
(4544, 'Pulse Therapeutics'),
(4545, 'Puma Biotechnology'),
(4546, 'Purdue Pharma'),
(4547, 'Pure Encapsulations'),
(4548, 'Pure Protein Llc'),
(4549, 'Puredel'),
(4550, 'Purepac'),
(4551, 'PX Biosolutions'),
(4552, 'Pygargus AB'),
(4553, 'Q&T Research Incorporated'),
(4554, 'QD Research'),
(4555, 'QA REFRESH SPONSOR'),
(4556, 'QBiotics Ltd'),
(4557, 'QGel'),
(4558, 'Qiagen Aarhus A/S'),
(4559, 'QIAGEN Hannover GmbH'),
(4560, 'QIAGEN Manchester'),
(4561, 'Qiagen'),
(4562, 'QLT'),
(4563, 'Q-Med'),
(4564, 'Q-Pharm'),
(4565, 'qPharmetra'),
(4566, 'QR Pharma'),
(4567, 'QRxPharma'),
(4568, 'QST Consultations'),
(4569, 'QSV Biologics'),
(4570, 'Qu Biologics'),
(4571, 'Quadrant Drug Delivery'),
(4572, 'QualiLife Pharma'),
(4573, 'Quality of Life Consulting'),
(4574, 'Quanterix Corporation'),
(4575, 'Quantitative Solutions BV'),
(4576, 'Quantum Genomics'),
(4577, 'Quantum Immunologics'),
(4578, 'QuantumLeap Healthcare'),
(4579, 'Quark Pharmaceuticals'),
(4580, 'Quartz Bio'),
(4581, 'Quatrx'),
(4582, 'Quell Pharma'),
(4583, 'Quest Diagnostics Nichols Inst'),
(4584, 'Quest Pharmatech/Altachem Pharma'),
(4585, 'Questcor'),
(4586, 'Quigley Pharma'),
(4587, 'Quimica Montpellier'),
(4588, 'Quintessence Biosciences'),
(4589, 'Quorum Consulting'),
(4590, 'Quotient Clinical'),
(4591, 'QURE Healthcare'),
(4592, 'Oncosynergy'),
(4593, 'Hero Spain - R&D'),
(4594, 'R&D Systems'),
(4595, 'ACImmune'),
(4596, 'AJ Roboscreen GmbH'),
(4597, 'Applied Immune Technologies'),
(4598, 'BIAL - Portela & C?., S.A.'),
(4599, 'Crossbeta Biosciences B.V.'),
(4600, 'MagQu Co. Ltd'),
(4601, 'Medifron DBT'),
(4602, 'MeMed Diagnostics'),
(4603, 'Mills DA'),
(4604, 'Nestl Nutrition'),
(4605, 'Neuroglobe'),
(4606, 'Neurolixis'),
(4607, 'ToolGen'),
(4608, 'R&R Inc'),
(4609, 'R.W. Johnson Pharma Research Institute'),
(4610, 'Hero Group'),
(4611, 'Ra Pharmaceuticals'),
(4612, 'Radient Pharmaceuticals'),
(4613, 'Radiation Oncology Consultants'),
(4614, 'RadioMedix'),
(4615, 'RadioRx'),
(4616, 'Radius'),
(4617, 'Radius Health'),
(4618, 'Radix BioResearch'),
(4619, 'Rafa Laboratories'),
(4620, 'RainDance Technologies'),
(4621, 'R?mistr'),
(4622, 'Ranbaxy'),
(4623, 'RAND Corporation'),
(4624, 'Randox Laboratories'),
(4625, 'Randox Toxicology'),
(4626, 'RAPID Pharma'),
(4627, 'Raptor Pharma'),
(4628, 'RaQualia'),
(4629, 'RareCyte'),
(4630, 'Rational Therapeutics'),
(4631, 'Raven biotechnologies'),
(4632, 'Ravenbhel Pharma'),
(4633, 'RayBiotech'),
(4634, 'Raze Therapeutics'),
(4635, 'Royal Bank of Scotland'),
(4636, 'RC Winneker Consulting'),
(4637, 'RDD Pharma'),
(4638, 'ReachBio'),
(4639, 'Reaction Biology'),
(4640, 'Real Endpoints'),
(4641, 'RealTime Oncology'),
(4642, 'Reata Pharma'),
(4643, 'Rebiotix'),
(4644, 'Recalcine'),
(4645, 'Recardio'),
(4646, 'Recepta Biopharma'),
(4647, 'ReceptoPharm'),
(4648, 'Receptos'),
(4649, 'Reckitt Benckiser'),
(4650, 'Recoly'),
(4651, 'RECOMBIO'),
(4652, 'Recordati'),
(4653, 'Recro Pharma'),
(4654, 'RedHill Biopharma'),
(4655, 'RedPath Integrated Pathology'),
(4656, 'Redwood Outcomes'),
(4657, 'Redx Oncology'),
(4658, 'Redx Pharma - Redx Oncology'),
(4659, 'Regado Biosciences'),
(4660, 'Regen BioPharma'),
(4661, 'ReGen Therapeutics'),
(4662, 'Regenera'),
(4663, 'Regenerex'),
(4664, 'Regeneron Pharmaceuticals'),
(4665, 'RegeneRx'),
(4666, 'Regenex'),
(4667, 'Regenocyte'),
(4668, 'ReGenX Biosciences'),
(4669, 'REGENXBIO'),
(4670, 'Regimmune'),
(4671, 'Regional Cancer Care Associates'),
(4672, 'Regulon'),
(4673, 'Reimagine'),
(4674, 'Rejuvenon'),
(4675, 'Relevare Pharma'),
(4676, 'Reliance GeneMedix'),
(4677, 'Reliance Life Sciences'),
(4678, 'Reliant Pharma'),
(4679, 'Relmada'),
(4680, 'Relypsa'),
(4681, 'Renapharma-Vifor'),
(4682, 'ReNeuron'),
(4683, 'Renovis'),
(4684, 'REPLICor'),
(4685, 'Replidyne'),
(4686, 'Repligen'),
(4687, 'Repros Therapeutics'),
(4688, 'Reprotect'),
(4689, 'ReqMed'),
(4690, 'Nagase ChemteX Corporation'),
(4691, 'Asceneuron'),
(4692, 'Lophius Biosciences GmbH'),
(4693, 'Cell Biotech'),
(4694, 'Seoul Pharma Co.'),
(4695, 'Swissray Global Healthcare Holding'),
(4696, 'AIT'),
(4697, 'Dclion Pharmaceuticals'),
(4698, 'Veridex LLC'),
(4699, 'Roche Diagnostics GmbH'),
(4700, 'Dong-A ST'),
(4701, 'Research Corporation Technologies'),
(4702, 'Research Diets'),
(4703, 'Research Genetic Cancer Centre, Ltd'),
(4704, 'RESEARCH IN REAL LIFE LIMITED'),
(4705, 'Q&T Research'),
(4706, 'Research Institute, Inc.'),
(4707, 'Research Pharmaceutical Services'),
(4708, 'Research Point Global'),
(4709, 'ADx NeuroSciences'),
(4710, 'MentAge'),
(4711, 'Resistentia'),
(4712, 'Resolution Bioscience'),
(4713, 'Resolvyx'),
(4714, 'Respicardia'),
(4715, 'Respiratorius'),
(4716, 'Respiratory Motion'),
(4717, 'RespiVert'),
(4718, 'ResProtect'),
(4719, 'Restoragen'),
(4720, 'Resverlogix'),
(4721, 'Retinal Consultants'),
(4722, 'RetinaPharma Technologies'),
(4723, 'Retrophin'),
(4724, 'Revalesio'),
(4725, 'Revance'),
(4726, 'ReveraGen/Validus Pharma'),
(4727, 'Reviva Pharma'),
(4728, 'Revivicor'),
(4729, 'Revlon'),
(4730, 'Revogenex'),
(4731, 'Revotar BioPharma'),
(4732, 'Rexahn'),
(4733, 'Rexahn Pharmaceuticals'),
(4734, 'Rexall Sundown'),
(4735, 'Reyon Pharma'),
(4736, 'RFS Pharma'),
(4737, 'rgb gmbh / studio rgb co.'),
(4738, 'RHEI'),
(4739, 'Rhein Biotech'),
(4740, 'Rheoscience'),
(4741, 'Rhizen Pharmaceuticals'),
(4742, 'Rho'),
(4743, 'Rhodes Pharma'),
(4744, 'Rhone Poulenc Rorer S.A.'),
(4745, 'Rhythm Metabolic'),
(4746, 'Rhythm Pharma'),
(4747, 'Rhythm'),
(4748, 'Ribapharm'),
(4749, 'Ribological'),
(4750, 'Ribosepharm'),
(4751, 'Ribozyme'),
(4752, 'Rib-X'),
(4753, 'Richter Gedeon'),
(4754, 'Rigel'),
(4755, 'Rinat'),
(4756, 'RIT Oncology'),
(4757, 'RNA Diagnostics'),
(4758, 'RNL BIO'),
(4759, 'Robugen'),
(4760, 'Roche (China Holdings Ltd)'),
(4761, 'Roche SSC Budapest - Roche Services (Europe) Ltd.'),
(4762, 'Roche Holding AG'),
(4763, 'Laboratorios Roche'),
(4764, 'Roche Glycart'),
(4765, 'Roche Moscow'),
(4766, 'Roche Products'),
(4767, 'Roche Slovensko s.r.o.'),
(4768, 'Rock Creek Pharma'),
(4769, 'Rocky Mountain Cancer Center'),
(4770, 'Rodeghier Consultants'),
(4771, 'ROHTO Pharma'),
(4772, 'Romark Laboratories'),
(4773, 'Rose Li and Associates'),
(4774, 'Rose Pharma/Gastrotech Pharma'),
(4775, 'Rosemont Pharma'),
(4776, 'Rosetta Genomics'),
(4777, 'RostaQuo'),
(4778, 'Roswell Park Cancer Institute - CureFAKtor Pharmaceuticals'),
(4779, 'Rottapharm'),
(4780, 'Rovi Pharma Laboratories'),
(4781, 'Roxall'),
(4782, 'Roxane Laboratories'),
(4783, 'Roxro Pharma'),
(4784, 'Royalmount Pharma'),
(4785, 'RRD International'),
(4786, 'R S G Consulting'),
(4787, 'R-Tech Ueno'),
(4788, 'RTI International'),
(4789, 'RxKinetix'),
(4790, 'Rxmidas'),
(4791, 'RxMP Therapeutics LLC'),
(4792, 'Court Pharmacy Group'),
(4793, 'S1 Biopharma'),
(4794, 'Sabinsa'),
(4795, 'Saegis'),
(4796, 'Safer Medical'),
(4797, 'Sagatech Electronic'),
(4798, 'SageMedic'),
(4799, 'Sahajanand Medical Technologies'),
(4800, 'SAIC-Frederick'),
(4801, 'SAJE Consulting'),
(4802, 'SAKAI Pharma'),
(4803, 'Saladax Biomedical'),
(4804, 'Salient Pharma'),
(4805, 'Salix Pharmaceuticals'),
(4806, 'Salmedix'),
(4807, 'SalterMitchell'),
(4808, 'Salvat'),
(4809, 'Samaritan Pharma'),
(4810, 'Samchundang'),
(4811, 'Samjin Pharmaceutical'),
(4812, 'Samsung BioLogics'),
(4813, 'Samsung Electronics'),
(4814, 'Samyang Biopharm'),
(4815, 'Samyang Biopharmaceuticals'),
(4816, 'Samyang Research'),
(4817, 'Sanaria'),
(4818, 'SanBio'),
(4819, 'Sandoz'),
(4820, 'Saneron CCEL Therapeutics'),
(4821, 'Sangamo BioSciences'),
(4822, 'Sangart'),
(4823, 'Sangstat Medical Corporation'),
(4824, 'Sanguine Diagnostics and Therapeutics'),
(4825, 'Saniona'),
(4826, 'Sankyo'),
(4827, 'SANOCHEMIA'),
(4828, 'Sanof R&D'),
(4829, 'Sanofi Canada'),
(4830, 'Sanofi-Aventis'),
(4831, 'Sanofi-Aventis Cambridge'),
(4832, 'Sanofi-Aventis Deutschland GmbH'),
(4833, 'Sanos Bioscien'),
(4834, 'Sanquin'),
(4835, 'Santa Maria Biotherapeutics'),
(4836, 'Santaris Pharma'),
(4837, 'Santarus'),
(4838, 'Santecu Co.'),
(4839, 'Santen'),
(4840, 'Santhera'),
(4841, 'SantoSolve Pharma'),
(4842, 'Sanwa Kagaku'),
(4843, 'Sanway Gene Technology'),
(4844, 'Sapphire Therapeutics'),
(4845, 'Sapporo Breweries'),
(4846, 'Oncology Hematology Care'),
(4847, 'Sarawak MediChem'),
(4848, 'SARcode'),
(4849, 'Sarepta Therapeutics/AVI BioPharma'),
(4850, 'Satiogen'),
(4851, 'Savient'),
(4852, 'Savvipharm'),
(4853, 'SBH Sciences'),
(4854, 'SBI Biotech'),
(4855, 'SBL Vaccines'),
(4856, 'SBPharma IND'),
(4857, '4 SC AG'),
(4858, '4SC - biopharmaceutical company'),
(4859, 'SCAI'),
(4860, 'Scancell'),
(4861, 'Scanco Holding AG'),
(4862, 'Scantibodies Laboratory'),
(4863, 'SHARP ELECTRONICS CORPORATION'),
(4864, 'Schering AG'),
(4865, 'Schering-Plough'),
(4866, 'Schering Nordiska AB'),
(4867, 'Schrodinger'),
(4868, 'Schwabe'),
(4869, 'Schwarz Pharma'),
(4870, 'SciClone'),
(4871, 'Sciele Pharma'),
(4872, 'AZ Science'),
(4873, 'Science Exchange'),
(4874, 'Science Group'),
(4875, 'IXICO PLC.'),
(4876, 'Transpharmation'),
(4877, 'Terumo BCT Europe NV'),
(4878, 'SciGen'),
(4879, 'Scil Biomedicals'),
(4880, 'Scimega Research'),
(4881, 'SciMetrika'),
(4882, 'Sciome'),
(4883, 'Scios'),
(4884, 'SCIREX'),
(4885, 'Scitech Medical'),
(4886, 'sci-telligent'),
(4887, 'SCIVAX Life Sciences'),
(4888, 'SCIVAX USA'),
(4889, 'SCOLR Pharma'),
(4890, 'Scotia Pharmaceuticals'),
(4891, 'Scott Cruickshank & Associates'),
(4892, 'Scottish HPV Reference Laboratory'),
(4893, 'Scottsdale Medical Imaging Ltd.'),
(4894, 'SCS Boehringer Ingelheim Comm.V.'),
(4895, 'S-cubed Biometrics'),
(4896, 'Scynexis'),
(4897, 'ScyTek Laboratories'),
(4898, 'SDE Services'),
(4899, 'Seaside Therapeutics'),
(4900, 'Seattle BioMed'),
(4901, 'Seattle Breast Pathology Consultants'),
(4902, 'Seattle Genetics'),
(4903, 'SeBo GmbH');

-- --------------------------------------------------------

--
-- Table structure for table `password_resets`
--

CREATE TABLE `password_resets` (
  `email` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `token` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `permissions`
--

CREATE TABLE `permissions` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `name` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `guard_name` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `permissions`
--

INSERT INTO `permissions` (`id`, `name`, `guard_name`, `created_at`, `updated_at`) VALUES
(1, 'admin-dashboard', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(2, 'user-dashboard', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(3, 'user-add', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(4, 'user-update', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(5, 'user-delete', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(6, 'user-extend-trail', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(7, 'user-subscription-details', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(8, 'subscription-dashboard', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(9, 'sub-plan-add', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(10, 'sub-plan-edit', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(11, 'sub-plan-delete', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(12, 'sso-clients-dashboard', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(13, 'mail-management', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(14, 'articles-dashboard', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(15, 'article-add', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(16, 'article-update', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(17, 'article-delete', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(18, 'categories-view', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(19, 'category-add', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(20, 'category-update', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(21, 'category-delete', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(22, 'tags-view', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(23, 'tag-add', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(24, 'tag-update', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(25, 'tag-delete', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(26, 'privacy-security-management', 'web', '2023-01-06 11:00:00', '2023-01-06 11:00:00'),
(27, 'invoice-download', 'web', '2023-01-09 06:45:06', '2023-01-09 06:45:06');

-- --------------------------------------------------------

--
-- Table structure for table `personal_access_tokens`
--

CREATE TABLE `personal_access_tokens` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `tokenable_type` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `tokenable_id` bigint(20) UNSIGNED NOT NULL,
  `name` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `token` varchar(64) COLLATE utf8mb4_unicode_ci NOT NULL,
  `abilities` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `last_used_at` timestamp NULL DEFAULT NULL,
  `expires_at` timestamp NULL DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `roles`
--

CREATE TABLE `roles` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `name` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `guard_name` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `roles`
--

INSERT INTO `roles` (`id`, `name`, `guard_name`, `created_at`, `updated_at`) VALUES
(1, 'Super Admin', 'web', '2023-01-07 06:21:53', '2023-01-07 06:21:53'),
(2, 'Admin', 'web', '2022-12-21 10:25:26', '2022-12-21 10:25:26'),
(3, 'Student', 'web', '2023-01-07 06:24:06', '2023-01-07 06:24:06'),
(4, 'Doctor', 'web', '2023-01-07 06:24:06', '2023-01-07 06:24:06'),
(5, 'Medical Center', 'web', '2023-01-07 06:24:06', '2023-01-07 06:24:06'),
(6, 'Pharmaceutical Organization', 'web', '2023-01-07 06:24:06', '2023-01-07 06:24:06'),
(7, 'Biotechnology Organization', 'web', '2023-01-07 06:24:06', '2023-01-07 06:24:06'),
(8, 'Partner', 'web', '2023-01-07 06:24:06', '2023-01-07 06:24:06');

-- --------------------------------------------------------

--
-- Table structure for table `role_has_permissions`
--

CREATE TABLE `role_has_permissions` (
  `permission_id` bigint(20) UNSIGNED NOT NULL,
  `role_id` bigint(20) UNSIGNED NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `role_has_permissions`
--

INSERT INTO `role_has_permissions` (`permission_id`, `role_id`) VALUES
(1, 1),
(2, 1),
(3, 1),
(4, 1),
(5, 1),
(6, 1),
(7, 1),
(8, 1),
(9, 1),
(10, 1),
(11, 1),
(12, 1),
(13, 1),
(14, 1),
(15, 1),
(16, 1),
(17, 1),
(18, 1),
(19, 1),
(20, 1),
(21, 1),
(22, 1),
(23, 1),
(24, 1),
(25, 1),
(26, 1),
(27, 1);

-- --------------------------------------------------------

--
-- Table structure for table `subscription_plans`
--

CREATE TABLE `subscription_plans` (
  `id` int(11) NOT NULL,
  `plan_name` varchar(255) NOT NULL,
  `plan_slug` varchar(255) NOT NULL,
  `actual_price` double NOT NULL,
  `paid_price` double NOT NULL,
  `accessible_users` varchar(255) NOT NULL,
  `conversion_rate` double NOT NULL,
  `tax` double NOT NULL,
  `status` enum('draft','active') NOT NULL DEFAULT 'draft',
  `created_at` timestamp NOT NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

--
-- Dumping data for table `subscription_plans`
--

INSERT INTO `subscription_plans` (`id`, `plan_name`, `plan_slug`, `actual_price`, `paid_price`, `accessible_users`, `conversion_rate`, `tax`, `status`, `created_at`, `updated_at`) VALUES
(1, 'Free', 'free', 0, 0, '1', 0, 0, 'active', '2022-12-22 06:02:18', '2023-01-06 04:11:44'),
(2, 'Student', 'student', 99, 99, '1', 82, 18, 'active', '2022-12-22 06:02:18', '2023-01-06 04:11:49'),
(3, 'Doctor', 'doctor', 299, 299, '1', 82, 18, 'active', '2022-12-22 06:02:18', '2023-01-06 04:11:53'),
(4, 'Biotech', 'biotech', 799, 799, '1', 82, 18, 'active', '2022-12-22 06:02:18', '2023-01-06 04:11:58'),
(5, 'Pharma', 'pharma', 3495, 3495, '1', 82, 18, 'active', '2022-12-30 10:25:49', '2023-01-06 04:12:03');

-- --------------------------------------------------------

--
-- Table structure for table `users`
--

CREATE TABLE `users` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `salutation` enum('Mr.','Ms.','Mrs.','Dr.','Prof.') COLLATE utf8mb4_unicode_ci NOT NULL,
  `firstname` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `lastname` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `username` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `email` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `phone` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `country_id` bigint(20) DEFAULT NULL,
  `other_details` longtext COLLATE utf8mb4_unicode_ci DEFAULT '{"qualification":"MBBS",     "medicalCenter":null,     "organization":null,     "collegeName":null,     "ongoingCourse":null,     "completionDate":null,     "alterPhone":null,     "alterEmail":null }',
  `email_verified_at` timestamp NULL DEFAULT NULL,
  `password` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `status` enum('active','deleted') COLLATE utf8mb4_unicode_ci DEFAULT 'active',
  `remember_token` varchar(100) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `users`
--

INSERT INTO `users` (`id`, `salutation`, `firstname`, `lastname`, `username`, `email`, `phone`, `country_id`, `other_details`, `email_verified_at`, `password`, `status`, `remember_token`, `created_at`, `updated_at`) VALUES
(1, 'Mr.', 'Maneet', 'Singh', 'INDA01', 'maneet@adi-group.com', '9815025032', 96, '{\"qualification\":\"MBBS\",\"medicalCenter\":null,\"organization\":null,\"collegeName\":null,\"ongoingCourse\":null,\"completionDate\":null,\"alterPhone\":\"\",\"alterEmail\":\"\"}', '2023-01-08 18:30:00', '$2y$10$QWnoPOVVKeO0wOV3BmzBDOsmIXoMrlbSkh/VaKEWt46snxzX.we4K', 'active', NULL, '2023-01-09 02:19:25', '2023-01-09 02:19:25'),
(2, 'Mr.', 'ADI', 'COMPANY', NULL, 'admin@quantinova.com', NULL, NULL, '{\"qualification\":\"MBBS\",     \"medicalCenter\":null,     \"organization\":null,     \"collegeName\":null,     \"ongoingCourse\":null,     \"completionDate\":null,     \"alterPhone\":null,     \"alterEmail\":null }', '2023-01-09 11:04:47', '$2y$10$8D6GqyNVqDfCNShezjiQH.TewuKLqO2/l0jm67nZWXY1spqxWmRLO', 'active', NULL, '2023-01-09 03:54:00', '2023-01-09 03:54:00');

-- --------------------------------------------------------

--
-- Table structure for table `user_educations`
--

CREATE TABLE `user_educations` (
  `id` int(11) NOT NULL,
  `type` varchar(255) NOT NULL,
  `specialty` text NOT NULL,
  `institute` text NOT NULL,
  `start_date` date NOT NULL,
  `end_date` date DEFAULT NULL,
  `user_id` bigint(20) UNSIGNED NOT NULL,
  `created_at` timestamp NOT NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

-- --------------------------------------------------------

--
-- Table structure for table `user_experiences`
--

CREATE TABLE `user_experiences` (
  `id` int(11) NOT NULL,
  `organization` varchar(255) NOT NULL,
  `location` varchar(255) NOT NULL,
  `designation` varchar(255) NOT NULL,
  `start_date` date NOT NULL,
  `end_date` date DEFAULT NULL,
  `user_id` bigint(20) UNSIGNED NOT NULL,
  `created_at` timestamp NOT NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

-- --------------------------------------------------------

--
-- Table structure for table `user_has_subscriptions`
--

CREATE TABLE `user_has_subscriptions` (
  `id` int(11) NOT NULL,
  `user_id` bigint(20) UNSIGNED NOT NULL,
  `plan_id` bigint(20) NOT NULL,
  `expire_at` timestamp NOT NULL DEFAULT current_timestamp() ON UPDATE current_timestamp(),
  `created_at` timestamp NOT NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

--
-- Dumping data for table `user_has_subscriptions`
--

INSERT INTO `user_has_subscriptions` (`id`, `user_id`, `plan_id`, `expire_at`, `created_at`, `updated_at`) VALUES
(1, 1, 1, '2024-01-01 08:49:28', '2023-01-09 08:49:28', '2023-01-09 08:49:28'),
(2, 2, 1, '2023-01-16 09:24:00', '2023-01-09 03:54:00', '2023-01-09 03:54:00');

-- --------------------------------------------------------

--
-- Table structure for table `user_invoices`
--

CREATE TABLE `user_invoices` (
  `id` int(11) NOT NULL,
  `invoice_number` varchar(255) NOT NULL,
  `order_id` varchar(255) NOT NULL,
  `payment_id` varchar(255) NOT NULL,
  `plan_id` bigint(20) NOT NULL,
  `user_id` bigint(20) UNSIGNED NOT NULL,
  `created_at` timestamp NOT NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

-- --------------------------------------------------------

--
-- Table structure for table `user_orders`
--

CREATE TABLE `user_orders` (
  `order_id` varchar(255) NOT NULL,
  `plan_id` bigint(20) NOT NULL,
  `user_id` bigint(20) UNSIGNED NOT NULL,
  `receipt_number` varchar(255) NOT NULL,
  `status` enum('created','paid') NOT NULL,
  `created_at` timestamp NOT NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

-- --------------------------------------------------------

--
-- Table structure for table `user_payments`
--

CREATE TABLE `user_payments` (
  `id` int(11) NOT NULL,
  `order_id` varchar(255) NOT NULL,
  `payment_id` varchar(255) NOT NULL,
  `bank_transaction_id` varchar(255) NOT NULL,
  `payment_method` varchar(255) NOT NULL,
  `payment_bank` varchar(255) DEFAULT NULL,
  `amount` tinyint(1) NOT NULL,
  `status` varchar(255) NOT NULL,
  `created_at` timestamp NOT NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

-- --------------------------------------------------------

--
-- Table structure for table `user_research_papers`
--

CREATE TABLE `user_research_papers` (
  `id` int(11) NOT NULL,
  `title` text NOT NULL,
  `url` text DEFAULT NULL,
  `user_id` bigint(20) UNSIGNED NOT NULL,
  `created_at` timestamp NOT NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4;

--
-- Indexes for dumped tables
--

--
-- Indexes for table `added_users`
--
ALTER TABLE `added_users`
  ADD PRIMARY KEY (`user_id`);

--
-- Indexes for table `blogs`
--
ALTER TABLE `blogs`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `blog_categories`
--
ALTER TABLE `blog_categories`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `blog_tags`
--
ALTER TABLE `blog_tags`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `countries`
--
ALTER TABLE `countries`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `degrees`
--
ALTER TABLE `degrees`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `failed_jobs`
--
ALTER TABLE `failed_jobs`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `failed_jobs_uuid_unique` (`uuid`);

--
-- Indexes for table `migrations`
--
ALTER TABLE `migrations`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `model_has_permissions`
--
ALTER TABLE `model_has_permissions`
  ADD PRIMARY KEY (`permission_id`,`model_id`,`model_type`),
  ADD KEY `model_has_permissions_model_id_model_type_index` (`model_id`,`model_type`);

--
-- Indexes for table `model_has_roles`
--
ALTER TABLE `model_has_roles`
  ADD PRIMARY KEY (`role_id`,`model_id`,`model_type`),
  ADD KEY `model_has_roles_model_id_model_type_index` (`model_id`,`model_type`);

--
-- Indexes for table `oauth_access_tokens`
--
ALTER TABLE `oauth_access_tokens`
  ADD PRIMARY KEY (`id`),
  ADD KEY `oauth_access_tokens_user_id_index` (`user_id`);

--
-- Indexes for table `oauth_auth_codes`
--
ALTER TABLE `oauth_auth_codes`
  ADD PRIMARY KEY (`id`),
  ADD KEY `oauth_auth_codes_user_id_index` (`user_id`);

--
-- Indexes for table `oauth_clients`
--
ALTER TABLE `oauth_clients`
  ADD PRIMARY KEY (`id`),
  ADD KEY `oauth_clients_user_id_index` (`user_id`);

--
-- Indexes for table `oauth_personal_access_clients`
--
ALTER TABLE `oauth_personal_access_clients`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `oauth_refresh_tokens`
--
ALTER TABLE `oauth_refresh_tokens`
  ADD PRIMARY KEY (`id`),
  ADD KEY `oauth_refresh_tokens_access_token_id_index` (`access_token_id`);

--
-- Indexes for table `organizations`
--
ALTER TABLE `organizations`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `password_resets`
--
ALTER TABLE `password_resets`
  ADD KEY `password_resets_email_index` (`email`);

--
-- Indexes for table `permissions`
--
ALTER TABLE `permissions`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `permissions_name_guard_name_unique` (`name`,`guard_name`);

--
-- Indexes for table `personal_access_tokens`
--
ALTER TABLE `personal_access_tokens`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `personal_access_tokens_token_unique` (`token`),
  ADD KEY `personal_access_tokens_tokenable_type_tokenable_id_index` (`tokenable_type`,`tokenable_id`);

--
-- Indexes for table `roles`
--
ALTER TABLE `roles`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `roles_name_guard_name_unique` (`name`,`guard_name`);

--
-- Indexes for table `role_has_permissions`
--
ALTER TABLE `role_has_permissions`
  ADD PRIMARY KEY (`permission_id`,`role_id`),
  ADD KEY `role_has_permissions_role_id_foreign` (`role_id`);

--
-- Indexes for table `subscription_plans`
--
ALTER TABLE `subscription_plans`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `users`
--
ALTER TABLE `users`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `users_email_unique` (`email`);

--
-- Indexes for table `user_educations`
--
ALTER TABLE `user_educations`
  ADD PRIMARY KEY (`id`),
  ADD KEY `user_id` (`user_id`);

--
-- Indexes for table `user_experiences`
--
ALTER TABLE `user_experiences`
  ADD PRIMARY KEY (`id`),
  ADD KEY `user_id` (`user_id`);

--
-- Indexes for table `user_has_subscriptions`
--
ALTER TABLE `user_has_subscriptions`
  ADD PRIMARY KEY (`id`),
  ADD KEY `user_id` (`user_id`);

--
-- Indexes for table `user_invoices`
--
ALTER TABLE `user_invoices`
  ADD PRIMARY KEY (`id`),
  ADD KEY `user_id` (`user_id`);

--
-- Indexes for table `user_orders`
--
ALTER TABLE `user_orders`
  ADD KEY `user_orders_ibfk_1` (`user_id`);

--
-- Indexes for table `user_payments`
--
ALTER TABLE `user_payments`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `user_research_papers`
--
ALTER TABLE `user_research_papers`
  ADD PRIMARY KEY (`id`),
  ADD KEY `user_id` (`user_id`);

--
-- AUTO_INCREMENT for dumped tables
--

--
-- AUTO_INCREMENT for table `blogs`
--
ALTER TABLE `blogs`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=7;

--
-- AUTO_INCREMENT for table `blog_categories`
--
ALTER TABLE `blog_categories`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=3;

--
-- AUTO_INCREMENT for table `blog_tags`
--
ALTER TABLE `blog_tags`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=4;

--
-- AUTO_INCREMENT for table `countries`
--
ALTER TABLE `countries`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=241;

--
-- AUTO_INCREMENT for table `degrees`
--
ALTER TABLE `degrees`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=78;

--
-- AUTO_INCREMENT for table `failed_jobs`
--
ALTER TABLE `failed_jobs`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `migrations`
--
ALTER TABLE `migrations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=21;

--
-- AUTO_INCREMENT for table `oauth_personal_access_clients`
--
ALTER TABLE `oauth_personal_access_clients`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `organizations`
--
ALTER TABLE `organizations`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=4904;

--
-- AUTO_INCREMENT for table `permissions`
--
ALTER TABLE `permissions`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=28;

--
-- AUTO_INCREMENT for table `personal_access_tokens`
--
ALTER TABLE `personal_access_tokens`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `roles`
--
ALTER TABLE `roles`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=11;

--
-- AUTO_INCREMENT for table `subscription_plans`
--
ALTER TABLE `subscription_plans`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=7;

--
-- AUTO_INCREMENT for table `users`
--
ALTER TABLE `users`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=3;

--
-- AUTO_INCREMENT for table `user_educations`
--
ALTER TABLE `user_educations`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `user_experiences`
--
ALTER TABLE `user_experiences`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `user_has_subscriptions`
--
ALTER TABLE `user_has_subscriptions`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=3;

--
-- AUTO_INCREMENT for table `user_invoices`
--
ALTER TABLE `user_invoices`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `user_payments`
--
ALTER TABLE `user_payments`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `user_research_papers`
--
ALTER TABLE `user_research_papers`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT;

--
-- Constraints for dumped tables
--

--
-- Constraints for table `added_users`
--
ALTER TABLE `added_users`
  ADD CONSTRAINT `added_users_ibfk_1` FOREIGN KEY (`user_id`) REFERENCES `users` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `model_has_permissions`
--
ALTER TABLE `model_has_permissions`
  ADD CONSTRAINT `model_has_permissions_permission_id_foreign` FOREIGN KEY (`permission_id`) REFERENCES `permissions` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `model_has_roles`
--
ALTER TABLE `model_has_roles`
  ADD CONSTRAINT `model_has_roles_role_id_foreign` FOREIGN KEY (`role_id`) REFERENCES `roles` (`id`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `role_has_permissions`
--
ALTER TABLE `role_has_permissions`
  ADD CONSTRAINT `role_has_permissions_permission_id_foreign` FOREIGN KEY (`permission_id`) REFERENCES `permissions` (`id`) ON DELETE CASCADE,
  ADD CONSTRAINT `role_has_permissions_role_id_foreign` FOREIGN KEY (`role_id`) REFERENCES `roles` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `user_educations`
--
ALTER TABLE `user_educations`
  ADD CONSTRAINT `user_educations_ibfk_1` FOREIGN KEY (`user_id`) REFERENCES `users` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `user_experiences`
--
ALTER TABLE `user_experiences`
  ADD CONSTRAINT `user_experiences_ibfk_1` FOREIGN KEY (`user_id`) REFERENCES `users` (`id`);

--
-- Constraints for table `user_has_subscriptions`
--
ALTER TABLE `user_has_subscriptions`
  ADD CONSTRAINT `user_has_subscriptions_ibfk_1` FOREIGN KEY (`user_id`) REFERENCES `users` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `user_invoices`
--
ALTER TABLE `user_invoices`
  ADD CONSTRAINT `user_invoices_ibfk_1` FOREIGN KEY (`user_id`) REFERENCES `users` (`id`);

--
-- Constraints for table `user_orders`
--
ALTER TABLE `user_orders`
  ADD CONSTRAINT `user_orders_ibfk_1` FOREIGN KEY (`user_id`) REFERENCES `users` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `user_research_papers`
--
ALTER TABLE `user_research_papers`
  ADD CONSTRAINT `user_research_papers_ibfk_1` FOREIGN KEY (`user_id`) REFERENCES `users` (`id`) ON DELETE CASCADE;
COMMIT;

/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
